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Thiomarinol is a novel hybrid antibiotic produced by Pseudoalteromonas rava sp. nov. 
SANK 73390. It is structurally similar to a clinically significant antibiotic mupirocin, but 
includes an additional pyrrothine moiety joined to the mupirocin-like marinolic acid via an 
amide bond. Thiomarinol has been shown to be more potent against a wider range of 
microorganisms. This potency was hypothesised to be due to either an increase in inhibition 
of its target enzyme, isoleucyl-tRNA synthetase (IleS) or an increase in antibiotic uptake 
and/or inefficient efflux by bacterial cells or a combination of both. 
Computer modelling identified eight residues on the IleS active site that may be 
responsible for increased binding of thiomarinol. A hydrophobic “patch” was also identified 
near the KMSKS loop that may allow pyrrothine to increase the overall binding affinity. 
Antibacterial susceptibility tests with Salmonella enterica serovar Typhimurium deleted for 
various efflux transporters identified the TolC-AcrAB complex as being more important in 
removing mupirocin from cells than thiomarinol. This suggests that thiomarinol is more able 
to avoid efflux from at least Gram-negative bacteria, allowing its intracellular concentration 
to rise rapidly. These findings lead to the hypothesis that thiomarinol potency is conferred 
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HPLC  High performance liquid chromatography 
Ile  Isoleucine 
Ile-AMP Isoleucyl-adenylate 
IleS  Isoleucyl-tRNA synthetase 
IM  Inner membrane 
IPTG  Isopropyl-β-D-thiogalactoside 
KR  Ketoreductase 
KS  Ketosynthase 
Ki  Inhibitory constant 
Km  Michaelis constant 
L-agar  Luria-Bertani agar 
L-broth Luria-Bertani broth 
Leu  Leucine 
Lys  Lysine 
Macp  Mupirocin acyl carrier protein 
MATE  Multidrug and toxic compound extrusion 
MFS  Major facilitator superfamily 
MIC  Minimal inhibitory concentration 
Mmp  Mupirocin multifunctional protein 
MRSA  Methicillin-resistant Staphyloccocus aureus 
MSSA  Methicillin-sensitive Staphylococcus aureus 
 
 
NCIMB  The National Collection of Industrial, Food and Marine Bacteria 
Ni-NTA  Nickel-nitriloacetic acid 
NMR  Nuclear magnetic resonance 
NRPS  Non-ribosomal peptide synthase 
OD  Optical density 
OM  Outer membrane 
PBP2  Penicillin-binding protein 2 
PCR  Polymerase chain reaction 
PDB  Protein Data Bank 
Phe  Phenylalanine 
PKS  Polyketide synthase 
PPi  Pyrophosphate 
Pro  Proline 
RNA  Ribonucleic acid 
RND  Resistance-nodulation division 
SAM  S-adenosyl methionine 
SDS  Sodium dodecyl sulfate 
SDS-PAGE SDS polyacrylamide gel electrophoresis 
SMR  Small multidrug resistance 
SSM  Secondary stage media 
STE  Sodium Tris EDTA 
TE  Thioesterase 
TEMED N, N, N’, N’-tetramethylethylene diamine 
Thr  Threonine 
Tm  Melting temperature 
Tmp  Thiomarinol multifunctional protein 
Tris  Tris(hydroxymethyl)aminomethane 
 
 
Tyr  Tyrosine 
TyrS  Tyrosyl-tRNA synthetase 
UV  Ultraviolet 
Val  Valine 
Vmax  Maximum velocity 












1  INTRODUCTION 
1.1 An overview of antibiotic resistance 
In the past few years, antibiotic resistance in healthcare institutions has become a 
topic frequently featured by the media, instigating concern amongst the public regarding the 
future and/or limit of effective antibiotic treatments. Bacterial resistance often results in 
treatment failure, which can be fatal. This is especially so for critically immunocompromised 
patients but also for immunocompetent individuals. Numerous antibiotic resistant 
pathogens have been so far described, ranging from methicillin-resistant Staphylococcus 
aureus (MRSA) to multi-drug resistant Gram-negative bacilli (Spellberg et al., 2008). As 
widely publicised in research journals and media reports, antibiotic resistance has 
indisputably become a global health concern, affecting both the developed and developing 
world (Davies, 2013). 
With hindsight, it is perhaps unsurprising that we are now faced with the reality of 
antimicrobial resistance. Following the accidental discovery of penicillin in August 1928 by 
Sir Alexander Fleming and the subsequent successes of early antibiotic therapies, the 
general sentiment of the medical community was that the “war against microbes was won” 
(Spellberg et al., 2008). However, this was clearly not the case, as Fleming went on to select 
and characterise mutants resistant to penicillin soon after he had discovered the antibiotic 
(Alekshun and Levy, 2007). Various studies and surveillances have since been performed to 
illustrate the prevalence of antibiotic resistance in hospitals and farm animals, where 
antimicrobials are heavily utilised (Aarestrup, 2004; Garcia-Migura et al., 2014).  
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Importantly, antimicrobial resistance has also been detected in natural habitats, 
where microbes are not intensively exposed to high and concentrated levels of antibiotics 
compared to the clinical environment. One particular study showed a collection of soil-
dwelling Streptomyces (responsible for producing many clinical antibiotics) to be multi-
resistant to a range of natural, synthetic derivatives and completely synthetic antimicrobials 
(D’Costa et al., 2006). Antibiotic producers are known to carry resistance elements in 
clusters to protect themselves against their own antimicrobial agents, as well as those 
produced by near-by competitors. Thus, many theorise that antimicrobial resistance 
mechanisms originated from antibiotic-producing organisms, as a means to protect 
themselves against auto-toxicity. Orthologous mobile genes of these resistance elements 
have been identified in clinically resistant pathogens, consistent with this evolutionary 
theory (D’Costa et al., 2006). 
Studies have illustrated the capability of microorganisms to adapt, exhibit resistance 
and survive under various environmental selection pressures. It has become clear that 
antibiotic resistance is not a new phenomenon. On the contrary, it is a natural and 
evolutionary process that microbes have undergone for approximately 3.5 billion years 
(Spellberg et al., 2008). Nosocomial and agricultural antibiotic resistance has become a 
threat to public healthcare because of our increases in antibiotic usage before our complete 
understanding of microbial survival mechanisms. It is clear that we need to stay vigilant with 
the epidemiology and rate of antibiotic resistance, continue with our efforts in 
understanding resistance and advance our developments in newer therapeutic agents. Such 
efforts are important for preventing increased morbidity, mortality and the costs of treating 
infectious diseases (Hawkey and Jones, 2009). 
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1.2 Antibiotic resistance mechanisms 
With the increase in bacteria against which antibiotic treatment is ineffective due to 
resistance, there is urgency in understanding how resistance can arise and how this can be 
prevented or interfered with. There are various mechanisms by which antimicrobials 
function that are summarised in Table 1.1.  
Table 1.1. Summary of antimicrobial mode of action (reproduced from Tenover, 2006). 
Principal mode of action of antimicrobials Examples
β-lactams: penicillins, cephalosporins, carbapenems,
monobactams
Glycopeptides: vancomycin
Bind to 50S ribosomal subunit: macrolides,
chloramphenicol
Bind to 30S ribosomal subunit: aminoglycosides,
tetracyclines
Bind to bacterial isoleucyl-tRNA synthetase: mupirocin
Inhibit DNA synthesis: fluoroquinolones
Inhibit RNA synthesis: rifampin
Inhibition of metabolic pathway Sulfonamides, folic acid analogues
Disruption of bacterial membrane structure Polymyxins, daptomycin
Interference with cell wall synthesis
Protein synthesis inhibition
Interference with nucleic acid synthesis
 
 
Bacteria that are innately susceptible to these antibiotics can become resistant by 
acquiring any of the following mechanisms by vertical or horizontal evolution. (Some 
bacteria are innately more resistant to certain classes of drugs, such as Gram-negative 
microorganisms to penicillins as these drugs cannot penetrate the outer membrane easily.) 
Vertical evolution involves the bacteria acquiring resistance from chromosomal mutation 
while horizontal evolution relies on the bacteria acquiring resistance genetic elements from 
other resistant microorganisms (Tenover, 2006). Firstly, bacteria may acquire genes that 
code for enzymes that can inactivate antimicrobials, such as β-lactamases. Secondly, they 
may acquire or upregulate efflux transporters that can transport antimicrobials out of the 
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cell before they reach their intracellular targets and cause damage. Similarly, they may 
downregulate or alter their porin expression to prevent antimicrobials from entering the cell. 
Thirdly, bacteria may acquire mutations that alter bacterial drug targets, preventing the 
antimicrobials from binding. Finally, bacteria may bypass the targets compromised by the 
antimicrobials, by producing them using alternative pathways or by producing altered 
versions that are less susceptible to the antimicrobials. 
1.3 Methicillin-resistant Staphylococcus aureus (MRSA) 
 Methicillin-resistant Staphylococcus aureus or MRSA is one of the few so called 
“superbugs” that have caught the media limelight in recent years. Its parent strain or 
methicillin-sensitive S. aureus has been prevalent in the nosocomial environment, with 
transmissions occurring between immunocompromised patients, and causing secondary skin 
infections, to invasive bacteraemia and septic arthritis (Morell and Balkin, 2010). MRSA was 
firstly detected in Europe in 1961, two years after methicillin was introduced as a solution to 
treating Gram-positive bacteria that had acquired resistance to penicillin through β-
lactamase production. By the 1980s, MRSA was widespread at a global level, both in 
hospitals and eventually in communities (Morell and Balkin, 2010; Walsh, 2003).  
The most common resistance mechanism of MRSA was found to be through the 
acquisition of the chromosomal mecA gene, which expresses an altered form of penicillin-
binding protein 2 (PBP2) called PBP2A. The native protein, PBP2 is part of a family of PBPs 
that are involved in peptidoglycan biosynthesis. PBP2 in particular is involved in cross-linking 
adjacent peptidoglycan chains (transpeptidation) and most β-lactams function by inhibiting 
these transpeptidase PBPs, which weaken the peptidoglycan wall and eventually cause cell 
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lysis. This new PBP2A protein has a lower binding affinity to methicillin and also higher rates 
of methicillin release, allowing it to continue cell wall assembly in the presence of the 
antibiotic (Stapleton and Taylor, 2002).  
In response to these problems with MRSA, mupirocin was first introduced in 1983 as 
a potential antibiotic for skin infections and nasal carriage of MRSA (Dacre et al., 1983; 
Wuite et al., 1983). At that time, it was sold commercially by GlaxoSmithKline as Bactroban, 
and later by generic drug sales by Medimetriks and Teva Pharmaceuticals (Thomas et al., 
2010). At present, it is used globally as a topical treatment for various bacterial infections 
and is considered an important antibiotic for reducing the risk of MRSA transmission in 
hospitals (Gilpin et al., 2010).  
1.4 Mupirocin 
Mupirocin is a polyketide antibiotic produced by the soil bacterium Pseudomonas 
fluorescens. It is composed of a mixture of pseudomonic acids.  First described in 1971, 
mupirocin has a range of activity against aerobic Gram-positive and selected Gram-negative 
bacteria (Nicolaou et al., 2009). Mupirocin is mainly made up of pseudomonic acid A (90%), 
pseudomonic acid B (8%), pseudomonic acid C (< 2%) and pseudomonic acid D (< 2 %) (El-
Sayed et al., 2003) (Figure 1.1). It is clinically used as a topical treatment against impetigo 
and secondary wound infections caused by S. aureus and Streptococcus pyogenes (Patel et 
al., 2009). It is also used as a nosocomial control measure against the spread of MRSA 





Figure 1.1. Structures of mupirocin and selected thiomarinol compounds (reproduced from 
Thomas et al., 2010). (a) Pseudomonic acid A is made up of a C17 monic acid esterified to a 
C9 saturated fatty acid, 9-hydroxynonanoic acid. The two cyclic ethers (products 1 and 2) are 
formed when the 7-hydroxyl group on the 10, 11-epoxide is attacked under either acidic or 
basic conditions (outside the range of pH 4-9). (b) Thiomarinols are structurally similar to 
pseudomonic acids but have a pseudomonic acid analogue (marinolic acid) and pyrrothine 
moiety (such as holomycin) at the end. 
 
1.5 Biosynthesis of mupirocin 
Mupirocin biosynthesis requires a 74 kb region in the chromosome called the mup 
cluster (El-Sayed et al., 2003). This cluster encodes 35 open reading frames (ORFs), of which 
six are mupirocin multifunctional polypeptides (mmpA to mmpF); of these five encode 
polyketide synthases (El-Sayed et al., 2003; Hothersall et al., 2007). Expression of this cluster 
is regulated by the quorum-sensing genes N-acylhomoserine lactone (AHL) synthase mupI 
and transcriptional regulator mupR (El-Sayed et al., 2001). The functions encoded by the 
mup cluster are summarized in Table 1.2. 
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Table 1.2. Summary of functions encoded by the mupirocin biosynthesis cluster 
(reproduced from Thomas et al., 2010)*. 
ORF Deduced functions of the encoded protein
mupA Reduced flavin mononucleotide (FMNH2) oxygenase
mmpA Polyketide synthase (ketosynthase, acyl carrier protein and ketoreductase)
mupB 3-Oxo-acyl carrier protein synthase
mmpB
Polyketide synthase (ketosynthase, dehydratase, ketoreductase, acyl
carrier protein and thioesterase)
mmpC Acyltransferase and enoyl reductase
mmpD
Polyketide synthase (ketosynthase, dehydratase, ketoreductase,
methyltransferase and acyl carrier protein)
mupC Dienoyl CoA reductase
macpA Acyl carrier protein
mupD 3-Oxo-acyl carrier protein reductase
mupE Enoyl reductase
macpB Acyl carrier protein
mupF Ketoreductase
macpC Acyl carrier protein
mupG 3-Oxo-acyl carrier protein synthase
mupH β-hydroxyl-β-methyl glutarate CoA synthase
mupJ Enoyl CoA hydratase
mupK Enoyl CoA hydratase






mupQ Acyl CoA synthase
mupS 3-Oxo-acyl carrier protein reductase
macpD Acyl carrier protein
mmpF Polyketide synthase (ketosynthase)
macpE Acyl carrier protein
mupT Ferrodoxin dioxygenase





mupI N -Acyl homoserine lactone synthase
 
*macp, mupirocin acyl carrier protein gene; mmp, mupirocin multifunctional polypeptide gene. 
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Mupirocin is synthesised by a Type I polyketide synthase (PKS) system, which is 
comprised of large multifunctional enzymes organised in non-iterative modules. The starting 
unit for polyketide synthesis is an acyl-CoA precursor (such as acetyl-CoA in the case of 
mupirocin synthesis). In some systems there is a very clear loading function, whereas in the 
mupirocin system such a function is not obvious and it may be that acetate is loaded directly 
to the first ketosynthase (KS) or indirectly via the first acyl carrier protein (ACP) by an 
acyltransferase (AT) before transfer to the first KS to start biosynthesis. Once the KS is 
occupied the ACP is loaded with the appropriate acyl-CoA (malonyl-CoA in the mupirocin 
system) before the KS catalyses a Claisen condensation, in which the acetate’s carboxylic 
acid forms a β-carbonyl group as part of the ACP-bound polyketide chain. The β-carbonyl 
group is then either left unreduced or modified by a combination of reactions by 
ketoreductases (KR), dehydratases (DH) and enoyl reductases (ER). This process is repeated 
along the modules until the polyketide is complete, and the chain remains on the ACP as a 
thiolester until it is released by a terminal thioesterase (TE) via hydrolysis. The released 
polyketide backbone may then undergo further modification to reach its final form, such as a 
variety of reductions and the addition of functional moieties. These post-PKS processes yield 
the wide selection of polyketides with different structures and functions. 
The proposed mupirocin synthesis pathway is summarised in a review by Thomas and 





Figure 1.2. The currently proposed mupirocin biosynthesis pathway (reproduced from 
Thomas et al., 2010). (a) The mupirocin biosynthesis (mup) cluster and (b) the proposed 
biosynthesis pathway of the polyketide backbone. DH, dehyratase; HSL, homoserine lactone; 
I, MupI; KR, ketoreductase; KS, ketosynthases; Mmp, mupirocin multifunctional polypeptide; 
MT, methyltransferase; PA, pseudomonic acid. 
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MmpD and MmpA are hypothesised to produce the monic acid component of mupirocin. 
MmpB is thought to be involved in the synthesis of 9-hydroxynonanoic acid. mAcpD, MupS 
and MupQ are suggested to collectively produce the starter compound of 9-
hydroxynonanoic acid, 3-hydroxypropionate, although further work is required to support 
this. It is also unclear as to whether monic acid is joined to 3-hydroxypropionate before 
being transferred to MmpB for further elongation, or whether 9-hydroxynonanoic acid is 
made before joining monic acid, although preliminary data indicate the former to be more 
plausible (Thomas et al., Unpublished). 
1.6 Aminoacyl-tRNA synthetases 
Mupirocin and all pseudomonic acids act by competitively inhibiting bacterial 
isoleucyl-tRNA synthetases (IleSs) (Figure 1.3). IleS belongs to a group of 20 aminoacyl-tRNA 
synthetases, which are responsible for charging tRNA with the cognate amino acid to 




Figure 1.3. Crystal structure of IleS complexed with mupirocin and tRNAIle (PDB: 1QU2) 







Figure 1.4. Cloverleaf secondary structure of aminoacyl-tRNA (adapted from 
http://www.wiley.com/college/boyer/0470003790/structure/tRNA/trna_intro.htm). All 




Each amino acid has its specific tRNA to which it must be correctly bound and hence, 
each aminoacyl-tRNA synthetase ensures this process by recognising the two substrates. The 
enzymes are divided into two classes (Table 1.3) based on their signature sequence motifs in 
the active site for amino acid activation and aminoacyl-tRNA synthesis (collectively known as 
aminoacylation) (Eriani et al., 1990). The catalytic site of class I aminoacyl-tRNA synthetases 
are comprised of three or more β-strands linked by two α-helices. They have two 
dinucleotide-binding Rossman folds which contain the two amino acid motifs “HIGH” and 
“KMSKS”. On the other hand, the active site of class II enzymes is a barrel-like structure of 
anti-parallel β sheet with loops and α-helices around it (Ochsner et al., 2007). Both Class I 
and Class II catalytic sites are important for the binding of amino acid and adenosine 
triphosphate (ATP) (Vondenhoff and Van Aerschot, 2011). 
Table 1.3. Class I and II aminoacyl-tRNA synthetases*. 
Class I aminoacyl-tRNA synthetases Class II aminoacyl-tRNA synthetases
a b c a b c
Methionyl (MetS) Tyrosyl (TyrS) Arginyl (ArgS) Seryl (SerS) Asparginyl (AsnS) Phenylalanyl (PheS)
Isoleucyl (IleS) Tryptophanyl (TrpS) Glutaminyl (GlnS) Threonyl (ThrS) Aspartyl (AspS)
Valyl (ValS) Lysyl (LysSI) Glutamyl (GluS) Prolyl (ProS) Lysyl (LysSII)
Leucyl (LeuS) Histidyl (HisS)
Cystinyl (CysS) Alanyl (AlaS)
Glycyl (GlyS)  
*Both classes are further subdivided based on their sequence homology and domain structure (Ochsner et al., 2007). Lysyl-
tRNA synthetase is classified in both classes because while most organisms contain the class II structural enzyme, some 
bacteria and archaea only have the class I enzyme (Vondenhoff and Van Aerschot, 2011). 
 
1.6.1 Function 
Class I and II aminoacyl-tRNA synthetases have three binding sites used for charging a 
tRNA with an amino acid: the ATP site, the amino acid site and the tRNA site. They charge 
tRNA by a two-step aminoacylation reaction (Figure 1.5) in which the amino acid first reacts 
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with ATP to form an aminoacyl-adenylate. ATP is cleaved to provide this step with energy. 
Secondly, the activated amino acid is covalently attached to the tRNA, releasing AMP. 
 
Figure 1.5. Two-step mechanism of (1) amino acid activation and (2) aminoacyl-adenylate 
transfer to the cognate tRNA (reproduced from Antonellis & Green, 2008). Abbreviations: 
ARS, aminoacyl-tRNA synthetase; AA, amino acid. 
 
This process can be further discussed at a biochemical level. During amino acid 
activation, the nucleophilic carboxylate group of amino acid attacks the α-phosphate of ATP, 
giving aminoacyl-adenosine-monophosphate (aaAMP) and pyrophosphate (PPi). The reactive 
aaAMP remains tightly but noncovalently bound to the aminoacyl-tRNA synthetase (Moran 
et al., 2011). Following activation, the carboxyl group of the aaAMP is esterified by a 
nucleophilic attack onto the 2’- or 3’ ribose hydroxyl group at the 3’-end of the tRNA, 
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resulting in an aminoacyl-tRNA (Figure 1.6). The position of esterification (2’- or 3’ hydroxyl 
group) is dependent on the aminoacyl-tRNA synthetase catalysing the reaction. However, an 
amino acid which is initially attached to the 2’-hydroxyl group is shifted to the 3’-hydroxyl 
group in an additional reaction (Moran et al., 2011). Once correctly aminoacylated, the 
aminoacyl-tRNA interacts with the bacterial elongation factor EF-Tu to translate mRNA in the 
ribosome.  
 
Figure 1.6. Two step mechanism of aminoacylation in Class II aminoacyl-tRNA synthetases 
(reproduced from Vondenhoff & Van Aerschot, 2011). Class I aminoacyl-tRNA synthetases 
esterify the amino acid at the 2’-hydroxyl group of the ribose moiety of the 3’-adenosine 
tRNA. Class II enzymes esterify at the 3’-hydroxyl group (as shown above). 
 
In some cases, incorrectly aminoacylated tRNAs are formed. The consequence of 
misaminoacylation leads to mistranslation, and the consequences may range from toxicity to 
cell death  (Guo and Schimmel, 2012). To prevent such errors, two editing mechanisms - a 
pre- and post-transfer editing exist, in which the amino acid is hydrolysed from ATP and 
tRNA respectively (Fukunaga and Yokoyama, 2006; Martinis and Boniecki, 2010). 
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Collectively known as the double-sieve model, pre-transfer editing takes place in the 
synthetic site and the post-transfer editing in the editing site of the aminoacyl-tRNA 
synthetase. The synthetic site acts as the first filter to eliminate amino acids that are too 
large or do not establish the correct interactions with the active site. However, some smaller 
amino acids, such as valine instead of isoleucine in IleS, may slip through unnoticed because 
they are able to establish enough interaction with the active site. The editing site follows this 
up by hydrolysing misactivated amino acids from the tRNA. Correctly activated amino acids 
are unable to fit in the editing site and therefore remain unhydrolysed. 
1.6.2 HIGH and KMSKS catalytic domains 
The above mentioned two step mechanism of aminoacylation takes place in the 
catalytic domain. In Class I aminoacyl-tRNA synthetases, this catalytic domain is 
distinguished by the conserved HIGH and KMSKS motifs. Both motifs have been extensively 
studied by site-directed mutagenesis and structural studies and observed to interact directly 
with each other and also with ATP (Perona et al., 1993).  
In the conserved HIGH motif, the first histidine was observed to play a key role in 
stabilising the transition state in Bacillus stearothermophilus (B. stearothermophilus) TyrS via 
interaction with the γ-phosphoryl group of ATP (Soll et al., 1995). On the other hand, the 
second histidine was shown to play a minor role in stabilising the transition state complex 
and also the tyrosyl-adenylate through interaction with the ribose group. 
In the bacterial KMSKS domain, the second lysine is highly conserved among the Class 
I aminoacyl-tRNA synthetases (Landès et al., 1995) and shown to interact with the α-
phosphate of the ATP in the transition state (Yaremchuk et al., 2002). However most 
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eukaryotic and some of archaeal TyrS lack this second lysine: for example, human TyrS has a 
KMSSS motif. Kinetic studies indicated that potassium functionally compensates for the lack 
of the second lysine in human TyrS and that the potassium stabilises the transition state for 
tyrosine activation via interaction with the pyrophosphate moiety of ATP (Austin and First, 
2002a). This particular study highlights an interesting point that the KMSKS motifs in the 
human and B. stearothermophilus TyrS play similar roles but the extent to which human 
KMSSS catalyses tyrosine activation is significantly less than in B. stearothermophilus TyrS. 
The first lysine in the crystal structures of Escherichia coli TyrS was found to bind to 
the tRNA backbone and stabilise the tRNA conformation to produce an open active site 
(Kobayashi et al., 2005). A detailed suggestion on ATP binding and tyrosine activation by the 
KMSKS loop can be found in the above mentioned paper. The main chain carbonyl group of 
the methionine residue was observed to hydrogen bond with the main chain amino group of 
the glycine of the HIGH motif (Perona et al., 1993). Finally, the two serines have also been 
observed to stabilise the transition state for tyrosine activation by interacting with the 
pyrophosphate moiety of ATP in human TyrS (Austin and First, 2002b). 
1.7 Mupirocin mode of action 
As mentioned previously, mupirocin and other pseudomonic acids act by 
competitively inhibiting bacterial IleS. In order to inhibit IleS, this particular class of 
antibiotics mimics the key elements involved in the aminoacylation of tRNA. According to 
the crystal structure of S. aureus IleS complexed with mupirocin, this antibiotic prevents 
normal aminoacylation by imitating isoleucine and ATP (with its C14 monic acid end and 
pyran ring respectively), blocking their binding sites (Silvian et al., 1999). 
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The 9-hydroxynonanoic acid was observed to stabilize the entire complex by the carboxylate 
tail binding to the second lysine residue of the KMSKS motif (Lys598) (Silvian et al., 1999). In 
the crystal structure of Thermus thermophilus IleS, stabilisation was observed to differ 
slightly – with the 9-hydroxynonanoic acid lying along the KMSKS loop and interacting with 
the side and main chain of the conserved methionine residue (Nakama et al., 2001). The 
difference in binding is thought to be due to the difference in conformation of the two IleS 
from S. aureus and T. thermophilus. The crystal structure of the former is in closed 
conformation while the latter is opened (Nakama et al., 2001).  
Once mupirocin blocks the active site of IleS and prevents the charging of isoleucyl-
tRNA with isoleucine, it leads to a depletion of aminoacylated isoleucyl-tRNA and an 
accumulation of uncharged isoleucyl-tRNAs (Reiss et al., 2012). An increase in uncharged 
tRNAs signals the cell of amino acid starvation and triggers the stringent response. The 
uncharged tRNAs enter the ribosomal A site and block the ribosome, leading to inhibition of 
protein synthesis. 
When the ribosome is blocked from functioning properly, the ribosome-associated 
RelA protein responds by catalysing the production of GTP 3’-diphosphate (pppGpp) and 
GDP 3’-diphosphate (ppGpp) from ATP and GTP/GDP. In E. coli, ppGpp then binds to RNA 
polymerase (RNAP) which blocks rRNA and tRNA gene transcription. Cell division and DNA 
synthesis initiation are also halted. In Bacillus subtilis, ppGpp does not directly affect RNAP 
activity; it is the decrease in intracellular GTP concentration (due to pppGpp synthesis) that 
affects rRNA gene transcription (Krásný and Gourse, 2004). In S. aureus, several genes are 
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thought to play a role in instigating the stringent response. A comprehensive study on the 
global response of S. aureus to mupirocin has recently been published (Reiss et al., 2012). 
1.8 Mupirocin resistance 
Mupirocin encompasses many desirable traits of an effective clinical drug. For 
example, mupirocin is approximately 10,000 times more potent on the bacterial IleS than on 
the corresponding eukaryotic enzyme, as it can only bind weakly to the latter (Hughes and 
Mellows, 1980; Marion et al., 2009; Nicolaou et al., 2009). This is essential in any 
pharmaceutical drug, because weak affinity to the eukaryotic equivalents of any drug target 
minimises eukaryotic toxicity and ensures its selectivity. Thus mupirocin and the 
pseudomonic acids have ideal structures and biological activity as pharmaceutical 
compounds. However, like many of the other antibiotics administered clinically, there are 
also potential issues to be addressed, such as mupirocin resistance. 
In S. aureus, mupirocin susceptibility and resistance has been described in three 
common categories (Patel et al., 2009). First, there is susceptibility, in which wild type 
bacteria succumb to a minimal inhibitory concentration (MIC) of mupirocin at ≤ 4 μg/ml. 
Second, there is low-level resistance, conferred by mutations in the native tRNA synthetase 
at a MIC range of 8-64 μg/ml. Lastly there is high-level resistance at a MIC of ≥ 512 μg/ml, in 
which resistance is mediated by the plasmid-encoded mupA, a secondary tRNA synthetase.  
Low-level resistance in clinical isolates of S. aureus, as well as other species such as E. 
coli has been shown to be acquired by one single amino acid change in the Rossman fold 
region of IleS (Antonio et al., 2002; Yanagisawa et al., 1994). The Rossman fold is normally 
the site of ATP binding and also where the 9-hydroxynonanoic acid of mupirocin binds. In S. 
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aureus (PDB: 1FFY), a Val-to-Phe change at either residue 588 or 631 was observed to confer 
low-level mupirocin resistance (Antonio et al., 2002). The change of residue to a much 
bulkier phenylalanine is suggested to disrupt the hydrophobic pocket of the Rossman fold, 
creating a van der Waals clash between the aromatic ring and the 9-hydroxynonanoic acid of 
mupirocin. It is also speculated that the bulky Phe588 can only be accommodated in the 
pocket of IleS by torsional rotation, leading to some solvent exposure of the benzene ring. 
This may trigger conformational changes and result in a loss of Val588 hydrogen bonding 
with mupirocin.  
On the other hand, high-level resistance to mupirocin is usually conferred by the 
presence of IleSs that have similarity to the eukaryotic enzymes, likely acquired by horizontal 
gene transfer. For example, mupirocin-producing strain of P. fluorescens expresses two 
different chromosomal IleSs, one of which is similar to eukaryotic IleSs called mupM 
(Yanagisawa and Kawakami, 2003). With this extra eukaryotic-type enzyme on hand, the 
strain is able to continue its protein biosynthesis, even when challenged with high 
concentrations of pseudomonic acids. Alternatively, clinical strains of S. aureus confer high-
level resistance to mupirocin by expressing a eukaryote-like IleS from the plasmid-mediated 
mupA (Hodgson et al., 1994). Collectively, these mupirocin-resistant eukaryote-like IleSs are 
called IleS2 and the mupirocin-sensitive proteins called IleS1. A summary of organisms with 
or without IleS2 and the relationship between IleS2 and mupirocin sensitivity is shown below 
(Table 1.4). While several studies have indicated high-level mupirocin resistance in S. aureus 
to be associated with mupirocin-treatment failure, the actual clinical significance of both 
high and low-level mupirocin resistance is yet to be elucidated by further epidemiological 
studies (Patel et al., 2009).  
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Furthermore, a new high-level mupirocin resistance gene called mupB was recently 
identified from Canadian clinical MRSA strains (Seah et al., 2012). This new gene has 65.5% 
DNA sequence identity with mupA but only 45.5% identity with ileS. The protein shares 
58.1% amino acid identity with MupA and 25.4% identity with IleS. Although limited in 
homology, the Class I conserved HIGH and KMSKS motifs were also identified in MupB. So far, 
there has been no other report of mupB detection. 
Table 1.4. Summary of organisms with or without IleS2 enzyme and the relativity to 
mupirocin sensitivity (Brown et al., 2003; Ferreira et al., 2002; Sassanfar et al., 1996; 









Mycobacterium tuberculosis - + Resistant >100
Bifidobacteria spp.* - + Resistant >1,800, >2,000
Oceanobacillus iheyensis - + Not Tested -
Staphylococcus aureus + - Sensitive 0.12
Staphyloccocus aureus + + Resistant >512 
Staphylococcus epidermidis + - Sensitive 12, 16
Staphylococcus epidermidis + + Resistant >1024
Bacillus cereus + + Not Tested -
Bacillus anthracis + + Resistant 64
Pseudomonas fluorescens + + Resistant >1,000  
 
1.9 IleS1 versus IleS2 
Intrinsic mupirocin resistance has also been observed in some bacterial species. A 
recent study on Bifidobacteria species investigated the reason behind this inherent 
resistance, in which the majority of the species tested exhibited high mupirocin resistance of 
over 2,000 μg/ml and a few were considered susceptible (relative to the former high 
concentrations) when affected at concentrations higher than 1,800 μg/ml (Serafini et al., 
2011). Unlike mupirocin-resistant S. aureus carrying a secondary eukaryote-like IleS2, 
Bifidobacteria species were found to express only one chromosomal IleS. When these 
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Bifidobacteria IleS sequences were compared to IleS1 and IleS2 sequences of mupirocin-
resistant P. fluorescens and S. aureus, as well as other mupirocin-sensitive organisms such as 
E. coli, it was noted that all organisms possessing high level resistance to mupirocin 
contained a tyrosine or alanine residue in the first region (HIGH or RG1) of the ligand binding 
site (or the Rossman fold) (Serafini et al., 2011). All Bifidobacteria species contained a 
tyrosine in RG1. Therefore, a tyrosine or alanine residue in the ligand binding site of the 
target enzyme may be responsible for conferring intrinsic resistance to mupirocin.  
An evolutionary study by Brown and colleagues also highlighted the occurrence of 
horizontal gene transfer of these IleS2 proteins (Brown et al., 2003) (Figure 1.7). IleS2 in P. 
fluorescens, B. cereus, B. anthracis and S. aureus were found to phylogenetically cluster 
amongst themselves and other intrinsically mupirocin-resistant organisms such as O. 
iheyensis. Phylogenetically, this cluster is more closely related to eukaryotic IleSs than the 
IleS1 of the above listed organisms. Additionally, this cluster of bacterial genes sits between 
the archael and eukaryotic IleSs, suggesting that it did not evolve as part of the organisms’ 
genome but rather was acquired horizontally. The BLAST results of TmlM also indicated its 
closer homology to eukaryotic IleS, with 50% identity to mouse/rat and 48% to human IleS 




Figure 1.7. Phylogeny of isoleucyl-transfer-RNA synthetase protein sequences (reproduced 




In addition to the potential risk of high-level mupirocin resistance spreading through 
horizontal gene transfer of IleS2 enzymes, mupirocin has other limitations as a systemic drug, 
despite the many attributes highlighted above as a topical treatment. Firstly it cannot be 
administered orally, as it is readily inactivated in body fluids, in which the ester bond 
between the monic acid and 9-hydroxynonanoic acid is hydrolysed (Sutherland et al., 1985). 
Secondly it binds strongly to serum, reducing its bioavailability (Sutherland et al., 1985). To 
address the concerns on rising mupirocin resistance in particular, efforts have been directed 
at deriving improved analogues of mupirocin. As such, potential analogues called 
thiomarinols (Figure 1.1) were found to be naturally produced by a marine bacterium 
Pseudoaltermonas rava sp. nov. SANK 73390. 
Thiomarinol A and H were the first of these potential compounds to be discovered in 
1993 and 1992 respectively, followed by the other minor components; thiomarinol B and C 
in 1995 and thiomarinol D, E, F and G in 1997 (Shiozawa et al., 1993, 1995, 1997; Stierle and 
Stierle, 1992). Thiomarinols display structural similarities to pseudomonic acids, and appear 
as a hybrid of two types of antibiotics; pseudomonic acids and pyrrothines such as 
holomycin and holothin, the precursor of the former compound (Shiozawa et al., 1993). For 
example, thiomarinol A and H both consist of a pseudomonic acid analogue called marinolic 
acid (an 8-hydroxyoctanoic acid instead of a 9-hydroxynonanoic acid) and holomycin and 
anhydroornithine respectively (Shiozawa et al., 1993, 1995; Stierle and Stierle, 1992) (Figure 
1.1). Compared to pseudomonic acid A, thiomarinol A shows a broader spectrum activity 
against both Gram-positive and Gram-negative bacteria (Shiozawa et al., 1993) (Table 1.5). 
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Thiomarinol H also has shown equal activity to that of tetracycline and streptomycin against 
S. aureus (Stierle and Stierle, 1992). The increased potency of these thiomarinol compounds 
indicates potential as new pharmaceutical analogues. Furthermore, thiomarinol H has 
recently been chemically synthesized (Marion et al., 2009), as well as thiomarinol analogues 
engineered by mutagenesis and mutasynthesis (Murphy et al., 2011). These advances 
indicate the possibilities of further hybrid production of mupirocin and thiomarinol 
derivatives. 
Table 1.5. Summary of mupirocin, thiomarinol and holomycin MIC against various 
organisms (Shiozawa et al., 1993; Sutherland et al., 1985; Oliva et al., 2001). 
MIC (µg/ml)
Test organism Mupirocin Thiomarinol Holomycin
Gram positive
Staphylococcus aureus 0.12-0.25 <0.01 4
Enterococcus faecalis <0.05 - >100 <0.01 4
Gram negative
Klebsiella pneumoniae 50 0.78 8
Escherichia coli >100, 128 3.13 <2
Pseudomonas aeruginosa >100, 6400 0.39 64
Salmonella enteritidis 100 3.13 -
Enterobacter cloacae >100 6.25 -
Serratia marcescens >100 25 -
Morganella morganii >100 12.5 64
Proteus vulgaris 100 0.39 -
Proteus mirabilis - - 4
Haemophilus influenza - - <0.3
 
 
1.11 Thiomarinol mode of action 
The exact mode of action of thiomarinol is yet to be elucidated. However, hypotheses 
can be drawn from its structural similarity to mupirocin, for which the mode of action is 
better understood. Experiments comparing these two antibiotics have established the wider 
spectrum of activity of thiomarinol (Shiozawa et al., 1993). However, the activity of marinolic 
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acid, the pseudomonic acid analogue of thiomarinol, has been shown to be less potent than 
mupirocin, and inhibits S. aureus at a MIC of 1 μg/ml and 0.125 μg/ml respectively (Fukuda 
et al., 2011). This strongly suggests that the pyrrothine moiety is responsible for the 
increased potency of thiomarinol, although holomycin on its own has weaker activity against 
S. aureus than thiomarinol (MIC values of 4 and <0.01 µg/ml respectively) (Qin et al., 2013a). 
On the contrary, holomycin has greater activity against E. coli than thiomarinol as shown in 
Table 1.5. 
Due to the hybrid nature of thiomarinol, it can be speculated that the antibiotic 
targets more than one cellular function. The mupirocin-like marinolic acid may have a similar 
function to mupirocin and competitively inhibit IleS and consequently inhibit protein 
synthesis. The holomycin moiety, on the other hand, is part of the dithiolopyrrolone group of 
antibiotics and is produced by the likes of Streptomyces species, Photobacterium 
halotolerans (Wietz et al., 2010) and Yersinia ruckeri (Qin et al., 2013b) as an independent 
antibiotic. The exact mechanism is not yet understood but dithiolopyrrolones have been 
shown to inhibit RNA polymerase at the stage of RNA elongation (Khachatourians and Tipper, 
1974; Oliva et al., 2001). Holomycin may therefore be contributing to the potency of 
thiomarinol by the additional targeting of RNA synthesis. 
However, preliminary data indicate that thiomarinol functions by solely inhibiting IleS 
(Fukuda et al., 2011). A single thiomarinol resistance gene, tmlM was identified on the 
plasmid pTML1 carrying the biosynthetic genes of the antibiotic. When this resistance gene 
was expressed in thiomarinol-susceptible E. coli, a high resistance phenotype was conferred 
(MIC ≥ 16 µg/ml), suggesting that the target of thiomarinol is only IleS. When the mupirocin 
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resistant IleS mupM was expressed in the same manner as tmlM and challenged with 
thiomarinol, it only conferred weak resistance of MIC= 1µg/ml. The baseline MIC of E. coli 
carrying the empty expression vector was 0.5 µg/ml. Therefore, thiomarinol may simply 
have a more potent effect on the same IleS target. To date, there are no reports on 
detection or analysis of thiomarinol resistance other than the native tmlM gene. 
Based on the above understanding of thiomarinol so far, the observed potency of this 
hybrid antibiotic is hypothesised to be conferred by the following possibilities of (1) 
increased binding to IleS, (2) efficient uptake by susceptible cells, (3) prevention of efflux by 
susceptible cells or (4) a combination of all the above mentioned.  
1.12 Biosynthesis of thiomarinol 
Work carried out by Fukuda and colleagues identified the biosynthesis genes of 
thiomarinol to be encoded in an approximately 97 kb plasmid named pTML1 (Fukuda et al., 
2011). Similarly to mupirocin, thiomarinol is also synthesised by type I polyketide synthase 
(PKS) genes. 27 ORFs out of the total 45 are hypothesised to encode products responsible for 
producing the marinolic acid component and 7 ORFs were found to be similar to several 
putative non-ribosomal peptide synthetase (NRPS) gene clusters and thus hypothesised to 
be responsible for producing the pyrrothine moiety. Mutational studies of tmlU have shown 
individual production of marinolic acid and pyrrothine but no intact thiomarinol products; 
hence it is hypothesised that TmlU is involved in joining the marinolic acid and pyrrothine 
moiety together (Fukuda et al., 2011). The gene order from tmpA to tmpD are organised 
similarly to the mupirocin biosynthesis cluster (El-Sayed et al., 2003) but with the 
thiomarinol biosynthesis cluster carrying an extra ACP in module 3 of TmpD and in module 6 
28 
 
of TmpA, and 2 extra ACPs in TmpB (one in a group of four and one after the KS domain). 
The cluster also lacks an mAcpE at the end of pseudomonic acid production and instead 
carries an extra KS and ACP in TmpB, indicating tailoring steps may occur at this site. A 
schematic summary of the thiomarinol biosynthesis cluster is shown below (Figure 1.8) 
 
Figure 1.8. Proposed thiomarinol biosynthesis pathway (reproduced from Fukuda et al., 
2011). KS, Ketosynthase; ACP, Acyl Carrier Protein, KR, Ketoreductase; DH, Dehydratase; ER, 
Enoyl Reductase; MT, Methyl Transferase; TE, Thioesterase, C, Condensation; A, Aminoacyl 
Adenylation Domain; T, Thiolation Domain or Peptidyl Carrier Protein. 
 
1.13 Statement of objectives 
This study will investigate the mode of action of thiomarinol and the two main 
hypotheses as to why it is more potent and broader spectrum antibiotic than mupirocin. The 
known target enzyme of mupirocin (IleS) will be the focal enzyme of study. The first 
hypothesis to be examined is that the pyrrothine moiety potentiates thiomarinol activity by 
increasing the binding affinity of thiomarinol and its target enzyme. The second is that the 
susceptible bacterial cell uptakes and accumulates thiomarinol better than mupirocin. 
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This study was designed to utilise both experimental and computational methods to 
address the above hypotheses. The plan was to attempt to identify key amino acid residues 
in the IleS enzyme that may be involved in increasing the binding affinity to thiomarinol, as 
well as conferring individual resistance phenotypes. Aminoacylation assays would be used in 
an attempt to characterise and compare the binding affinities (Ki) of thiomarinol and 
mupirocin. The study would also attempt to produce 14C labelled thiomarinol and mupirocin, 
which would hopefully allow us to track the transport of these antibiotics in and out of 
bacterial cells and deduce whether uptake and/or efflux are key mechanisms of the former 












2  GENERATING THIOMARINOL-RESISTANT MUPM MUTANTS 
USING SPONTANEOUS AND UV MUTAGENESIS 
2.1 Introduction 
Isoleucyl-tRNA synthetase (IleS) is the known target enzyme of mupirocin. As 
discussed in Chapter 1, high-level resistance to mupirocin has been linked to either the 
presence of a second, plasmid- or chromosomally-encoded, eukaryotic-like IleS (called 
generically as IleS2) or the presence of just this eukaryotic-like enzyme as the sole IleS 
(Chapter 1, Table 1.4). MupM and MupA are both eukaryotic-like chromosomal IleS2 
enzymes carried by Pseudomonas fluorescens and methicillin resistant or sensitive 
Staphylococcus aureus (MRSA/MSSA) respectively that confer high-level resistance against 
mupirocin. The only known resistance mechanism against thiomarinol is also a eukaryotic-
like plasmid-encoded IleS2 called TmlM carried by the producer Pseudoalteromonas rava sp. 
nov. SANK73390. Based on the structural similarity between mupirocin and thiomarinol and 
the only mechanism of resistance against thiomarinol being an IleS2, IleS was chosen as the 
focal enzyme of this study. 
The aims of this section were firstly to identify the MIC values of thiomarinol against 
wild-type Escherichia coli DH5α (expressing no IleS2 by carrying an empty pJH10 vector) and 
also those expressing MupA, MupM and TmlM. Following MIC determination, these E. coli 
strains were challenged with thiomarinol concentrations ≥ MICs directly or after UV 
irradiation respectively, in order to select for spontaneous and UV-induced thiomarinol-
resistant mutants. It was hoped that these mutants would reveal the amino acid residues in 
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the enzyme responsible for the resistance phenotype, as well as the site of pyrrothine 
binding without changing the MIC for mupirocin. 
2.2 Materials and Methods 
2.2.1 Bacterial strains, growth conditions and plasmids 
All bacterial strains and plasmids used in this study are listed in Table 2.1 and Table 
2.2. 
All bacterial strains were grown overnight at 37°C in L-broth (Oxoid, United Kingdom) 
before being sub-cultured for future experiments.  Tetracycline (15 µg/ml) was added in the 
cultures for selection of plasmid pJH10, and 1 mM IPTG was added to induce expression of 
mupA, mupM and tmlM.  Ampicillin (100 µg/ml) was used for selection of plasmid pUC18. 
Table 2.1. Bacterial strains used in this study. 
 
Bacterial Strain Genotype Phenotype Source/Reference
E. coli  DH5α
endA1 recA hsdR17 lacZΔM15
supE44 gyrA96 thi-I relA1  F
- High transformation efficiency strain. Gibco BRL
E. coli  GM2163
F
-
 dam-13:Tn9 dcm-6 ara-14
hisG4 leuB6 thi-1 lacY1 galK2
galT22 glnV44 hsdR2 xlyA5
mtl-1 rpsL 136 rtbD1 tonA31
tsx78 mcrA mcrB1
For producing non-methylated DNA to cut
with Dam or Dcm sensitive restriction
enzymes. Also useful for mutagenesis, where
non-dam methylated DNA is more prone to
mutation that cannot be corrected by
mismatch repair.
Woodcock et al.,  1989
P. rava  sp.
SANK73390




Table 2.2. Plasmids used in this study. 
Plasmid Size (kb) Properties Source/Reference
pUC18 2.7 pMB1 replicon, Apr, lacZ  , polylinker Yanisch-Perron et al.,  1985
pJH10 14.5
IncQ replicon, pOLE1 IncC1 deleted,
with EcoRI-SacI polycloning site, Tcr
from pDM1.2
El-Sayed et al.,  2003
pJH10mupA 17.7
pJH10 derivative with cloned 3233 bp
mup A  fragment (EcoRI-XbaI)
Fukuda et al.,  2010
pJH10mupM 17.5
pJH10 derivative with cloned 3092 bp
mupM  fragment (EcoRI-XbaI)
El-Sayed et al.,  2003
pJH10tmlM 17.6
pJH10 derivative with cloned 3146 bp
tmlM  fragment (EcoRI-XbaI)
Fukuda et al.,  2010
pUC18mupM 5.7
pUC17 derivative with cloned 3092 bp
mupM fragment (EcoRI-XbaI)
E. Stephens; This study
pJH10mupMO1 17.5









2.2.2 Thiomarinol production, extraction and quantification 
A single colony of P. rava sp. nov. SANK 73390 was inoculated into 25 ml Marine 
Broth (BD, United Kingdom) and the culture grown at 23°C at 200 rpm before 5 ml was sub-
cultured into 500 ml fresh Marine Broth and grown for another 2 days in the same 
conditions. To stabilise the thiomarinol compounds, the pH of the culture was then adjusted 
to approximately 6.0 by adding 5 ml of 1M HCl. A volume of acetone equal to that of the 
culture (500 ml) was added and mixed, and the culture left in the refrigerator for at least 1 
hr to allow complete decomposition of the bacterial cell walls. The acetone was then 
evaporated using a rotary evaporator before an equal volume of ethyl acetate (500 ml) was 
added and mixed well to extract the thiomarinols. The mixture was decanted into a 
separating funnel, where the thiomarinols separated from the remaining cell debris to form 
a clear yellow upper layer. The bottom cloudy layer was discarded while the ethyl acetate in 
the yellow layer was completely evaporated using the rotary evaporator. The dried 
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thiomarinol extract was dissolved in 2 ml absolute methanol and stored in the refrigerator 
until further use. Further dilutions of the thiomarinol extract were prepared using methanol 
only. The concentration of extracted thiomarinol was quantified using the HPLC and 
thiomarinol A powder stock provided by Daiichi Sankyo (Tokyo, Japan) as a standard. HPLC 
was performed using the Unipoint LC system software and a reverse phase C18 column (15 
cm x 4.6 mm) at a UV detection of 385 nm. A mobile phase water/acetonitrile ratio of 65% 
and 35% respectively was used with 0.01% acetonitrile trifluoroacetic acid. The programme 
was run for 24 minutes at 1 ml/min flow rate and thiomarinol A detected at around 8 
minutes. 
2.2.3 Determination of Minimal Inhibitory Concentration 
Two final inoculum sizes were used in determining the MICs: 5 x 105 cfu/ml and 5 x 
104 cfu/ml. The former inoculum follows the guideline provided by the British Society for 
Antimicrobial Chemotherapy (BSAC) and the latter was used previously by the group. 
Overnight cultures were diluted to the appropriate cell density using L-broth. Thiomarinol 
serial dilutions were prepared with L-broth containing 15 μg/ml tetracycline and 1 mM IPTG 
and made at one step higher concentrations than the final dilution range required, i.e. for 
final dilution range of 1, 2, 4, 8, 16, 32, 64, 128 μg/ml, master mixes of 2, 4, 8, 16, 32, 64, 128, 
256 μg/ml were prepared to compensate for the addition of an equal volume of inoculum. 
Likewise, tetracycline and IPTG concentrations were also doubled in the mixture. 75 μl of 
each thiomarinol dilution was distributed into 64-well flat bottom cell culture plates and 
inoculated with 75 μl of the diluted overnight cultures. The final methanol concentration in 
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each well was ≤ 5%. (v/v) The plates were incubated overnight at 37°C at 200 rpm and the 
optical density read at 620 nm using a plate reader. 
2.2.4 Generating and validating spontaneous mutants 
Overnight cultures of DH5α carrying pJH10, pJH10tmlM and pJH10mupM were sub-
cultured to a cell density of 5 x 105 cells/ml in 5 ml L-broth containing 15 μg/ml tetracycline 
and 32, 64 or 128 μg/ml thiomarinol. These cultures were incubated for 2 days,  at which 
point they were re-inoculated into fresh medium with the same tetracycline and thiomarinol 
concentrations and grown overnight in the same conditions. The overnight cultures were 
then streaked onto L-agar with 15 μg/ml tetracycline to yield single colonies. These single 
colonies (along with single colonies of the same strains untreated with thiomarinol as 
negative control) were then streaked with a toothpick from the centre of the L-agar plate to 
the edge in a repeated order of potential mutant followed by its wild-type parent strain. 8, 
64 or 128 μg of thiomarinol were impregnated onto 9 mm paper discs (Whatman, United 
Kingdom) and dried for at least 30 min before being carefully placed in the centre of the 
streaked L-agar plates. The plates were incubated overnight at 37°C and the mutants 
validated as “true mutants” if they grew closer to the thiomarinol disc than their wild-type 
strains. 
2.2.5 Generating UV-induced mutants 
Overnight cultures of GM2163 carrying pJH10mupM were sub-cultured in 5 ml L-
broth containing 15 μg/ml tetracycline and grown to an OD600nm of 0.4-0.6. The GM2163 
strain was chosen for this study because of its dam- and dcm- genotype, in which it is unable 
to methylate DNA and is consequently more prone to induced mutations. An aliquot of the 
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culture (2 ml) was then transferred into a glass petri dish and subjected to irradiation for up 
to 14 minutes in an UV light box. At 60 sec intervals, 100 μl of culture was collected, spread 
on L-agar containing 15 μg/ml tetracycline and wrapped in foil to prevent photoreactivation. 
The covered plates were incubated overnight at 37°C. Single colonies were then tested in the 
same thiomarinol streak test method outlined above. 
2.2.6 Preparation of competent bacteria 
DH5α bacteria were made competent by following the protocol of Cohen et al. 
(1972). Volumes of L-broth (5 ml) were inoculated with a single colony and incubated 
overnight at 37°C at 200 rpm, following which the culture was diluted 1:50 with fresh L-broth 
and grown again in the same conditions until an OD600nm 0.4-0.6. The bacteria were 
harvested at 5,000 xg for 7 min at 4°C and the supernatant discarded. The cell pellet was re-
suspended in 2 ml of 100 mM pre-chilled calcium chloride (CaCl2) per 5 ml of culture, 
vortexed and left on ice for 20 min before centrifugation at 5,000 xg for 7 min at 4 °C. The 
supernatant was again discarded and the cell pellet re-suspended gently in 0.5 ml of 100 mM 
pre-chilled CaCl2 per 5 ml culture. The competent cells were then stored at 4°C until future 
use. 
2.2.7 Plasmid DNA isolation and transformation 
Mutant plasmids pJH10mupA and pJH10mupM were prepared using Bioneer 
Accuprep® Plasmid Extraction Kit and transformed into competent cells by adding 5 μl of the 
plasmid extraction into 100 μl of competent cells. The mixture was gently mixed by tapping 
and left on ice for 30 min before heatshocking at 42°C for 2 min. 1 ml L-broth was then 
introduced and the suspension incubated at 37°C at 200 rpm for at least 1 hr. 50 μl of the 
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incubated suspension was spread on L-agar plates with 15 μg/ml tetracycline and incubated 
overnight at 37°C. 
2.2.8 Cloning mutant genes into new vectors 
Mutant plasmids prepared as outlined above were digested using EcoRI and XbaI to 
excise the mupM gene. The recipient vector pJH10 or pUC18 was also cut using the same 
restriction enzymes. For cloning mupM into pJH10, the vector (and insert) was isolated from 
the GM2163 strain, to ensure no dam methylation of the XbaI site. The DNA fragment was 
then ligated into new pJH10 or pUC18 vectors using the Quick LigationTM Kit (New England 
Labs) and introduced by transformation into DH5α as outlined above. 
2.2.9 DNA Sequencing 
All thiomarinol-resistant spontaneous and UV mupM mutants were sequenced in the 
high copy number pUC18 vector using the primers listed in Table 2.3. 
Table 2.3 Oligonucleotide primers used for checking the sequence of spontaneous and UV 
mupM mutants. 
Gene/Vector Sequence Checking Primer Source/Reference















2.3.1 MIC values are dependent on inoculum size 
The first part of the study was to determine the thiomarinol MIC values of wild-type 
DH5α and DH5α expressing thiomarinol resistant tmlM and mupirocin resistant mupM and 
mupA. Two final inoculum sizes were used as outlined in the methods. The larger inoculum 
(5 x 105 cfu/ml) was recommended by BSAC (http://www.bsac.org.uk) and the MIC against 
this cell density was at least two-fold higher than that against the lower inoculum of 5 x 104 
cfu/ml (Table 2.4). 
Table 2.4. Summary of thiomarinol MIC values*. 
Thiomarinol MIC (μg/ml)
Strain 5 x 10
4 
cfu/ml 5 x 10
5 
cfu/ml
DH5α pJH10 4-8 8-16
DH5α pJH10mupA 16-32 > 128
DH5α pJH10mupM 16-32 32-64
DH5α pJH10tmlM > 128 > 128  
*Two inoculum sizes were used, the larger recommended by BSAC. The smaller was also used in previous MIC studies by 
other lab colleagues and used in this study for comparative purposes. The MIC tests were repeated at least three individual 
times in duplicate. A variability of 2-fold was observed in some MIC values during repetition and was noted as such (e.g. 4-
8) instead of an average value. Values > 128 indicate that the MIC exceeds the tested concentration in this study. 
 
In addition to the slight discrepancies between MIC values, it was also observed that 
at the higher thiomarinol concentrations of 64 and 128 μg/ml (and this being before 
inoculation and incubation), the basal OD620nm values of the culture broth were more than 
double that of plain L-broth i.e. the cultures looked cloudy and less transparent. Therefore, 
un-inoculated L-broth containing various concentrations of thiomarinol was also included in 
the cell culture plates and the basal optical density deducted from all values after growth. At 
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zero thiomarinol concentration, the basal OD620nm was approximately 0.05. At a thiomarinol 
concentration of 128 µg/ml, OD620nm was approximately 0.4. 
2.3.2 mupM spontaneous mutants 
The overall strategy devised in this study to generate thiomarinol-resistant 
spontaneous and UV mutants is summarised in Figure 2.1.  
In the initial stages of generating spontaneous mutants, 5 ml L-broth cultures of 
DH5α (pJH10) and strains carrying mupA, mupM and tmlM were grown up to 3 days in 32 or 
64 µg/ml thiomarinol. The required days of incubation until detectable growth of the 











5x105 cells/ml inoculation + 5 
ml LB + Tet + 1 mM IPTG + 128 
µg/ml thiomarinol 
2 days incubation at 37°C
Streak out on LA + Tet
Streak test single colonies for 
thiomarinol resistance phenotype
Plasmid prep streak showing 
resistance phenotype
Transform and 
repeat streak test to 
check whether 
plasmid-mediated
Ligated, reclone into 
fresh pJH10 and 




into pUC18 for 
sequencing
2 ml of GM2163 pJH10 
mupM grown up to OD600nm
0.4-0.6 
100 µl every 60 seconds
Covered in tin foil and 
incubated overnight at 37 °C
UV treated
 





Table 2.5. Initial incubation period for generating spontaneous mutants in 32 and 64 μg/ml 
thiomarinol*. 
Strain Day 1 Day 2 Day3
DH5α pJH10 - + +
DH5α pJH10mupA +
DH5α pJH10mupM - +
DH5α pJH10tmlM +
DH5α pJH10 - - -
DH5α pJH10mupA - +















*+ indicates visible culture growth and – indicates no growth. 
 
As expected, DH5α (pJH10) failed to grow in 64 μg/ml thiomarinol, even after 3 days 
of incubation, while DH5α (pJH10tmlM) grew well after overnight incubation at both 
thiomarinol concentrations. DH5α (pJH10mupM), on the other hand, grew after 3 days of 
incubation but failed to grow overnight when re-inoculated into fresh L-broth with 
thiomarinol and tetracycline. This indicates that no “true mutants” have been obtained and 
suggests that the thiomarinol activity in the culture may significantly decrease by day 3 of 
incubation. Therefore, only cultures that grew after a maximum of 2 days incubation were 
progressed to the next stage of streaking to isolate potential thiomarinol-resistant mutants. 
mupA mutants grew overnight in 32 and 64 μg/ml of thiomarinol while mupM 
mutants only grew in 32 μg/ml thiomarinol. mupA and mupM cultures that initially grew in 
32 μg/ml thiomarinol were re-inoculated in the higher 64 μg/ml concentration to determine 
whether they could also grow at the higher concentration. Only mupA mutants were 
confirmed as growing well in the latter concentration. mupM mutants did not show signs of 
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visible growth. At this stage, mupM was selected to use for further optimisation of the 
methods and mupA left to follow up on once an effective protocol was determined. 
After several attempts to grow DH5α (pJH10mupM) cultures at thiomarinol 
concentrations of 32 and 64 μg/ml but with varying degrees of success, 128 μg/ml was 
tested to see if it could yield visible growth. Growth was observed after 2 days incubation for 
all tested cultures and this higher thiomarinol concentration was chosen for yielding all 
future mutants. Cultures that grew were streaked against discs impregnated with 64 μg 
thiomarinol as detailed in the Methods. A selection of representative streak test plates is 
shown in Figure 2.2 and Figure 2.3. The streak test indicated that some of the putative 
mutants were able to grow up to the thiomarinol impregnated discs while others failed to 
grow as close (Figure 2.2; Figure 2.3). The streaks that grew closest to the disc were taken for 
further experimentation to determine whether this thiomarinol resistance phenotype was 
firstly plasmid-mediated and secondly conferred by the mutated mupM gene and not other 
changes in the expression vector. 
The plasmids from the mutants of interest were isolated by standard procedure and 
transformed into new DH5α cells and found to still exhibit the same thiomarinol resistance 
phenotype on the streak test (Figure 2.4). The plasmid preparations from spontaneous 
mupM mutants obtained in a previous study performed by Claire Riemer (pJH10mupMO1 




Figure 2.2. Spontaneous mupM mutants identified on L-agar streak tests (circled in red). 
mupM mutant streaks are labelled “M1” and “M2”. DH5α (pJH10) streaks that were treated 
with thiomarinol are labelled “M”. Wild-type DH5α (pJH10) that were not treated are 
labelled “WT pJH10”. (A) DH5α (pJH10) cultures (M) were grown for 2 days in 128 µg/ml 
thiomarinol as a control before streaking, to ensure no alternative resistance phenotype 
arose from the empty vector. As expected, all M streaks grew to the same distance as the 
wild-type streaks. (B) M1 (circled in red) was streaked in triplicate and all streaks grew closer 




Figure 2.3. Spontaneous mupM mutants identified on L-agar streak tests (circled in red). 







Figure 2.4. Streak tests of transformed spontaneous mupM mutants (A) M1 and (B) M2. 
M1 results were replicated 5 times and M2 results replicated 6 times. 
 
 
Figure 2.5. Streak tests of transformed spontaneous mupM mutants yielded in this study 
(M1-4) and from a previous study by Claire Riemer (O1 and N1). (A and B) The streak test 
was repeated twice for each mutant. M1, 2 and 4 showed visible thiomarinol resistance 





The newly transformed DH5α bacteria were able to grow up to the thiomarinol disks 
in the simple plate tests, confirming that the resistance phenotype is plasmid-mediated. The 
mupM genes from these mutant plasmids were re-cloned into new pJH10 vector to 
determine whether the resistance phenotype is solely due to changes in the mupM gene. 
The genes were also inserted into pUC18, a high-copy number vector for sequencing to 
determine what changes, if any, had occurred in mupM. 
Streak tests were performed to determine whether the increased thiomarinol 
resistance conferred by the mutant plasmids is associated with the mupM gene. The results 
of these tests were disappointing; instead of the clear resistance indicated by the streaks 
growing close to the disc, as observed for the original mupM expression plasmids, none of 
the plasmids containing the re-cloned mupM gene showed any difference in growth to the 
wild-type thiomarinol-sensitive controls (Figure 2.6). A selection of original and cloned 
mutants was re-streaked against each other towards a larger 128 µg thiomarinol 





Figure 2.6. Thiomarinol resistance streak test for strains carrying pJH10 with re-cloned 
mupM fragments from mutants O1 and N1. Clones derived from O1 and N1 were replicated 




Figure 2.7. Repeat of streak tests comparing the original and re-cloned mutants mupM 
fragments against wild-type. (A and B) Repeat streak tests of N1 mutants. (C and D) Repeat 
streak tests of O1 mutants. Two original mutant streaks appear to display thiomarinol 
resistance (circled in red) but were deemed unreliable because the results are not 





A selection of the mutants was sequenced using the primers designed by Claire 
Riemer (Table 2.3). Sequencing results initially showed two amino acid changes in the MupM 
mutants, where Thr400 and Val886 were both changed to alanines. However, the same two 
changes were identified across all potential mutants, raising suspicion that these were not 
true mutations but perhaps represented errors in the original sequencing. The wild-type 
mupM cloned into pUC18 in this study, as well as a stock previously prepared by Elton 
Stephens were both sequenced and were found to have the same sequences as the putative 
mutants. This therefore confirmed that these “changes” were almost certain to be due to 
errors in the original sequencing or deposit process and Tony Haines has included these in 
the list of corrections that have been made to the reference sequence file. No further 
possible mutations were identified in the mupM sequence results. (A detailed discussion on 
these sequencing errors can be found in Chapter 4.) 
To ensure that there was no mistake concerning the resistance conferred by the 
mutant plasmids, an MIC test of thiomarinol was performed on the same selection of 
original and cloned mutants. The results indicated that bacteria carrying the original mutant 
plasmids had reduced susceptibility to thiomarinol than bacteria carrying the plasmids 
produced by re-cloning the mupM gene from the mutant plasmids (Figure 2.8). However, the 




























Figure 2.8. Thiomarinol MIC for DH5α (pJH10mupM) (Wild-Type) with original O1 and N1 
mutants and ligated O1 and N1 clones. No IPTG induction. The MIC values are an average of 
samples in triplicates. The MIC of wild-type was unexpected compared to previously 
obtained values and repeated later in this study. The original O1 and N1 mutants are two-
fold more tolerant to thiomarinol compared to the re-cloned genes. 
 
Following observation that the level of thiomarinol resistance differed between 
original and cloned mupM mutants, it was hypothesised that this increased resistance in the 
original mutants was conferred by the overexpression of mupM, caused by the changes in 
the vector instead of the mupM gene. If increase in resistance could be achieved by simple 
overexpression, then it would be possible for mutation to occur in the lac repressor which 
would result in misfolding and consequent de-repression. This would be more likely than 
site-specific mutation(s) occurring in the tac promoter, with associated increase in promoter 
strength and mupM expression, because the tac promoter already possesses almost perfect 
-10 and -35 regions. When the lac repressor activity was screened in a preliminary study by 
Claire Riemer using GFP, results suggested that the lac repressor was not functioning 
properly. A wild-type and mutant pJH10mupM were individually expressed in DH5α with 
another high copy number plasmid based on the vector pBR322 and carrying a gfp gene 
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under the control of a lac promoter. If the lac repressor on pJH10mupM was functioning 
correctly, it would also repress the lac promoter on pBR322 and prevent gfp expression. It 
was observed that both wild-type and mutant pJH10mupM cells produced GFP, indicating 
the vector to have leaky expression, with or without IPTG induction. 
To investigate this observation further, an MIC test with and without IPTG was 
performed using the original and cloned mutants. It was expected that the original mutants 
would have the same MIC values with or without IPTG because if the repressor was truly 
mutated, it would be unable to repress mupM expression in the presence or absence of IPTG. 
However, it was expected that in the presence of IPTG, the MIC results of the re-cloned 
mutants would shift up to the value of the original mutants’ because IPTG would de-repress 
LacI and allow an increase in mupM expression. Results were inconclusive, with one out of 
the two mutants demonstrating the hypothesised shift in MIC values and the other not 
















Figure 2.9. Thiomarinol MIC results comparing original mupM mutants with re-cloned 
genes with and without IPTG induction. The MIC values are an average of samples in 
triplicates. O1 and ligated O1 behaved as expected while N1 and its clone did not.  
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The unexpected low MIC value of wild-type DH5α (pJH10mupM) in Figure 2.8 was re-
visited and compared to the values obtained previously (Table 2.4). The significant decrease 
in MIC value led to suspicions that the strain used for generating spontaneous mutants was 
somehow not functioning as it used to. A fresh stock was streaked onto L-agar from the -
80°C stock and tested against mupirocin for their resistance phenotype. The new stock 
showed restored MIC values of 64 µg/ml thiomarinol, highlighting the importance in 
refreshing L-agar stocks of the strain – as continual re-streaking of the same stock may have 
caused the loss of the pJH10mupM plasmid. 
2.3.3 mupM UV mutants 
UV was chosen as a method for inducing an increased rate thiomarinol-resistance 
mutagenesis in the mupM gene. UV irradiation causes adjacent thymines to dimerise, which 
block DNA replication and induce error prone repair across the lesion. The mupM gene is 
rich in TT positions, despite its relatively high GC content of approximately 60 % and 
therefore UV mutagenesis was deemed a suitable method for generating thiomarinol-
resistant mutants (Figure 2.10).
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 E    A  T   P  R  I  L   A  D  L  K  S  S  G  L  L  F  K  Q  E 
1081  gaa gcc acg ccg cgc atc ctt gca gat ctg aag agc agt ggc ttg ctg ttc aag caa gaa 1140 
 Q   I   E  H  N   Y  P  H  C  W  R  C  D  N  P  L  I  Y  R  T 
1141  cag atc gaa cac aac tac cca cac tgc tgg cgt tgc gat aac cct ctg atc tat cgc acg 1200 
 V   E  S  W  F  I  R  A  S   A  L  R   E  Q  L  V  E  N  N  S 
1201  gta gag tcc tgg ttc atc cgc gcg tcg gcg ctg cgc gag cag ttg gtg gaa aac aac agc 1260 
 Q   V  N  W  V  P   E  H  V  K  E  G   R  F  G  D  W  I  R  N 
1261  cag gtc aac tgg gtg ccc gag cat gtg aag gaa gga cgc ttc ggg gac tgg atc cgt aat 1320 
 A   R  D  W  A  V  S  R  N  R  F  W  G  A  P  I  P  V  W  R 
1321  gcc cgc gat tgg gcg gtg tca cgc aac cgt ttc tgg ggt gcg ccc atc ccg gta tgg cgc 1380 
 C   D  Q  C  G  T  V  E   V  M  G  S   I  A  Q   I   E  A  R  S 
1381  tgt gac cag tgc ggc acc gtc gag gtg atg ggc agc atc gcg cag atc gaa gcg cgt tcc 1440 
 G    R  K  V  E  D  L  H  V  P  H  I  D  E  H  R  F  A  C  Q 
1441  ggg cgc aag gtc gaa gac ctg cat gtg cct cat atc gac gag cat cgt ttc gcc tgc cag 1500 
 C  C  E  G  T  M  S  R  V  T  G  V  F  D  C  W  F  E  S  G 
1501  tgc tgc gag ggc acc atg agt cgg gtg acc ggt gtc ttc gat tgc tgg ttc gaa tcg ggc 1560 
 A   M  P  F  A  S  R  H  Y  P   F  E  N  K  Q   E  F  E  Q  T 
1561  gca atg ccg ttc gcc agt cgg cac tac ccg ttc gaa aac aag cag gag ttc gaa cag act 1620 
 F   P  A  D  F  I  V  E  Y  L  A  Q  T  R  G  W  F  Y  T  M 
1621  ttc cct gcc gac ttc atc gtc gag tac ctt gcg cag acc cgc ggt tgg ttc tac acg atg 1680 
 M  V   I  S  T  G  C  F  E  Q  N  P  F  K  N   A  M  C  H  G 
1681  atg gtc atc tcc acc ggc tgt ttc gag cag aac ccc ttc aag aac gcc atg tgc cac ggg 1740 
 V   I  L  A  K   D  G  R  K  M  S  K  R   L  K  N  Y  P   N   P 
1741  gtg att ctg gcc aag gac ggt cgc aag atg tcc aag cgc ctg aag aac tac ccc aac ccg 1800 
 M  D  L  M  Q   T  H  G  S  D  A  L  R  V  A  L  L  A  S  P 
1801  atg gat ctc atg cag acc cac ggt tcg gac gcc ttg cgc gtg gcc ttg ctg gca tcg ccg 1860 
 V  C  K   G  E   D   I  K  F  S  E  E   S  V  R   D  V  V  R  R 
1861  gtc tgc aag gga gag gac atc aag ttc agt gaa gag tcg gtg cgc gac gtg gtg cgc cgc 1920 
 Y  H  L  L  F  W  N  C  L  Q  F  Y  K  T  F  T  E   I  D  Q 
1921  tac cat ctg ctg ttc tgg aat tgc ctg cag ttc tat aaa acg ttc acc gaa atc gac cag 1980 
 F  S  P  S  G   D  P  G  Q  P  P  D  N  V  L  D  H  Y  L  L 
1981  ttc agt cct tcc ggc gac cct ggc cag ccc ccg gac aat gtc ctg gac cac tac ttg ttg 2040 
 H   E  L  A  A   L  E  S  D  I  K  M  W  M  E  S  L  D  F  S 
2041  cat gag ttg gcg gcg ctg gaa tcg gat atc aag atg tgg atg gag tct ctg gat ttt tcc 2100 
 K    I  Y  S  R  I  E  V  F  I  N  V  L  S  T  W  H  L  R  L 
2101  aag atc tat tcg cgt atc gaa gtg ttc atc aac gtc ttg agt acc tgg cac ctg cgc ttg 2160 
 N   K   A  R  I  W  R   D  G  L  D  D  D   K  R  Q  C  Y  E  V 
2161  aac aag gca cgc atc tgg cgc gat ggc ctg gat gac gac aag cgc cag tgc tat gaa gtg 2220 
 L   H  Y  A  L  S N  F  A  R  L  L  A  P  F  M  P  F  L  A 
2221  ctg cac tac gcg tta tct aat ttt gct cgt ctg ctg gcg ccc ttc atg ccg ttt ctg gct 2280 
 E    A  V  Y  T  E   L  G  Y  A  D  S  V  H  L  Q  D  W  P  S 
2281  gag gcg gtc tac acc gaa ctg ggg tat gcc gac tct gtg cac ctg caa gac tgg ccg agc 2340 
 I    D  R  Q  Y  L  S  Y  E  L  A  D  E  M  S  S  L  R  N  L 
2341  atc gat cgc cag tac ctg tcg tac gag ttg gcc gat gaa atg agt agc ctg cgt aac ttg 2400 
 I    A  S  V  C  N  V  R  E  T  N  G  V  S  Q  K  F  P  L  R 
2401  atc gcc agc gtg tgc aat gtg cgc gaa acc aat ggg gtt tcg cag aag ttt ccg ttg cgc 2460 
 S    I  R  V  A  G   I  E  Q   A  V  L  E  R  Y  A  Q  F  L  E 
2461  agc att cgc gtc gcg ggt atc gaa cag gcc gta ctg gag cgc tat gca cag ttc ctc gag 2520 
 E    E  L  N  V  K   Q  V  Q  W  A  A  D   A  D  E  W  A   Q  P 
2521  gag gaa ctc aac gtc aag cag gtc cag tgg gcc gcc gat gcc gac gag tgg gcg cag ccc 2580 
 V   V  V  L  I  F  S  L  L  G  K  R  L  G   P  A  M  K   A  V 
2581  gtg gtg gta ttg atc ttc tcc ttg ctc ggc aag cga ctg ggc ccg gcg atg aag gcg gtc 2640 
 T    T  A  V  K  V  G  E  Y  V   I  D  E   Q  G  G   L  V  A  A 
2641  acc aca gcg gtg aag gtt gga gag tat gta atc gat gaa cag ggg ggg ctg gtt gcc gca 2700 
 G    Q  T   I  Q  P  H  E  F  E  R  R   L  T  V  R  D  T   L  N 
2701  ggg cag acg atc cag ccc cac gag ttc gag cgt cgc ctg acc gtg cgt gac acg ctc aat 2760 
 N   V  G   I  V  E  N  M  V  V  W  L  D  L  D  I   D  A  P  L 
2761  aac gtc ggg att gtc gag aac atg gtg gtc tgg ctg gac ttg gac atc gat gcc ccg ctc 2820 
 K   R   E  G   A  V  R  E  L  N  R  R   L  Q  D   L  R  K  K   A 
2821  aag cgc gaa ggc gcc gta cgt gag ctc aac cgc agg ctg caa gac ctg cgc aag aaa gcc 2880 
 K   L   G  Y  T  E   K  V  D   I  A  V  L  G   G  A  Y  V  D  E 
2881  aag ctg ggc tac acc gaa aaa gtc gac atc gcc gtg ctc ggc ggt gcc tat gtc gat gag 2940 
 I   L   V  H  H  E  D  W  L  K   S  Q  L  L  V  Q  S  L  L  R 
2941  atc ctg gtg cac cac gag gac tgg ctc aag agc cag tta ctg gtc cag agc ttg ttg cgc 3000 
 S   D  L  E  A   P  L   A  V  D  E   V  E  L  P   E  G  D  P  V 
3001  agc gat ctt gag gcg ccg ctg gca gtg gac gaa gtc gag ctg ccc gag ggc gac cct gtg 3060 
 R   I  Q  L  R  R  S   V  L  A  * 
3061  cgt att caa ctg cgc cgt agc gta ctg gcc tga 3093 
 M   S  T  E   G  S  G   P  V  R F  P  A   M  E  D  A  V  L  E 
1 atg agt acg gaa gga agt ggg ccg gtt aga ttt ccg gca atg gaa gat gcg gta ctc gag 60 
 R   W  E  K   E  K   T  F  E   Q  S  I  S   A  R  E  G  K  P  V 
61 cgg tgg gaa aaa gaa aag acg ttc gag caa tcc atc agc gcc cgt gag ggt aag ccg gtg 120 
 Y  V  F  Y  D  G  P  P  F  A  T  G  L  P   H  Y  G  H  I  L 
121 tac gta ttt tat gac ggc ccg ccg ttt gct acc ggc ctg ccg cac tac ggc cat att ctg 180 
 T   S  Y  I  K  D   V  I  P  R  Y   Q  T  M  L  G  K  Q  V  P 
181 act tcc tat atc aaa gac gtc ata ccg cgt tac cag acg atg ctc ggc aaa cag gtc cca 240 
 R   R  W  G  W  D  C  H  G  L  P  V  E  F  E  V  E  K   A  M 
241 cgc cgc tgg ggc tgg gat tgc cac ggc ttg ccg gtg gag ttc gaa gtc gag aag gcc atg 300 
 G   F  K  S  K  R  D   I  L  E  F  G  V  E  Q  F  N  D   E  C 
301 ggc ttc aag tcc aag cgc gat att ctc gag ttt ggc gtg gag cag ttc aac gac gag tgc 360 
 R   E   L  V  L  K  Y   A  D  D  W  R  G  F V  N  R  M  G  R 
361  aga gag ctg gtg ctc aag tac gcc gat gac tgg cgt ggc ttt gtc aac cgg atg ggc cgt 420 
 W  V  D  F  D  G  A  Y  K  T  M  D  N  D  Y  M  E  S  V  L 
421  tgg gtc gat ttc gat ggc gcc tac aag acc atg gat aac gac tac atg gag tcg gtg ctg 480 
 W  G  F  K  T  L  H  D  K   G  H  V  Y  E  G  G   K  I  V  P 
481  tgg ggc ttt aaa acc ttg cat gac aag ggg cat gtc tac gag ggc ggc aag atc gtg cct 540 
 Y  C   V  R  C  Q  T  V  L  S  N  F  E  A  R  L   D  D  A  F 
541  tac tgc gtg cgt tgc cag acg gtg ttg tcg aat ttc gag gcg cgc ctg gac gac gcc ttc 600 
 R    P  R  R  D  M  S  A  Y  V  K  F  R  Q  Q  D  R   P  D  T 
601  cgc ccg cgc cgc gat atg tcc gcc tat gtc aag ttc agg caa caa gac cgc ccg gac act 660 
 F  F  L  A  W  T  T  T   P  W  T  L  P  A  N   V  A  L  A  V 
661  ttc ttc ctg gca tgg acc acc aca ccc tgg acg ttg cct gcc aac gtc gca ctg gcc gtg 720 
 A    A  D  E  N  Y  V  C  I  E   H  G   E  E  R  L  W  L  A   E 
721  gcc gcc gat gaa aac tat gtg tgc atc gag cac ggc gaa gag cgc cta tgg ctg gcc gaa 780 
 G   C  L  G  G  L  F  D  E  P  V   I  L  E  R  C  T   G  A  E 
781  ggt tgc ctg ggc ggc ttg ttc gat gag ccg gtg atc ctg gaa cgc tgt acc ggc gca gag 840 
 L   A  G  L  R  Y  L  P  V  V   G  E  V   I  D  A  S  A  H  R 
841  ctg gct ggg ctg cgt tat ctg ccg gtg gtc ggc gag gtg atc gat gcc tcg gcc cat cgc 900 
 V   V  T   A  D  F  V  Q  M  G  D  G  S  G  I  V  H  I  A  P 
901  gtg gtc acc gcc gac ttc gta cag atg ggc gat ggc tct ggc att gtc cac att gcc cct 960 
 A   F  G  E   D  D  A  L  L  G   Q  Q  Y  E  L  P  A  P  N  P 
961  gcg ttc ggt gag gac gac gcc ttg ctc ggg cag caa tac gag ttg cct gca cct aac cct 1020 
 V   R  D  D  G  T  F  S  D  A  V  A  Q  Y  A  G  Q  N  I  F 
1021  gtt cgc gac gac ggt acc ttt tcc gat gcg gtg gcg cag tat gcc ggg cag aat att ttc 1080  
Figure 2.10. Thymine-Thymine positions in mupM DNA sequence and its corresponding amino acid residues (both highlighted in 
yellow). Adenine-Adenine positions have also been highlighted in blue as they correspond to Thymine-Thymine positions on the other 
DNA strand. EMBOSS Sixpack used to translate DNA sequence to amino acid sequence. The two highly conserved HYGH and KMSKR 





Preliminary experiments were performed by Claire Riemer to find the optimal UV 
dosage for generating mutants. High, intermediate and low UV intensity sources were used 
(using a gel imager, UV lightbox and gel cutting board respectively) and the cell death in 1 ml 
L-broth cultures monitored at 30 second intervals for up 12 minutes. The UV lightbox was 
deemed most appropriate for generating mutants (with 50% death rate at 10 minutes 
irradiation). Due to time constraints, no further tests were performed on the mutants. 
The protocol outlined in the Methods for generating UV mutants was thus based on 
Claire Riemer’s preliminary results. Sampling was altered from 30 second intervals to 60, 
reducing the number of samples handled at the increased irradiation period of 14 minutes. 
Confluent growth was observed at up to 3 minutes irradiation and decreasing numbers of 
visible single colonies between 4 to 14 minutes. Single colonies were chosen from time 
intervals of 8 minutes and above and tested for thiomarinol resistance phenotype by streak 
testing. 
Unfortunately, the same results were observed with the mupM mutants irradiated 
with UV as with the spontaneous mutants (Figure 2.11; Figure 2.12). Although the original 
mutants from the culture irradiated with UV displayed thiomarinol resistance in the streak 
test, sequencing results indicated no changes to be found in the mupM gene. The UV 
mutants were not checked for plasmid and gene-mediated resistance phenotype as a time 
saving exercise. Instead, the potential mutant mupM genes were directly cloned into pUC18 




Figure 2.11. Streak tests of potential mutants obtained from UV mutagenesis Trial 1. M1 
taken at 8 min UV interval and M4 taken at 12 min UV interval were selected for sequencing 





Figure 2.12. Streak tests of potential mutants yielded from UV mutagenesis. M1 taken at 8 
min and 10 min UV intervals and M2 taken at 13 min and 14 min UV intervals were selected 




This study aimed to firstly identify the MIC of thiomarinol against wild-type DH5α 
carrying the empty pJH10 vector, pJH10mupM, pJH10mupA and pJH10tmlM. Secondly, it 
attempted to generate thiomarinol-resistant mupM mutants by spontaneous and UV 
mutagenesis. By sequencing these mutants, it was hoped that the amino acids responsible 
for this resistance phenotype would be highlighted and elucidate the site of pyrrothine 
binding for increased binding affinity and a mechanism for thiomarinol potency.  
2.4.1 Assessing MIC method for mutant characterisation 
Using two different inoculum sizes for the MIC test has shown that cell density 
affects overall MICs. Relatively, a higher cell density would require a higher concentration of 
thiomarinol to achieve inhibition of growth. Therefore, future MIC values taken from various 
studies and literature should only be compared once their inoculum sizes have been 
determined to be the same. In this study, the MIC values identified from the higher inoculum 
(recommended by BSAC) was selected over the lower inoculum, as following a standard 
would allow future comparisons with other MIC values. 
2.4.2 Thiomarinol resistance conferred by mupM overexpression 
The hypothesis that thiomarinol tolerance can be conferred by the overexpression of 
mupM is consistent with the data but needs further tests to confirm whether the mutations 
are indeed in the tac promoter or lac repressor. One of the methods to consider is using PCR 
to amplify the promoter and repressor regions and to sequence them for identification of 
any mutations. Other methods would be to measure the gene expression of mupM by 
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measuring the level of mupM mRNA by RT-PCR, Northern blotting or using a reporter gene 
to measure mupM expression. 
Alternatively, a simpler method would have been to include a key control DH5α 
strain expressing its native ileS in pJH10 in the initial MIC tests. If the MIC of thiomarinol 
increased against this control strain compared to DH5α pJH10, it would suggest that 
overexpression of IleS is a mechanism of thiomarinol resistance. 
Induced antibiotic resistance caused by overexpression of the target is a well-
documented phenomenon, as discussed in Chapter 1. A recent study found sub-lethal 
concentrations of methionyl-tRNA synthetase inhibitors to induce resistance in the 
protozoan Trypanosoma brucei by overexpression of the target (Ranade et al., 2013). 
Overexpression was shown by the higher levels of MetRS mRNA on Northern blots and 
increased gene expression on Southern blots. Interestingly, overexpression came at a fitness 
cost to the parasites and no mutations were observed on the MetRS enzyme – similar to the 
results obtained in this study, although fitness cost was not considered. It will be of great 
interest to continue the work carried out in this study to confirm whether thiomarinol 
resistance is truly conferred by overexpression of the target enzyme. 
2.4.3 Spontaneous and UV mutants may be difficult to obtain 
Results from this study indicate thiomarinol resistance may not arise frequently by 
spontaneous and UV mutagenesis causing changes in the structural gene. In terms of 
resistance developing in the clinical setting after thiomarinol usage, this is an advantage, as 
drugs that yield resistant microorganisms too quickly have a limited shelf-life. However, the 
mutagenesis method needs to be revised to prove that resistance is difficult to obtain.  
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Investigation of the available literature suggests that sub-inhibitory (SI) 
concentrations of antibiotics are effective in selecting for antibiotic tolerant mutants 
(Baquero, 2001; Girgis et al., 2009). This would make sense, as in the environment and even 
in clinical settings, microorganisms are constantly subjected to SI concentrations of various 
bioactive compounds produced by other living organisms. In the clinical context, antibiotics 
that are administered to patients enter the body and form a concentration gradient, before 
reaching the effective dose. At times, this effective dose is never reached, with patients 
neglecting to finish their prescribed course or limitations in the drugs to access certain 
tissues (Kohanski et al., 2010). Clinical resistance is thought to develop in the same gradual 
manner, with some bacteria surviving the initial antibiotic exposure and allowing the 
population to accumulate enough low level mutations that lead to higher tolerance and 
finally, clinically significant high level resistance (Baquero, 2001; Drlica and Zhao, 2007). Low 
level selection pressure appears to be key in allowing changes that are beneficial but low in 
fitness cost. 
However, SI concentrations of bactericidal antibiotics have been shown to cause a 
wide range of responses other than resistance to that particular selection pressure. Kohanski 
et al. (2010) found that sub-lethal levels of antibiotics can act as mutagens and affect a 
variety of drug targets, causing multidrug resistance and not always including resistance 
against the antibiotics used. Other studies have observed more general cellular responses 
such as the production of reactive oxygen species (ROS) that directly damage DNA and cause 
mutation (Demple and Harrison, 1994; Freiberg et al., 2004; Imlay and Linn, 1988; Kohanski 
et al., 2010). The literature highlights the importance and advantages of understanding SI 
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antibiotic concentrations in relation to not only tolerance and resistance but also to the 
effect they have on whole genomes. 
A popular approach to understanding the mode of action of antibiotics (and how 
organisms confer resistance) is by profiling whole genome expression at an mRNA and/or 
protein level (Brazas and Hancock, 2005; Freiberg et al., 2004). For a snapshot of a bacterial 
transcriptome, DNA microarray is commonly used. Microarray surfaces (such as chips or 
beads) are fixed with DNA probes for every open reading frame of the organism of interest, 
so for the purpose of this study, they could be set up from P. fluorescens. The microorganism 
can then be separately grown at sub-inhibitory concentrations of thiomarinol and its mRNA 
purified to generate cDNA using reverse transcriptase. The cDNA is then labelled, such as 
with fluorescence dye, and hybridised to the microarray. The fluorescence or signal detected 
can be analysed to map out the whole genome response of P. fluorescens to thiomarinol, 
including any changes in expression of mupM. 
For proteomic analysis, two-dimensional gel electrophoresis (2-DE) is commonly used 
to separate proteins, first by their isoelectric point (i.e. the pH at which the protein has no 
net electrical charge) and second by their protein mass. The first step, called isoelectric 
focusing (IEF), utilises a pH gradient to separate proteins. An electric potential is applied 
across the gel and proteins accumulate at their isoelectric point. In the second step, the 
proteins are denatured and bound to negatively charged SDS molecules and separated by 
application of again an electric potential by their mass but at a 90 degree angle from the first 
step. The gel is then stained either by silver or Coomassie Brilliant Blue. Therefore, a 
proteomic analysis of P. fluorescens can be performed to also determine whether MupM is 
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over-expressed during thiomarinol exposure and whether any other proteins are up-
regulated for resistance/tolerance to the antibiotic.  
It would be of interest to compare various bacterial transcriptome and proteome 
profiles in response to thiomarinol and mupirocin, as these techniques may elucidate 
whether any targets other than IleS are expressed and/or upregulated by thiomarinol but 
perhaps not mupirocin. This technique could also, in theory, be used to elucidate the cause 
of the loss in thiomarinol resistance phenotype when mutant mupM genes in this study were 
cloned into fresh pJH10 vectors. The transcriptome analysis may elucidate whether this was 
due to a defective LacI in the construct or perhaps other changes in the host DH5α bacterial 
gene expression.  
In this study, thiomarinol concentrations of 32, 64 and 128 µg/ml were used in 
attempt to yield resistant mutants. The lower concentrations were initially tested but did not 
always yield growth in the cultures after 2 days of incubation. The highest concentration, on 
the other hand, guaranteed growth after 2 days and was chosen as the set concentration for 
yielding spontaneous mutants. However, 128 µg/ml is approximately 2 to 4-fold greater in 
concentration than the MIC against DH5α (pJH10mupM) (32-64 µg/ml). It is plausible that 
many of the cultures that grew in this high thiomarinol concentration for two days but failed 
to grow at subsequent inoculation onto L-agar with the thiomarinol impregnated discs were 
persister cells. Persisters were first noted by Bigger in 1944 and have since then been linked 
to high tolerance levels against antibiotics, although they are non-replicating, not resistant 
to antibiotics and do not exhibit high MIC values (Keren et al., 2004; Kester and Fortune, 
2014). This, however, does not provide an explanation for the mutants that maintained their 
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resistance phenotype in the original streak tests but not when the mupM genes were cloned 
into fresh pJH10 vectors.  
This study’s use of high thiomarinol concentrations (> MIC) has failed to generate 
true mupM mutants. Although the use of SI concentrations appears to generate genome-
wide mutations other than solely those related to the primary target(s), it is undeniable that 
the SI methodology also yields true resistant mutants. SI levels of thiomarinol may be the 
better choice for selecting mutations in mupM, with gradual incremental increases in the 
antibiotic concentration as low tolerance accumulates in the population (Ranade et al., 
2013). Alternatively, direct approaches such as mutagenic PCR could also be beneficial and 
time efficient, and allow mutations to be focused on only the structural gene (Cadwell and 
Joyce, 1994). 
Other methods to consider are using pre-existing mupirocin resistant mutants to 
derive thiomarinol resistant mutants or changing the heterologous host of the plasmids in 
this study from E. coli to S. aureus. Mupirocin resistant S. aureus IleS mutants were 
spontaneously selected by Hurdle et al. (2004) using four times the MIC of mupirocin. These 
mutants could have been tested for thiomarinol resistance and/or used as a template for 
selecting thiomarinol resistant mutants by passaging with gradually increasing antibiotic 
concentrations. S. aureus may have also been the better host for the plasmids used in this 
study instead of E. coli, as MIC tests show the former to be more susceptible to thiomarinol 
than the latter (Table 1.5). The difference in susceptibility is yet to be understood but more 
efficient efflux of the antibiotic in E. coli may play a role in its reduced susceptibility. 
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Therefore, using S. aureus instead of E. coli may avoid the possible complications of efflux 
and show clearer thiomarinol resistance phenotypes of the mutated IleSs. 
In summary, this study has highlighted the importance of selecting the optimal 
inoculum size and antibiotic concentration for generating antibiotic resistant mutants. It 
would be of interest to optimise the methodology with the above suggestions and to 
elucidate the sites of MupM that are important for its mupirocin resistance phenotype, as 
well as its sensitivity against thiomarinol. Once optimised using mupM, it would also be of 
interest to resume the same work on mupA as an additional means to understand if the sites 












3  IDENTIFYING AMINO ACID RESIDUES OF INTEREST ON 
MUPM AND TMLM USING STRUCTURAL MODELLING 
3.1 Introduction 
Thiomarinols (A-G) are a group of hybrid polyketide antibiotics produced by the 
marine bacterium Pseudoalteromonas rava sp. nov. SANK 73390. As discussed in Chapter 1, 
they share structural similarity to mupirocin (or pseudomonic acid A) but have an additional 
pyrrothine moiety. While mupirocin is widely used in hospitals, thiomarinol is not clinically 
available but has demonstrated activity against a range of Gram-positive and negative 
organisms (Shiozawa et al., 1993). Understanding what potentiates the activity of 
thiomarinol compared to mupirocin is of interest, as it may elucidate ways to synthesise 
better analogues of mupirocin and to counter the rising trend of mupirocin resistance in the 
clinical setting. 
In this study, the mode of action of thiomarinol is investigated based on what is 
already known about mupirocin. The target of mupirocin is the isoleucyl-tRNA synthetase 
(IleS), a Class I aminoacyl-tRNA synthetase characterised by its Rossman fold catalytic 
domain and conserved HIGH and KMSKS signature motifs. Structural studies of 
Staphylococcus aureus mupirocin-sensitive IleS complexed with mupirocin has revealed that 
the antibiotic targets this catalytic domain; as discussed in Chapter 1, the C14 end of the 
monic acid imitates the isoleucine side chain, the pyran ring sits where ATP normally binds 
and the 9-hydroxynonanoic acid stabilizes the entire complex via the  
65 
 
carboxylate tail binding to the second lysine of the KMSKS motif (Nakama et al., 2001; Silvian 
et al., 1999). 
When organisms such as S. aureus and Escherichia coli gain a single amino acid 
change in the Rossman fold (valine to phenylalanine V588F and leucine to phenylalanine 
L594F respectively), they develop low level mupirocin resistance (Antonio et al., 2002; 
Yanagisawa et al., 1994). With the Rossman fold altered, the 9-hydroxynonanoic acid of 
mupirocin can no longer bind and stabilise the antibiotic, allowing the organism to gain low 
level resistance at a low fitness cost. On the contrary, high level mupirocin resistance has 
been observed to be conferred by the presence of IleSs that are similar to the eukaryotic 
enzymes, likely acquired by horizontal gene transfer. For example, the mupirocin-producing 
strain Pseudomonas fluorescens has been shown to express two different chromosomal IleSs, 
one of which is similar to eukaryotic IleSs called MupM (El-Sayed et al., 2003; Yanagisawa 
and Kawakami, 2003). 
Thiomarinol is also proposed to target IleS because of its structural similarity to 
mupirocin but also from observation that E. coli becomes highly thiomarinol resistant when 
it expresses the thiomarinol resistant IleS gene tmlM from P. rava (Fukuda et al., 2011). The 
pyrrothine moiety is of particular interest, as a previous study observed marinolic acid 
(thiomarinol without the pyrrothine moiety) to be less active against S. aureus than 
mupirocin, indicating pyrrothine to be important for the increased potency of thiomarinol 
(Fukuda et al., 2011). Although yet to be determined experimentally, structural similarity 
between the two antibiotics suggests that thiomarinol should bind to IleS in the same 
orientation as mupirocin.  
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Based on the above proposal, this study homology modelled MupM and TmlM using 
the solved crystal structure of mupirocin-sensitive S. aureus IleS complexed with mupirocin 
(PDB: 1QU2) as a template. The aim was to use these models to investigate the structural 
basis for thiomarinol’s potency via the hypothesised enhanced binding affinity. In addition, 
the residues on the active site that may constitute the resistance phenotype of TmlM against 
thiomarinol was also investigated. 
3.2 Materials and Methods 
3.2.1 Homology Modelling MupM, MupA and TmlM 
Template structures were selected by performing BLAST searches of MupM, MupA 
and TmlM sequences individually against solved protein structures in the PDB, using the web 
interface at the NCBI with default settings (http://www.ncbi.nlm.nih.gov/). The best 
template candidate was selected by choosing the structure with the lowest E-value, which 
represents the number of PDB hits expected by chance. The template structure was also 
required to have a high resolution of ≤ 2.5Å. An IleS structure from S. aureus complexed with 
isoleucyl-tRNA (tRNAIle) and mupirocin (PDB: 1QU2) was chosen as the best template for all 
three proteins. The template, query (MupM, MupA and TmlM) and homologous sequences 
were automatically aligned using ClustalX (Larkin et al., 2007) and further aligned manually 
using SeaView (Gouy et al., 2010). The secondary structures of the query sequences were 
obtained by the DSSP algorithm and taken into account during manual alignment (Kabsch 
and Sander, 1983). 
Once the chosen templates were deemed appropriate and the sequences all aligned, 
the alignments and structure were read by Modeller (Eswar et al., 2006) and 25 models 
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generated for evaluation. The best model was chosen based on its discrete optimised 
protein energy (DOPE) (Shen and Sali, 2006) and genetic algorithm (GA) score (John and Sali, 
2003; Melo et al., 2002). The DOPE score indicates the threading potential or the energetic 
measure between two amino acids next to each other and the more negative the value, the 
better. The GA score assesses the overall fold quality of the model and a value closer to 1 is 
deemed more native-like than a value closer to 0. Therefore, the model with the lowest 
DOPE and highest GA score was chosen. 
3.2.2 Active site characterisation 
The Builder function on PyMOL, Version 1.7 was used to modify the mupirocin 
structure from the PDB structure 1QU2 by adding the pyrrothine moiety to generate a 
thiomarinol A structure. UCSF Chimera (Pettersen et al., 2004) was then used to energy-
minimise the newly drawn thiomarinol structure (complexed in IleS) using the Minimise 
Structure function (with default Amber and Antechamber force field parameters). This 
function is intended for cleaning up small molecule structures and improves localised 
interactions within larger systems; hence it is appropriate for resolving minimal distortions in 
the drawn pyrrothine ring. 
Pocket v.2 (Chen and Lai, 2006) was used to derive pharmacophore models (that is, 
key interaction sites) of 1QU2, MupM and TmlM respectively. Mupirocin and thiomarinol 
were used separately as the known ligand for each of the three structures, giving six results 
in total. The binding features of each protein were then compared against each other. 
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3.2.3 Identifying amino acid residues of interest 
The LIGPLOT programme (Wallace et al., 1995) was used as the starting point for 
identifying amino acids that may be of interest in protein-ligand interactions of 1QU2. This 
programme automatically generates schematic 2D diagrams of protein-ligand complexes and 
highlights the intermolecular interactions which include hydrogen bonds, hydrophobic 
interactions and atom accessibility to solvent (Wallace et al., 1995). Any interesting residues 
highlighted by LIGPLOT were further studied on the 3D structural models. 
The Evolutionary Trace (ET) programme (Lichtarge et al., 1996) was also utilised to 
identify functional amino acid residues. This programme was developed to provide an 
alternative to experimental mutagenesis for characterising protein functional sites. It 
analyses evolutionary patterns in amino acid sequences, i.e. their conservation within clades, 
and ranks every residue in the query protein’s sequence by their likely importance for 
structure and function. The ET results, in conjunction with the LIGPLOT results allowed 
better analysis of the amino acid residues of interest. 
Finally, PyMOL was used to identify residues within an 8 Å radius of the mupirocin 
ligand. Residues of potential interest were selected manually by comparing the residues 
between 1QU2, MupM and TmlM. 
3.3 Results 
3.3.1 Pharmacophore models of 1QU2, MupM and TmlM 
Pocket v.2 relies on a known ligand in the query protein to help with the 
identification of crucial features in the active site (Chen and Lai, 2006). Since 1QU2 
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complexed with mupirocin was used as the template during the homology modelling of 
MupM and TmlM, mupirocin was used as the ligand of choice for the running of Pocket v.2 
for the latter proteins. To ensure that the results from the programme are not sensitive to 
the choice of ligand used, i.e. the computer algorithm and its implementation are robust, 
MupM was run twice with mupirocin and thiomarinol individually (Figure 3.1). As hoped, the 
models generated were similar, indicating that the use of mupirocin as the known ligand 
should not influence the results (Figure 3.2). 
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MupM with mupirocin MupM with thiomarinol  
Figure 3.1. Close-up of MupM structure complexed with (A) mupirocin from PDB structure 
1QU2 and (B) thiomarinol generated using PyMOL. The thiomarinol structure is sub-optimal 
with no reliable parameters available to describe the peptide-linked pyrrothine moiety. It 
was intended for geometric speculation as to where the pyrrothine moiety may interact with 
other residues on the protein. 
 
MupM with mupirocin MupM with thiomarinol  
Figure 3.2. Pocket v.2 results of MupM complexed with (A) mupirocin and (B) thiomarinol. 
Both pharmacophore models are similar to each other, including the hydrophobic patch 
highlighted by the red circles. The three differently coloured areas represent the following: 
light blue = hydrophobic sites; dark blue = hydrogen-bond donor sites; red = hydrogen-bond 
acceptor sites. All these sites are created by single or multiple amino acid residues on the 
query enzyme (in this case MupM). (B) Thiomarinol is depicted with hydrogens while 
mupirocin is not. This is because the hydrogens were placed on the sub-optimal thiomarinol 





The pharmacophore profiles of mupirocin-sensitive IleS 1QU2 and mupirocin-
resistant MupM were more similar to each other than to that of thiomarinol-resistant TmlM 
(Figure 3.3). TmlM appears to be much more hydrophobic around the fatty acid binding site. 
General similarity of MupM to 1QU2 was supported by the results of running a BLAST 
analysis with TmlM, which showed its closer homology to mammalian IleS from rat, mouse 
and human than MupM, which showed closer homology to bacterial IleS (Figure 3.4). 
TmlM with mupirocin MupM with mupirocin 1QU2 with mupirocin  
Figure 3.3. Pocket v.2 results of (A) 1QU2, (B) MupM and (C) TmlM all complexed with 
mupirocin (in purple). The hydrophobic patches of interest are highlighted by the red circles. 
Colour scheme as described above. 
 





Figure 3.4. Snapshot of BLAST results of (A) MupM and (B) TmlM. 
 
The most striking characteristic of these profiles was the hydrophobic patch at the 9-
hydroxynonanoic tail of mupirocin for all three IleSs. This hydrophobic region appears 
geometrically in a place where the pyrrothine moiety can interact with the KMSKS loop 
(Figure 3.2 and Figure 3.3). The two amino acid residues responsible for this hydrophobicity 
were the aliphatic parts of lysine and arginine in MupM and TmlM, and only lysine in 1QU2 
(Figure 3.5). This lysine is the second lysine in the KMSKS motif in Class I aminoacyl-tRNA 
synthetases and associated with ATP hydrolysis and/or tRNA stabilisation in E. coli IleS 













Figure 3.5. The aliphatic chains of lysine and/or arginine that are responsible for the 
hydrophobic patches (highlighted in red circles) in (A) 1QU2, (B) MupM and (C) TmlM. 








Figure 3.6. KMSKS loop highlighted on 1QU2 in (A) cartoon and (B) sticks format. The 
second lysine (in yellow) is the critical residue for ATP interaction. 
 
In addition to the possibility of the pyrrothine binding to this hydrophobic patch, the 
moiety also has the capacity to hydrogen bond (subject to distance) with the residues on the 
KMSKS loop of the susceptible IleS enzyme. The pyrrothine has two amide groups, one in the 
heterocycle and one linking the moiety to the rest of the thiomarinol structure. Each amide 
has the potential to accept a hydrogen bond via the carbonyl group (C=O) and donate one 
A B 
A B C 
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via the amine group (NH). The KMSKS residues on the loop appear unburied and likely to 
interact with the surrounding solvent (Figure 3.6) and therefore, the amide groups on the 
pyrrothine may interact with the side chains as well as the backbones of the amino acid 
residues. For example, the carbonyl group on the heterocycle of pyrrothine moiety may 
hydrogen bond with the amine group from the side chain or backbone of the second lysine 
of the KMSKS loop. Alternatively, the amide groups on the pyrrothine moiety may simply 
interact with the solvent while the ring binds to the hydrophobic patch. 
In comparison, mupirocin has a carboxylate tail which appears to form a salt bridge 
with the second lysine residue (Silvian et al., 1999). (Silvian et al. only noted lysine to bind to 
the carboxylate tail but Marion et al. (2009) also highlighted the neighbouring methionine to 
hydrogen bond with the terminus (Figure 3.11)). These possible differences in interaction of 
mupirocin and thiomarinol with 1) the KMSKS loop (from forming a salt bridge or two 
potential hydrogen bonds to several hydrogen bonds respectively) and 2) the latter having 
the additional interaction with the hydrophobic patch may be important factors in the 
increased binding affinity of the latter antibiotic to susceptible IleS. 
3.3.2 Active site residues that may contribute to increased binding of 
mupirocin/thiomarinol or to individual resistance phenotypes 
The important interactions taking place between 1QU2 and its known ligand 
mupirocin were deduced using Ligplot (Figure 3.7) and verified for their conserved 
importance using Evolutionary Trace (ET). The equivalent residues were then sought out on 
the 3D structures of MupM and TmlM using PyMOL. Residues that were identical in all three 
proteins were ignored, while residues that were different were investigated further. On the 
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3D structures of 1QU2, MupM and TmlM, the distances between the residues of interest and 
mupirocin were also noted to determine whether interactions were likely. 
 
Figure 3.7. Ligplot result of PDB structure 1QU2 complexed with mupirocin. 
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In addition to the residues identified by Ligplot and ET, residues within 8 Å of 
mupirocin were highlighted on the 1QU2, MupM and TmlM structures using PyMOL. The 
residues were then manually compared and those that appeared to interact with the ligand 
also selected for further work. The selected residues from the Ligplot, ET and PyMOL results 
are summarised in Table 3.1, Figure 3.8 and Figure 3.14. The residues highlighted in Figure 
3.8 will be discussed first in detail. 
Phe587 in the mupirocin-sensitive 1QU2 is a bulkier residue than Val581 and Ile590 
in MupM and TmlM respectively. It may allow better hydrophobic interaction with 
mupirocin, or due to the residue’s position at the base of the KMSKS loop, it may affect the 
loop’s dynamics. Tyr44 and Tyr48 in MupM and TmlM respectively are slightly bulkier than 
His53 in 1QU2 but seem too distant from the ligand to play any particular role.  
Tyr597 and Tyr606 in MupM and TmlM respectively are bulkier residues than Val603 
in 1QU2. ET results of MupM and the multiple sequence alignment from the BLAST results 
indicate this residue to vary from aromatic residues tyrosine and phenylalanine to non-bulky 
residues valine and alanine depending on the organism (Figure 3.9). The amino acid 
sequence of MupA, a highly mupirocin-resistant protein (Hodgson et al., 1994) carries a 
valine instead of tyrosine. However, further scrutiny of the structures and multiple sequence 
alignment reveal that the IleSs represented in the multiple sequence alignment have a bulky 
residue at one of the equivalent positions of Val581 and Tyr597 in MupM (except Thermus 
thermophilus IleS (PDB 1JZQ), which has a leucine and valine respectively). This indicates that 
the Tyr597 and Tyr606 in MupM and TmlM respectively may only be compensating for the 
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lack of bulky residue in the position of Val581 and Ile590 and are not functionally important 
to mupirocin/thiomarinol resistance. 
Table 3.1. Summary of the amino acid residues of interest that may be important in 













*The residues were selected from Ligplot, Evolutionary Trace (ET) and manual visualisation on PyMOL. A total of 18 residues 
were initially identified by Ligplot and ET, while manual visualisation on PyMOL identified an additional 36 residues. Any 
identical residues across 1QU2, MupM and TmlM were discarded. The remaining residues were carefully considered using 
PyMOL and the residues most likely to interact with mupirocin/thiomarinol and thus influence the resistance/susceptible 
phenotype were selected for the above table. The residues in red are highlighted in Figure 3.8. The residues in black are 
highlighted in Figure 3.14. 
 















Mupirocin Sensitive Mupirocin Resistant Thiomarinol Resistant 
 
Figure 3.8. Amino acid residues of interest from Table 3.1 highlighted on structures 1QU2, 
MupM and TmlM. Mupirocin is highlighted in purple. The equivalence between residues is 





Figure 3.9. Multiple sequence alignment of 1QU2, MupM, MupA, TmlM and their 
homologues around the KMSKS motif. The purple arrow is highlighting Tyr597 from MupM 
and the equivalent residues in all other aligned IleSs. The red arrow is highlighting Val581 
from MupM and the equivalent residues in all other aligned IleSs. Where there is an aliphatic 
residue at the position of the red arrow, there is an aromatic residue at the position of the 
purple arrow and vice versa, with the exception of 1JZQ, suggesting the difference noted in 
1QU2 (Val603, Phe587) and MupM/TmlM (Tyr597, Val581 and Tyr606, Ile590 respectively) 
to be a compensatory change. 
 
The residues of particular interest are Asn70 and Gly601 in 1QU2 (Figure 3.8). Asn70 
in 1QU2 is approximately 4 Å from the pyran ring of mupirocin (Figure 3.10). This suggests 
that Asn70 may interact via hydrogen bonding with the ligand, although the observation was 
not highlighted in the Ligplot results. The equivalent residues on MupM and TmlM (Thr61 
and Ala65 respectively) are smaller and therefore may not be able to interact with the pyran 
ring. This may significantly reduce mupirocin/thiomarinol binding stability, allowing MupM 
and TmlM to be highly mupirocin/thiomarinol resistant. This hypothesis is supported by the 
map of main molecular interactions published by Marion et al., based on the X-ray crystal 
structure of mupirocin complexed with IleS and tRNA solved by Silvian et al. (Figure 3.11) 
(Marion et al., 2009; Silvian et al., 1999). They predicted both Asn70 and also its 
neighbouring Glu554 to interact with the second hydroxyl group on the pyran ring of 
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mupirocin. The equivalent residues to Glu554 on MupM and TmlM are also glutamic acids 
(Glu548 and Glu557 respectively, Figure 3.10). 





Figure 3.10. The proximity of Asn70, Thr61 and Ala65 and their respective glutamic acid 
residues to the pyran ring of mupirocin. Asn70 on 1QU2 appears to be favourably placed to 
interact with the ligand, while the equivalent Thr61 and Ala65 on MupM and TmlM 
respectively appear to be too distant from the ligand for any interaction (>4 Å). A typical 
hydrogen bond (measured from the hydrogen) is between 1.5 to 2.6 Å (Berg et al., 2002). 
 
 
Figure 3.11. Main molecular interactions of mupirocin and 1QU2 solved by Silvian et al. 
(1999), adapted from Marion et al. (2009). Interactions of Glu554 and Asn70 with the 




Further inspection of the IleS models identified Lys74 and Asp54 in 1QU2 to be 
favourably placed to interact with Glu554 instead of the pyran ring to create a salt bridge 
(Figure 3.12). 













Figure 3.12. The positioning of glutamic acid, lysine and aspartic acid on 1QU2, MupM and 
TmlM. In 1QU2, Asp54 interacts with Lys74 which interacts with Glu554 rather than with 
Asn70, allowing the latter residue to interact with the pyran ring of mupirocin. Thr61 and 
Ala65 on MupM and TmlM respectively are positioned to be more likely to interact with the 
neighbouring glutamic acids. 
 
These residues can create an overall network of electrostatic charges and hydrogen bonding 
that may stabilise the site for mupirocin to bind with Asn70. This network is also conserved 
in MupM and TmlM. However in MupM, Asn70 is replaced with Thr61 and the latter residue 
appears to be placed favourably for interaction with Glu548 instead of the pyran ring of 
mupirocin. With Thr61 too far away to interact with the pyran ring, mupirocin may be 
prevented from effectively binding to the active site, allowing MupM to be resistant to 
mupirocin. In TmlM, the methyl group of Ala65 is non-polar and incapable of hydrogen 
bonding with the pyran ring or neighbouring residues. Glu557 appears buried and unlikely to 
interact in this model (although the orientation of these residues may be an artefact of the 
model). This may play a role in mupirocin/thiomarinol resistance by creating an 
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unfavourable environment where the ligand should bind, compared to the stable 
environment created by Asn70, Glu554, Lys74 and Asp54 in mupirocin-sensitive 1QU2. 
Finally, Gly601 in 1QU2 may play a role in the flexibility of the KMSKS loop, while 
MupM and TmlM have non-flexible residues Lys595 and Arg604 respectively at the 
equivalent position (Figure 3.8). Three separate ET analyses were run on 1QU2, MupM and 
TmlM using individual multiple sequence alignments generated by default (a FASTA search 
of each proteins over the Swiss Protein Databank). ET results ranked Gly601 to be highly 
conserved within 1QU2 and its homologues, while Lys595 and Arg604 were ranked not as 
functionally important (Table 3.2). With less flexibility, the resistant proteins may prevent 
the loop from stabilising the mupirocin/thiomarinol complex. 
Table 3.2. Residue variation of Gly601 (1QU2), Lys595 (MupM) and Arg604 (TmlM) from 
three separate ET analyses*. 
Protein Alignment# Residue# AA type Coverage Variability Score (rvET)
1QU2 667 601 G 3 GWQ 3.26
MupM 869 595 K 5 KRQNG 19.02
TmlM 936 604 R 6 RGKQND 21.64
 
*Alignment# is the alignment position in the multiple sequence analysis (MSA). Residue# is the residue position in the query 
protein. Type is the one letter amino acid name in the query protein. Coverage is the relative importance position for each 
residue. Low coverage implies evolutionary importance. Variability shows the residue variation in the column of the MSA. 
Evolutionary scores for residues are calculated with rvET method. Low score implied evolutionary importance. (Column key 
reproduced from Mihalek et al., 2004).  
 
3.3.3 Residues near the key structural differences of mupirocin and 
thiomarinol 
There are a few structural differences between mupirocin and thiomarinol. The main 
and most obvious difference is the addition of the pyrrothine moiety on thiomarinol. 
However, there are other smaller differences to note. Firstly the fatty acid chain attached to 
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the monic acid backbone of mupirocin is one carbon longer than that on the marinolic acid 
of thiomarinol. Secondly, thiomarinol has a hydroxyl group at position C4 and finally, the 
C10-11 epoxide bond on mupirocin is replaced with an E alkene in thiomarinol. Based on the 
hypothesis that thiomarinol binds in the same orientation as mupirocin, the active site near 
the differing residues of the marinolic acid was investigated for any residues that may be 
further interacting with thiomarinol to allow the antibiotic to bind more strongly to the 
enzyme. Asp557 in 1QU2 was identified as potentially interacting with the C4 hydroxyl group 
of thiomarinol (Figure 3.13). This observation was also made by Marion and colleagues, 
although they also identified His64 to potentially interact with the C4 hydroxyl group 
(Marion et al., 2009). The corresponding residue of Asp557 in MupM is Ala551 and unlikely 
to interact due to its lack of hydrogen bonding capacity in the main chain as well as the 
distance (>4 Å). However on TmlM, the residue is also an aspartic acid (Asp560) which goes 
against the hypothesis that an aspartic acid residue could contribute to stronger binding of 
thiomarinol to susceptible targets unless there are sufficient other changes to decrease 
binding. All other residues identified near the differing residues did not appear to contribute 




Figure 3.13. Residues near the C4 hydroxyl and C10-11 E alkene groups on thiomarinol 
highlighted in yellow on 1QU2. Thiomarinol is highlighted in pink. The distance between 
Asp557 and the C4 hydroxyl group in this model is 4.3 Å and theoretically too distant for 
interaction. However, within the uncertainty of the model and the known flexibility of the 
enzyme, Asp557 may still interact with the C4 hydroxyl group at a closed confirmation. 
Marion et al. (2009) has predicted His64 to also interact with the hydroxyl group. 
 
3.3.4 Residues highlighted in the literature 
Residues identified by previous literature such as Asp557 in 1QU2 were also 
highlighted on the IleS structures and included in further studies (Figure 3.14). Marion et al. 
(2009) also noted the amine group from Gly555 may interact with the hydroxyl group on C6 
of the pyran ring of mupirocin. The corresponding residue in MupM is Tyr549, which may 
not interact and thus may confer the mupirocin resistance phenotype. However on TmlM, 
this residue is also a Gly558 as with Gly555 in 1QU2, so it would be interesting to see 
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whether changing Tyr549 in MupM to a glycine residue would confer the phenotype of 
1QU2 or TmlM i.e. whether it would improve or worsen the enzyme’s resistance against 
mupirocin and thiomarinol (see Chapter 4 for results). 
Nakama and colleagues identified His581 and Thr48 on the mupirocin sensitive 
Thermus thermophilus (T. thermophilus) IleS to be important residues for conferring its 
sensitive phenotype. They proposed His581 to interact with the pyran ring via hydrophobic 
stacking interactions. However in eukaryotic IleSs, they noted this residue to be replaced 
with an asparagine or serine and suggest this change to weaken the hydrophobic interaction 
with the pyran ring. Regarding Thr48, no specific interactions were proposed but they noted 
this residue to be replaced with phenylalanine in eukaryotic IleSs. They created a double 
mutant, replacing these residues with asparagine and phenylalanine respectively to mimic a 
eukaryotic IleS and found the Ki value to increase by one order of magnitude compared to 
the wild type T. thermophilus (Nakama et al., 2001). The corresponding residues on MupM 
are His579 and Phe49 respectively, which partially support Nakama’s observations on 
phenylalanine conferring weaker binding by the enzyme. On TmlM, the residues are Asn588 
and Phe53 (Figure 3.14), which may be an important factor in preventing auto-toxicity in the 




Mupirocin Sensitive Mupirocin Resistant Thiomarinol Resistant 
 
Figure 3.14 Amino acid residues of interested highlighted by Marion et al. (2009) and 
Nakama et al. (2001). Mupirocin is highlighted in purple. The equivalence between residues 
is summarised in Table 3.1 (in black). 
 
3.4 Discussion 
This study modelled MupM and TmlM by homology with the structure of a 
mupirocin-sensitive IleS complexed with mupirocin (PDB: 1QU2) and performed active site 
analyses, in an attempt to understand the interactions taking place between specific amino 
acid residues and thiomarinol that render this antibiotic more potent than mupirocin. In 
particular, this study aimed to understand what additional interactions, if any, the 
pyrrothine moiety may bring to increase the binding affinity of thiomarinol to susceptible 
IleS. 
This study also reviewed previous studies conducted by Marion et al. (2009) and 
Nakama et al. (2001) and with the active site analysis findings, concluded that a total of eight 
residues in the mupirocin-sensitive active site of IleS1 (Phe587, Asn70, Val603, Gly601, 
His585, Asp577, Gly555 and Tyr58) may interact with mupirocin and/or thiomarinol and 
render the enzyme sensitive (Figure 3.8; Figure 3.14). Four out of the eight residues on 
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mupirocin and thiomarinol-resistant TmlM (Arg604, Ala65, Asn588 and Phe53) were 
hypothesised to confer the thiomarinol resistance phenotype through a combination of 
reducing (i) flexibility of the IleS enzyme and (ii) the molecular interaction of marinolic acid in 
the active site (Figure 3.15). 
ARG604: Reduces 
flexibility of KMSKS 




mutant study by 
Nakama et al. 
(2001) identified 
this residue and 
above Asn588 to 
increase Ki of 
mupirocin. 
ASN588: Not an aromatic 
residue and therefore 
unable to stack with pyran
ring; weakens hydrophobic 
interaction (Nakama et al., 
2001).
ALA65: No hydrogen 
bonding capacity in 





Figure 3.15. Summary of hypothesised amino acids responsible for TmlM thiomarinol 
resistance phenotype. Mupirocin is highlighted in pink. 
 
3.4.1 Reduced flexibility of the KMSKS loop 
The flexibility conferred by the glycine residue (Gly601) at the base of the KMSKS 
motif in 1QU2 is proposed to be important for binding of mupirocin and thiomarinol and 
part of the resistance to these antibiotics in MupM and TmlM is thought to be due to this 
position being occupied by amino acids that confer less flexibility (Lys595 and Arg604 
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respectively). This difference in amino acid may restrict the movement of the loop and 
prevent interactions between the protein and mupirocin/thiomarinol. The aromatic Phe587 
residue at the base of 1QU2’s KMSKS loop may restrict movement but may also hold the 
mupirocin in place. This conserved KMSKS motif has been structurally observed to undergo 
conformational rearrangement during catalysis of aminoacyl-adenylate in TyrS, TrpS and 
LeuS, including the change in positioning of the critical second lysine in the conserved motif 
to interact with the α-phosphate of the ATP in the transition state (Cusack et al., 2000; Ilyin 
et al., 2000; Yaremchuk et al., 2002). The crystal structure of mupirocin-sensitive S. aureus 
IleS complexed with tRNAIle and mupirocin also shows the carboxylate tail of mupirocin to 
bind to the second lysine (Lys598) of the KMSKS motif instead of the α-phosphate of ATP 
(Silvian et al., 1999). Additionally, the backbone amide of the first lysine (Lys595) and the 
backbone carbonyl of Gly593 (upstream KMSKS) binds to the tRNA backbone, stabilising 
tRNA onto IleS and opening the IleS active site. The lack of glycine downstream from the 
KMSKS motif may restrict the flexibility of the loop just enough to prevent the second lysine 
from binding to the mupirocin tail, giving rise to mupirocin and/or thiomarinol resistance. 
However, this restriction should be at a low fitness cost and not disable aminoacylation 
completely. 
3.4.2 Difference in binding of marinolic acid versus mupirocin 
The possible reduction of flexibility of the KMSKS loop does not appear to be the only 
changes found in MupM and TmlM compared to 1QU2 to render the first two enzymes 
resistant to mupirocin and/or thiomarinol. Comparison of the three enzymes has revealed 
eight amino acid differences between the active sites and suggests a collective change in 
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active site residues confers the resistance phenotype against mupirocin and thiomarinol. In 
particular, four residues appear to be involved in the thiomarinol resistance phenotype of 
TmlM (Figure 3.15). Observations by Nakama et al. (2001) and this study suggest that the 
residues in the binding pocket of mupirocin and marinolic acid are important in determining 
the resistance phenotype of the enzyme. Their T. thermophilus double mutant suggests that 
resistance in TmlM is conferred by multiple changes in the active site, instead of one point 
mutation as seen in low mupirocin resistant S. aureus enzymes (Antonio et al., 2002).  
As for the susceptible enzymes, the marinolic acid must bind strongly to the Rossman 
fold. However, a previous study observed marinolic acid to inhibit growth of S. aureus but 
less well than mupirocin (MIC of 0.125 μg/ml and 1 μg/ml respectively) (Fukuda et al., 2011). 
The implication of this was that marinolic acid does not bind as well to IleS as mupirocin, and 
that the increased potency of thiomarinol is solely due to the addition of the pyrrothine 
moiety. However, this may be due to the fact that the marinolic acid moiety is one carbon 
shorter than mupirocin and the shortening of the polyketide chain prevents the second 
lysine of KMSKS from binding to the ligand. 
All IleS residues in the proximity of where marinolic acid and mupirocin differ were 
carefully considered. However, only Asp557 in 1QU2 was observed to be within interacting 
distance of the C4 hydroxyl group on thiomarinol. The equivalent residue is Ala551 in MupM 
and therefore it was hypothesised that the C4 hydroxyl group may contribute to stronger 
binding to susceptible IleS. However, the same aspartic acid residue was found on TmlM 
which went against the hypothesis. Since no other notable residues were identified in this 
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study, there appears to be no molecular explanation for better mupirocin binding than 
marinolic acid, except for the suggested difference in carbon chain length. 
Site-directed mutagenesis studies have been conducted to confirm the importance of 
the amino acids highlighted in this work as well as from the literature (Chapter 4). It was 
hypothesised that by changing single amino acids on the active site of MupM to mimic that 
of TmlM, the mutant enzyme will gain increased tolerance or even resistance against 
mupirocin and thiomarinol. Likewise, altering residues on MupM to corresponding residues 
of 1QU2 was hypothesised to decrease tolerance against mupirocin and thiomarinol. 
Multiple mutants were also constructed to see whether the resistance phenotype was 
dramatically improved or weakened by multiple amino acid changes.  
3.4.3 Does pyrrothine increase binding to the hydrophobic patch? 
The above observations of likely reduced flexibility and multiple amino acid changes 
in the active site may explain the resistance mechanism of TmlM against thiomarinol and 
also the increased potency of the drug against susceptible targets via increased affinity to 
the active sites. However, the role of pyrrothine in the potency of thiomarinol is yet to be 
understood. Pocket v.2 has identified a hydrophobic patch created by the aliphatic chains of 
the highly conserved second lysine of the KMSKS motif in 1QU2 and the additional arginine 
residue in MupM and TmlM. This could be the site where the pyrrothine moiety sits to 
increase overall binding of the antibiotic to the target IleS. 
As mentioned in the Results, there is also the potential of pyrrothine to form several 
hydrogen bonds with the IleS enzyme (although this may also be only to solution). The two 
amide groups on the pyrrothine moiety may hydrogen bond with residues on the KMSKS 
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loop and increase overall binding of thiomarinol to susceptible IleS. According to 
computation work performed by Maddipati (2007), it is energetically unfavourable to embed 
a salt bridge in a hydrophobic environment, as a salt bridge is highly polar and hence, 
difficult to completely displace all water molecules that interact with it. On the contrary, 
dehydration of a hydrogen bond is spontaneous and when fully embedded in a hydrophobic 
environment, the bond becomes stabilised (Maddipati, 2007). Therefore, compared to the 
salt bridge interaction between the carboxylate tail of mupirocin and the IleS enzyme, the 
hydrogen bonding of amides in the pyrrothine moiety may allow a more stabilised 
interaction with the KMSKS loop when it is fully embedded in the hydrophobic patch, made 
accessible by the eight carbon length fatty acid chain. 
This study also proposes that the length of the eight carbon chain of marinolic acid is 
important for the pyrrothine moiety to fit in the hydrophobic patch. An additional carbon on 
the marinolic acid may disrupt the interaction between pyrrothine and the target IleS – by 
moving the moiety out of the hydrophobic zone and into solution. The pyrrothine moiety 
does not sit in the hydrophobic patch in Figure 3.2 but this is most probably due to the sub-
optimal thiomarinol structure used. The available structure of thiomarinol B in the Daresbury 
Chemical Database (https://cds.dl.ac.uk/) confirms the planarity of the pyrrothine moiety in 
relation to the rest of the thiomarinol structure. Quantum mechanics calculations were 
performed using MolPro (Werner et al., 2012) on the pyrrothine moiety constructed in this 
study to fix its rotation. (The entire thiomarinol A structure could not be optimised by 
MolPro due to its size.) Further work is required to attach this optimised pyrrothine moiety 
on the marinolic acid and to confirm that the amide groups of the former is proximal for 
interacting with the the KMSKS loop within the hydrophobic patch. The length of a 
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mupirocin/thiomarinol analogue may be crucial in determining its activity against IleS. This 
may also be of interest in future mutasynthesis and molecular dynamics simulation studies. 
It can also be hypothesised that pyrrothine binding to the enzyme would be lethal, as 
the moiety would block the enzyme from undergoing conformational changes to activate 
isoleucine with ATP. However, this hydrophobic patch is also present in MupM and TmlM, 
the latter enzyme conferring high level resistance to thiomarinol. 
The current hypothesis is that the pyrrothine moiety does increase the potency of 
thiomarinol against 1QU2 and MupM by better interaction with the KMSKS loop within the 
hydrophobic patch. This interaction is made possible by the specific 8 carbon length of the 8-
hydroxyoctanoic acid (Figure 3.16). 
2. Optimal 8 carbon length 
for pyrrothine to sit in 
hydrophobic patch
3. Hydrogen bonding capacity of 
pyrrothine to increase overall 
thiomarinol binding to IleS, 




Figure 3.16. The hypothesised mechanism of thiomarinol A potency via increased binding 
to target IleS (adapted from Thomas et al., 2010). R1 = OH, R2 = OH, R3 = H, R4 = OH. 
 
In TmlM, the pyrrothine may also able to interact with the same hydrophobicity; however, 
multiple changes elsewhere in the active site of TmlM (as proposed in Figure 3.15) prevent 
the marinolic acid from binding and consequently confer thiomarinol resistance. This is 
difficult to prove experimentally because the hydrophobic area is created mainly by lysine, a 
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highly conserved residue of the KMSKS motif. Mutating or replacing this residue may 
compromise the functionality of the IleS enzyme and hence this was not pursued in Chapter 
4. 
A possible future experiment would be to generate a thiomarinol analogue but with a 
shorter marinolic acid chain (such as a three or five carbon tail instead of the original seven). 
The shorter chain should prevent the pyrrothine moiety from sitting in the hydrophobic 
patch, if this analogue binds to the active site in the same manner as the wild-type marinolic 
acid. The Ki value of the shorter analogue should be higher, indicating less binding to the 
enzyme. Various analogues have been created and tested for their biological activity against 
Bacillus subtilis and MRSA by Murphy and colleagues (Murphy et al., 2011). However, all 
analogues have been drastically altered from the original thiomarinol structure such as 
analogues with an intact pyrrothine moiety but the marinolic acid exchanged with MeCO. An 
analogue with a fully intact marinolic acid, but with a shorter carbon tail, may elucidate 
more on whether the hydrophobic patch is important in increasing the overall binding 












4  CHARACTERISING THE RESIDUES IN THE ILES ACTIVE SITE 
4.1 Introduction 
As explained in Chapter 1, thiomarinol is of interest as it exhibits higher potency than 
mupirocin against a wide range of microorganisms (Table 1.5). One of the hypotheses to 
explain this potency is that the pyrrothine moiety and the small differences between 
marinolic acid and mupirocin increase the binding affinity of thiomarinol for its target 
enzyme, isoleucyl-tRNA synthetase (IleS). The active site of mupirocin-sensitive IleS1 was 
compared to that of mupirocin-resistant MupM and mupirocin/thiomarinol-resistant TmlM 
in the previous computational study (Chapter 3) and several amino acid residues highlighted 
for their possible involvement in greater or lesser binding to mupirocin and/or thiomarinol 
(Figure 3.8). 
Also discussed in Chapter 3 are residues suggested by other studies that may be 
increasing the binding affinity of susceptible IleS to mupirocin and/or thiomarinol (Marion et 
al., 2009; Nakama et al., 2001; Silvian et al., 1999) (Figure 3.14). Most notable were residues 
His581 and Thr48 identified in the mupirocin-sensitive T. thermophilus IleS by Nakama et al. 
(2001), in which they created a double mutant replacing these residues to mimic those of an 
eukaryotic IleS. They found the Ki value of mupirocin was increased by one order of 
magnitude compared to the wild-type IleS. All other residues reviewed in the previous 




In this study, I describe studies in which the residues identified computationally were 
substituted in MupM to determine their importance in conferring the mupirocin/thiomarinol 
resistance or sensitivity phenotype. Both single and multiple changes were made to mimic 
the active site of IleS1 or TmlM and it was hypothesised that any changes made to important 
residues would change the minimal inhibitory concentration (MIC) of mupirocin and 
thiomarinol compared to wild-type MupM. Two methodologies were also used in an attempt 
to confirm the functionality of these MupM mutants by (1) protein purification for 
subsequent use in aminoacylation assays and (2) expressing them in P. fluorescens with ileS1 
and mupM deleted by suicide mutagenesis. 
4.2 Materials and Methods 
4.2.1 Bacterial strains, plasmids and growth conditions 
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For the construction of all mupM mutants, pGBT30mupM was used as the starting 
point and E. coli DH5α used as the bacterial host. The mutants’ mupirocin and thiomarinol 
resistance phenotypes were characterised in E. coli DH5α pJH10 by Minimal Inhibitory 
Concentration (MIC) tests with 1 mM IPTG induction as described in Chapter 2.  
For protein purification, various IleSs were individually expressed in E. coli BL21, C41 
(DE3) or C43 (DE3) cells carrying plasmid pET28a (Novagen, United Kingdom). This pET28a 
vector carries a kanamycin resistance gene, a T7 lac promoter and N-terminus His Tag and is 
therefore inducible by the addition of isopropyl-β-D-thiogalactoside (IPTG) in the cell culture. 
Plasmid pJH10 carries a tetracycline resistance gene, a tac promoter, an oriT region and a 
multiple cloning site, thus being selectable and also inducible by IPTG. All strains were grown 
in L-broth or Overnight ExpressTM Instant Terrific Broth (TB) medium (Novagen, United 
Kingdom) at 200 rpm, with the appropriate selection antibiotic, with or without IPTG and 
incubated at appropriate temperature and duration. 
4.2.2 Generating and characterising mupM mutants 
QuikChange Lightning Site-Directed Mutagenesis kit (Agilent, United Kingdom) was 
used to create all mupM mutants. Primers were designed using the QuikChange Primer 
Design tool (Agilent, United Kingdom) to introduce mutations at the residues of interest 
identified computationally in Chapter 3 (Table 4.3). A total reaction volume of 50 µl was 
made per mutation containing 5 µl of buffer, 0.6 µl of dsDNA template, 1.7 µl of primers (10 
pmole/µl) each, 1 µl dNTP (10 mM), 1.5 µl of QuikSolution, 37.5 µl of ddH2O and 1 µl of 
QuikChange DNA polymerase. The recommended PCR programme for the kit was used 
(Table 4.4). Once amplified, the reaction was digested with 2 µl of DpnI, in order to degrade 
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the unwanted parental template (without the mutation). All initial mutants were sequenced 
to ensure only the desired changes were present in the gene.  
Table 4.3. Oligonucleotide primers designed and used for QuikChange mutagenesis*.  

















*Bases that have been altered from the original MupM sequence are highlighted in red. 
 
Table 4.4. PCR programme for QuikChange mutagenesis as recommended by the supplier. 
Cycles Temperature Time
1 95°C 2 minutes
18 95°C 20 seconds
60°C 10 seconds
68°C 30 seconds/kb of plasmid length*
1 68°C 5 minutes  
*In this study, 4.5 minutes was used for the 6 kb-sized pGBT30 mupM. 
 
Once the mutants were confirmed by sequencing, the plasmids were transformed 
into E. coli GM2163 to yield DNA with no dam methylated sites. The mutant mupM genes 
were then digested with EcoRI and XbaI, ligated with the expression vector pJH10 and 
transformed into DH5α for biological characterisation. Further combinations (double and 
multiple mutants) were generated by digesting gene fragments containing the desired single 
mutations from the individual pGBT30 mupM mutants using EcoRI and KpnI. Corresponding 
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EcoRI-KpnI fragments were digested out from another set of pGBT30 mupM mutants 
carrying the desired secondary/tertiary mutations and the former fragments (with the 
primary mutation) ligated to form complete pGBT30 constructs carrying multiple mutations 
in the mupM gene. Once successfully cloned into pGT30, the same process outlined above 
was performed to transfer the genes into pJH10. 
All mutants were characterised by performing MIC tests using thiomarinol and 
mupirocin as outlined in Chapter 2. An inoculum size of 5 x 105 cfu/ml (as recommended by 
the British Society for Antimicrobial Chemotherapy or BSAC) was used. 
4.2.3 Suicide mutagenesis 
Biparental mating was performed by vortexing 500 µl of overnight culture of S17-1 
carrying the appropriate plasmid with 500 µl of P. fluorescens ΔmupM overnight culture, 
filtered onto a nylon membrane which was then placed on an L-agar plate for up to six hours 
at 30°C to ensure conjugation. Once incubated, the filter was transferred into a universal 
bottle with 1 ml saline and vortexed to remove the bacteria from the filter. This mixture was 
then serially diluted from 10-1 to 10-5 with saline and 200 µl of each dilution spread on 
minimal media (MM) agar (Table 4.5) with 15 µg/ml tetracycline and 100 µg/ml ampicillin for 
selection of P. fluorescens carrying pJH10mupM wild-type or mutants. The plates were left at 
30°C for up to four days to give single colonies. At least 10 single colonies were then 
streaked individually onto MM agar with tetracycline and ampicillin and again incubated for 
up to four days at 30°C. At least 10 single colonies were then streaked onto L-agar plates 
with the same antibiotics.  
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For selection of P. fluorescens ΔmupM pJH10mupM carrying suicide plasmid pJHIle01, 
MM agar and L-agar containing 15 µg/ml tetracycline and 50 µg/ml kanamycin were used 
instead. For removal of the suicide plasmid, single colonies of P. fluorescens ΔmupM 
pJH10mupM carrying pJHIle01 were grown in 5 ml L-broth overnight cultures and streaked 
onto L-agar with 15 µg/ml tetracycline and 5% sucrose. 
Table 4.5. Preparation of minimal media (MM) agar. 
Minimal Media Agar Preparation
200 ml 3 % agar
200 ml M9 x 2 (Prewarmed at 48°C)
400 µl 1M MgSO4
400 µl Thiamine HCl
400 µl 0.1M CaCl2
2 ml 40% glucose
400 µl required antibiotic
 
 
4.2.4 Protein expression and purification of IleS proteins 
Total protein expression. Overnight cultures of strains expressing the protein of 
interest in appropriate plasmids were prepared by inoculating 5 ml L-broth with a single 
colony and the antibiotic for selection. The overnight cultures were then diluted 1:50 into 
fresh L-broth containing the selection antibiotic and grown to an OD600nm 0.4. Once the 
required cell density was reached, the appropriate amount of IPTG was added and incubated 
for the desired length of time at the desired temperature. 1 ml samples were taken at 
appropriate intervals and the bacteria harvested by centrifugation at 4°C at 14,000 xg for 5 
min. The supernatant was removed and 500 μl of STE buffer (10mM Tris-Cl pH 8.0, 0.1M 
NaCl, 1mM EDTA pH 8.0) added before the centrifugation was repeated with the same 
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conditions. The supernatant was again removed and the cell pellet resuspended by 
vortexting into a slurry before storage at -20°C. For analysis by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE), the samples were defrosted and the slurry 
re-suspended in 20 μl of 1xSDS loading buffer (50mM Tris-Cl pH 6.8, 2% w/v SDS, 0.1% 
bromophenol blue, 10% v/v glycerol and an addition of 100mM dithiotheitol (DTT) before 
use) and boiled for 3 min. 
Soluble and insoluble protein expression. The protocol for “total protein expression” 
(above) was followed with harvesting of 1 ml samples for storage at -20°C until future use. 
The slurry was defrosted and re-suspended with 100 μl of BugBusterTM Protein Extraction 
Reagent (Novagen, United Kingdom) before incubation at room temperature with rocking 
for 20 min. The sample was centrifuged at 4°C at 14,000 xg for 5 min and the supernatant 
(containing soluble protein) transferred into a fresh microfuge tube. 100 μl of 2xSDS loading 
buffer was added. The remaining cell pellet was re-suspended in 100 μl 1% SDS and 100 μl of 
2xSDS loading buffer added. All samples were boiled for 3 min prior to running on SDS-PAGE. 
As an alternative method for lysing cells, the cell pellet was resuspended in 1 ml 0.1 
M Tris-HCl (pH7.6) and sonicated for 6x 10 second bursts at an amplitude of 15 while kept on 
ice. The sample was then centrifuged for 5 minutes at 18,000 xg and the supernatant 
transferred into a fresh microfuge tube. 100 µl of supernatant was added to 100 μl of 2xSDS 
loading buffer. The remaining cell pellet was re-suspended in 1 ml 1% SDS and 100 μl of the 
mixture added to 100 μl of 2xSDS loading buffer. All samples were boiled for 3 min prior to 
running 10 µl on SDS-PAGE. 
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SDS-PAGE. The recipes for the SDS-PAGE gels are summarised below (Table 4.6). 
Dependent on the size of the protein of interest, the proportions of ingredients in the 
resolving gel were altered. The resolving and stacking gels were made according to Table 4.6. 
Ammonium persulphate (APS) was made fresh before use or taken from a frozen aliquot. 
Tetramethylethylenediamine (TEMED) was added immediately prior to pouring to catalyse 
polymerisation of the gel. A BIO-RAD Mini-PROTEAN® electrophoresis system (BIO-RAD, 
United Kingdom) was used for pouring and running the gels and these were assembled 
according to the manufacturer’s instructions. TEMED was added to the resolving gel solution, 
mixed quickly and pipetted in-between the gel plates up to approximately 1 cm from the top. 
A layer of isopropanol was pipetted on top of the resolving gel and left to set for 
approximately 30 min. Isopropanol was removed and the top of the gel washed with two 
volumes of water. All traces of water were removed from the top before adding the stacking 
gel solution. TEMED was added to the stacking gel, quickly mixed and pipetted on top of the 
set resolving gel. An SDS-PAGE comb was inserted and TEMED pippetted into any visible 
gaps to seal it. The gel was left to set for another 30 min. Once set, the gels were removed 
from the holders and assembled in the gel tank by clipping the gels into the white electrode 
piece holder and placed into the clear tank. Tris-glycine electrophoresis buffer (5x 
concentrated solution consisting of 25mM Tris pH 8.3, 250mM glycine, 0.1% w/v SDS, diluted 
to 1x before use) was added to the gel tank before the combs in the gels were removed. The 
boiled protein samples were then loaded into the wells using longer gel tips (Alpha 
Laboratories, United Kingdom) and the gel run at 100 volts, 20 mA for approximately 4 hrs. 
Once complete, the gels were removed from the equipment and submerged in Coomassie 
Blue stain (Phastgel® Blue R (Sigma-Aldrich, United Kingdom) tablets dissolved in water and 
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methanol as recommended by supplier) for at least 1 hr. The Coomassie Blue stain was 
poured back into the bottle and the gels rinsed with water before being placed in destain 
(30% methanol, 10% glacial acetic acid, made up to total volume with water) for a minimum 
of 1 hr on the rocker at room temperature. The destain was then replaced with fresh 
solution and left overnight in the fume cupboard covered with aluminium foil. The gels were 
sandwiched between two clear cellophane films and dried for storage. 
Table 4.6. Preparation of SDS-PAGE gels*. 
10% Resolving Gel 15% Resolving Gel 3% Stacking Gel
Standard Distilled Water (SDW) 4 ml 2.3 ml 3.24 ml
Tris 2.5 ml Lower 2.5 ml Lower 1.25 ml Upper
10% Ammonium persulphate 240 μl 240 μl 120 μl
Acrylamide 3.35 ml 5 ml 0.6 ml
TEMED 8 μl 8 μl 15 μl
10% SDS 50 μl 100 μl -  
*Lower Tris consists of 1.5M Tris-Cl pH 8.8, 0.4% SDS. Upper Tris consists of 0.5M Tris-Cl pH 6,8, 0.4% SDS. 10% resolving gel 
is for separation of protein size 20-80 kDa. 15% resolving gel is for 10-43 kDa.  
 
Protein purification by nickel affinity chromatography. Soluble protein samples 
were prepared, following the same protocol as above with insoluble and soluble protein 
expression but at larger culture volumes. Therefore, the cultures grown at appropriate IPTG 
concentration, temperature and duration were washed in 20 ml STE buffer and centrifuged 
for 10 min at 11,000 xg at 4°C. The pellets were stored in the same slurry condition at -20°C 
until required. 
The slurry samples were defrosted and re-suspended in 5 ml BugBusterTM per gram 
of wet pellet and incubated at room temperature with rocking for 1 hr. The cultures were 
then centrifuged at 11,000 xg for 20 min at 4°C to separate the cell debris from the soluble 
protein fraction. The supernatant was transferred to a fresh microfuge tube and 20 μl saved 
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for analysis. The cell pellet was also kept for analysis and re-suspended in an equal volume 
(of the initial total volume of culture with BugBusterTM) of 1% SDS. 1 ml of Ni-NTA Agarose 
(QIAGEN, United Kingdom) per 4 ml of lysate was added and the mixture rotated for 1 hr at 
4°C before being transferred to a 5 ml polypropylene column (QIAGEN, United Kingdom). 
The flow-through was collected for analysis before washing the column three times with 
Wash Buffer A (50mM sodium phosphate buffer pH 6.0, 300mM NaCl, 10% glycerol). A 1 ml 
sample was collected from the final wash. Soluble proteins were eluted with 1 ml of each 
elution buffer (consisting of Wash Buffer A with increasing concentrations of imidazole) and 
all samples collected for analysis. 20 μl of all samples were then mixed with 2xSDS loading 
buffer on a 1:1 ratio and boiled for 3 min prior to running on SDS-PAGE. 
Dialysis. Fractions containing the soluble protein of interest were collected from 
nickel affinity chromatography and pooled together. Spectra/Por 1 dialysis membrane 
(Spectrum® Laboratories, Inc., Europe) was cleaned as specified by the manufacturer, prior 
to dialysis to remove sulphide and metal residues. Sulphide was firstly removed by washing 
the membrane for one minute at 80°C in two part dH2O and one part Solution A (1 g sodium 
sulphite in 100 ml H20). The membrane was then washed with dH2O at 60°C for two minutes 
before adding 2 ml of Solution B (0.4 ml sulphuric acid (99.999%) in 100 ml dH2O) per 50 ml 
of total solution. The solution was mixed thoroughly for one minute before rinsing with 
dH2O for several minutes. Metal residues were then removed by washing the membrane 
with 0.05M EDTA (pH 8.0) for 10 minutes before rinsing with dH2O. The pooled fractions of 
soluble protein were pipetted into the prepared dialysis membrane, clipped at both ends 
and left stirring overnight at 4°C in 100 times the volume of soluble protein of Tris-HCl 
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(50mM, pH7.9). Contents of the dialysis tube were transferred into a falcon tube and stored 
at 4°C until further use. 
4.3 Results 
4.3.1 Phenotypic effects of mutations in mupM 
Ten QuikChange mupM mutants were constructed to investigate whether changing 
single and double amino acids to resemble the active site of a) TmlM would confer the 
thiomarinol resistance phenotype and b) IleS1 (PDB:1QU2) would confer mupirocin and 
thiomarinol sensitivity (Table 4.7). The only exception was Mutant 4 (M4) with changes 
mimicking both TmlM and IleS1. This double mutant was constructed to observe which 
phenotype will be conferred, resistance or sensitivity. A recapitulation of the residues 




Table 4.7. Summary of all amino acid changes performed using QuikChange Lightning Site-







TmlM ALA PHE GLY ASP ASN ILE ARG TYR
Mutant # M1 M4 M5 M7
MupM THR61 PHE49 TYR549 ALA551 HIS579 VAL581 LYS595 TYR597
Mutant # M2 M3 M4 M6 M8


















Mupirocin Sensitive Mupirocin Resistant Thiomarinol Resistant 
 
Figure 4.1. Summary of residues selected in Chapter 3 for QuikChange mutagenesis. (A) 
Residues highlighted in the computational study (Chapter 3). (B) Residues highlighted 





Wild type mupM (EcoRI-XbaI fragment) was cloned into pGBT30 to provide a 
template for construction of further QuikChange mutagenesis to produce M1-8. M1+7 and 
M3+4 were constructed by digesting the relevant fragment carrying the mutation from the 
respective mutants (pGBT30 M1, 7, 3 and 4) with EcoRI and KpnI and ligating them together 
to create further double and triple mutants. Several unsuccessful attempts were also made 
to construct M2+6, until it was later realised that when creating M2 using QuikChange, an 
additional EcoRI site was introduced by changing Thr61 (DNA sequence: act) to asparagine 
(aat). With two EcoRI sites, the initial digestion using EcoRI and KpnI enzymes was releasing 
two fragments and yielding a smaller ligated product compared to the successful M1+7 and 
M3+4. Due to time constraints, attempting to get this mutant was aborted and the 
remaining ten mutants were subjected to MIC tests. 
M1 and M2 (Thr61Ala and Thr61Asn respectively) were constructed to test whether 
Asn70 in IleS1 is important for interaction with the 6-hydroxyl group on the pyran ring of 
mupirocin and thiomarinol as proposed from the in silico modelling. M3 (Phe49Tyr) was 
constructed to investigate whether the phenylalanine is as important as proposed by 
Nakama and colleagues to confer mupirocin and/or thiomarinol resistance (Nakama et al., 
2001). 
M4 (Tyr549Gly/Ala551Asp) is a double mutant that introduces the same residues 
found in both IleS1 and TmlM. Asp557 and Gly555 in IleS1 were proposed by Marion et al. 
(2009) to interact with the hydroxyl group on C4 of the marinolic acid and C6 of the pyran 
ring of mupirocin respectively. Since both residues are also found in TmlM, these changes 
should retain function and not make any difference to the resistance phenotype. 
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M5 (His579Asn/Val581Ile) is also a TmlM-like double mutant. The role of His579 in 
mupirocin susceptibility was investigated by Nakama et al. (2001), by constructing a double 
mutant of mupirocin sensitive T. thermophilus His581Asn/Thr48Phe. His581 is equivalent to 
His579 and Thr48 to Phe49 on MupM respectively. They found that these two amino acid 
changes increased the Ki value for mupirocin by one order of magnitude. M5 mimics the 
same change of histidine to asparagine while retaining its wild-type phenylalanine residue. 
Nakama et al. (2001)’s findings suggest that the mupirocin and/or thiomarinol resistance 
phenotype should increase for M5. 
The mutation Val581Ile was also created in M5 because the residue’s close proximity 
to the first mutation (His579 to asparagine) made it experimentally easy to create a double 
mutant. A single mutation of valine to isoleucine was not expected to confer any significant 
changes in phenotype because sequence results in Chapter 3 suggest that this Val581 
position and Tyr597 position (in MupM) alternated in having one bulky residue, presumably 
to maintain the hydrophobic pocket of the active site (Chapter 3, Figure 3.9). This change 
was included in the double mutant to confirm the above hypothesis. 
To further test the importance of one bulky residue at this site, M6 was created so 
that the mutant protein would now carry two bulky residues. Therefore Val581 in MupM 
was mutated to phenylalanine, to mimic IleS1. It was hypothesised that having two bulky 
residues would create a larger hydrophobic patch for the antibiotics to bind more strongly to 




Finally, Lys595 was mutated to arginine in M7 to determine whether reduced 
flexibility of the KMSKS loop would increase resistance to mupirocin and thiomarinol. A 
double mutant M8 was created to firstly replace Lys595 with the flexible residue glycine to 
determine whether increased flexibility would render the enzyme more susceptible to both 
antibiotics. Tyr597 was also exchanged with valine to abolish the important hydrophobic 
patch created by altering the bulky residue mentioned for M6. Although these two 
mutations render the active site of M8 more like IleS1, the lack of bulky residues may allow 
the enzyme to become more tolerant/resistant to mupirocin and/or thiomarinol. 
Double and triple mutants M1+7 and M3+4 respectively were constructed to create 
mutants with possibly more significant phenotypic changes than the single and double 
mutants M1-8. M1+7 was hypothesised to be more thiomarinol resistant due to its inflexible 
KMSKS loop and the alanine residue having no hydrogen bonding capacity in its side chain to 
form the important interaction with the pyran ring. M3+4 was hypothesised to show more 
susceptibility to mupirocin and/or thiomarinol, with three residues mimicking IleS1. 
MIC tests were performed on the QuikChange mutants using a range of mupirocin 
and thiomarinol concentrations. Results were not all as hypothesised. While the IleS1-like 
mutants (M2, 3, 6, 8 and 3+4) all showed a decrease in thiomarinol and mupirocin MICs 
compared to wild-type as hypothesised, most of the TmlM-like mutants (M1, 5, 7, 1+7) also 
had unexpected MIC decreases (Figure 4.2). Of the above mentioned decreases, only M2, 
3+4, 5 and 1+7 mutants showed over two fold decrease in the MIC of thiomarinol compared 
to wild-type and thus deemed significant. Likewise, M6, 3+4, 5 and 1+7 had significant 
decreases in the MIC of mupirocin. The only mutant to show increased resistance against 
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thiomarinol was M7, although this was not considered significant. Against mupirocin, only 




TmlM-like IleS1-like   
Figure 4.2. MIC of (A) thiomarinol and (B) mupirocin against wild-type DH5α pJH10mupM 
and QuikChange mutants. The wild-type mupM is highlighted by a darker shade of colour. 
M1, 5, 7 and 1+7 carry TmlM-like mutation(s) and M2, 3, 6, 8 and 3+4 carry IleS1-like 
mutation(s). M4 have changes that mimic both corresponding TmlM and IleS1 residues. MIC 






M7 (Lys595Arg), as discussed above, has a bulkier residue at the base of the KMSKS 
loop and this change was hypothesised to reduce the flexibility of the loop and consequently 
the ability of the enzyme to interact with the pyrrothine, increasing its resistance phenotype 
against thiomarinol. Although it appears to have a slight increase in MIC of thiomarinol, this 
is less than a two fold increase and thus insignificant, just as its decrease in MIC of mupirocin. 
This is peculiar, as it was speculated that by reducing the flexibility of the loop, it may 
prevent the carboxylate tail of mupirocin interacting with the second lysine of the KMSKS 
loop and weaken the overall binding strength of mupirocin to M7. 
M1 (Thr61Ala) was hypothesised to lose the ability to interact with the 6-hydroxyl 
group on the pyran ring of both mupirocin and thiomarinol, causing the mutant to become 
more resistant to both antibiotics. However, this change only increased the mutant’s MIC of 
mupirocin and decreased its MIC of thiomarinol (although both again insignificant). 
Interestingly, double mutant M1+7, which combines the above two changes, had a 
significant and unexpected decrease in resistance against both antibiotics. 
M4 (Tyr549Gly/Ala551Asp) has altered residues found in both IleS1 and TmlM and 
hence hypothesised to show no change in phenotype against mupirocin and thiomarinol. 
Interestingly, there was a decrease in MIC of both antibiotics, although not within the 
significant fold change. 
The MIC results are conflicting, as well as unexpected with some of the mutants. A 
possible cause for this is that the functionality of these mutant MupMs has been 
compromised by changing important active site residues and that an optimal combination of 
changes must be made for the advantageous resistance phenotype to be conferred. This 
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may be an explanation for the significant decrease in resistance phenotype of double mutant 
M1+7, compared to the individual single mutants M1 and M7. If too many drastic alterations 
are made, it may instead impose a fitness cost on the mutants and render them susceptible 
to the antibiotics. 
Alternatively, there may have been a problem with the template mupM used to 
generate these mutants – the average MIC value of pJH10mupM was 5 µg/ml thiomarinol in 
this study and lower than the 32-64 µg/ml identified in Chapter 2, Table 2.4. A similar issue 
with lower MIC against pJH10mupM was observed in Chapter 2, which suggests that perhaps 
the functionality of the template mupM was already reduced before mutations were 
introduced. 
4.3.2 Functionality of the mupM mutants 
In order to check the functionality of the mupM mutants, two approaches were 
undertaken. Firstly, the wild-type mupM gene was cloned into pET28a for protein expression 
and purification. Once the optimal conditions for soluble MupM expression were found, the 
plan was to purify all mutant MupMs and test their functionality by using them in the 
aminoacylation assay. The second method for checking functionality was to express the 
mutants in P. fluorescens ΔileS1 ΔmupM. 
4.3.3 Insolubility of MupM in heterologous BL21 pET28a system 
The pGBT30mupM construct was digested at restriction sites EcoRI and HindIII, and 
cloned into BL21 pET28a for protein expression and purification.  5 ml and 100 ml cultures 
were grown in L-broth at 37°C up to OD600nm 0.4, before protein expression was induced at 
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IPTG concentrations of 0.001, 0.01, 0.05, 0.1, 0.5 and 1 mM and temperatures of 16, 18, 30 
and 37°C. 1 ml samples were taken at 4 and 6 hours IPTG induction and overnight at the 
lower temperatures (16 and 18°C) and checked on SDS-PAGE gels for total and soluble 
protein expression. The various conditions tested did not yield soluble protein in the sample 



































































































































Figure 4.3. SDS-PAGE gel of BL21 (pET28amupM) total, insoluble (cell pellet) and soluble 
(supernatant) protein expression at various IPTG concentrations. 100 ml cultures were 
induced with 0.05, 0.1 and 0.5 mM IPTG for 4 hours at 37°C. There are comparable MupM 
bands in the total and cell pellet lanes but none in the supernatant lane, indicating no 
soluble MupM was produced under these conditions. The position of the MupM band is 















































































































































































































































































































































































































































Figure 4.4. SDS-PAGE gels of BL21 (pET28a) and (pET28amupM) total, insoluble (cell pellet) 
and soluble (supernatant) protein expression at various conditions. 100 ml cultures were 
induced with 0.01 and 0.001 mM IPTG for 4 hours and overnight at (A) 18°C and (B) 16°C. No 
MupM band is seen on the BL21 (pET28a) lane (negative control). No significant soluble 
MupM bands are visible in these conditions. The position of the MupM band is indicated by 





Overnight ExpressTM Instant TB media (Novagen, United Kingdom) was used instead 
of L-broth in an attempt to promote soluble protein production. Instant TB is an 
autoinduction (AI) culture media formulated to automatically express IPTG-inducible protein 
once the culture reaches high cell density. The culture uses the available glucose in the 
media until it is depleted, and then switches to lactose – which in turn is converted to the 
inducer allolactose by β-galactosidase. Allolactose de-represses the lac repressor and 
induces T7 RNA polymerase-dependent protein expression. The media therefore would 
provide an alternative method to express soluble MupM without the need to check cell 
density or optimise IPTG induction levels. 5 ml cultures were grown at 22, 30, and 37°C for 
24 hours and samples treated in two different methods, using BugbusterTM and sonication. 
The results were similar to that of the L-broth cultures. No soluble protein was produced in 









































































































































































































































































































Figure 4.5 SDS-PAGE gels of BL21 (pET28a) and (pET28amupM) grown at various 
temperatures and treated by (A) Bugbuster and (B) sonication. No soluble MupM was 




The pET28amupM plasmid was transformed individually into C41 (DE3) and C43 
(DE3) strains, which were kindly donated by Dr. Yanina R. Sevastsyanovich, University of 
Birmingham. These strains were chosen for their effectiveness in overexpressing toxic 
proteins. C41 (DE3) was derived from BL21 (DE3) (Miroux and Walker, 1996) and has at least 
one uncharacterised mutation that prevents autotoxicity from toxic protein expression. C43 
(DE3) is a further derivative from C41 (DE3) which contains no plasmid (Miroux and Walker, 
1996). 100 ml cultures were grown at 25°C to OD600nm 0.6, before inducing expression with 
0.01 mM IPTG overnight. As with the other conditions tested, no soluble MupM protein was 





































































































































































Figure 4.6. SDS-PAGE gel of C41 and C43 (pET28amupM) total and soluble protein 
expression. The red arrow indicates the size of MupM (117.81 kDa). A faint band of MupM is 
visible in C41 and C43 total and cell pellet samples at 0.01 mM IPTG induction. The position 
of the MupM band is indicated by the red arrow. 
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With no success in yielding soluble MupM, it was hypothesised that the mutant 
MupMs would also be insoluble using the pET28a system. Attention was therefore 
concentrated on testing function by complementing a strain lacking ileS gene activity. 
4.3.4 Expressing mupM mutants in P. fluorescens ΔileS1 ΔmupM 
For creating P. fluorescens ΔmupM ΔileS1 pJH10mupM, a two part strategy was 
chosen to maximise the success rate. The wild-type and mutant pJH10mupM constructs 
were transferred into P. fluorescens ΔmupM first, before deleting the chromosomal ileS1 
copy. This would allow P. fluorescens ΔmupM to rely on the wild-type or mutant mupM copy 
when it loses its chromosomal ileS1. Jo Hothersall and Elton Stephens (University of 
Birmingham) had previously constructed the suicide plasmid pJHIle01 and shown that ileS1 
can be deleted from P. fluorescens with a functional mupM gene without affecting the 
viability of the strain. However, an attempt to construct P. fluorescens ΔmupM ΔileS1 yielded 
no colonies (unpublished) showing that ileS1 and mupM are the only genes present encoding 
isoleucyl-tRNA synthetase activity. Therefore, to test for mupM function, it was proposed to 
transfer wild-type/mutant pJH10mupM into P. fluorescens ΔmupM before attempting to 
delete ileS1. If it were possible to do this, then it would show that mupM was still active. 
Wild-type and all pJH10mupM mutants were first transformed into E. coli S17-1, in 
preparation for mating with P. fluorescens ΔmupM (previously constructed by Elton 
Stephens, University of Birmingham). Conjugation of the wild-type and mutant pJH10mupM 
plasmids into P. fluorescens ΔmupM was successful except for pJH10mupM5. The 




In the second stage, E. coli S17-1 with the suicide plasmid pJHIle01 was mated with P. 
fluorescens ΔmupM pJH10mupM (all mutants were mated first because it was assumed that 
at least some of the mutants would still be functional). Unexpected difficulties were noted in 
this step because liquid overnight cultures of P. fluorescens strains did not grow consistently 
well in the presence of tetracycline at either 7.5 or 15 µg/ml despite a variety of attempts to 
diagnose the problem. These discrepancies suggest that tetracycline concentrations must be 
carefully controlled.  
P. fluorescens ΔmupM pJH10mupM M1-8 (except M5) that had grown were mated 
with S17-1 carrying the suicide vector pJHIle01 and serial dilutions of the cultures grown on 
MM agar plates with 50 µg/ml kanamycin (to select for the suicide vector) and 15 µg/ml 
tetracycline. The cultures were grown for 6 days at 30°C but no colonies were yielded. 
It was unexpected for the mating of P. fluorescens ΔmupM pJH10mupM1-8 and S17-1 
pJHIle01 to fail at this stage as only the first recombination step (integration) would have 
occurred and the ileS1 would still be intact. The cultures were then to be streaked out onto 
L-agar plates with tetracycline and 5% sucrose to remove the suicide vector. Therefore, if the 
functionality of the mupM mutants was compromised from the QuikChange mutagenesis, it 
was hypothesised that no colonies would be yielded at the later stage when the suicide 
plasmid was excised from the chromosome. 
To ensure the basic replacement strategy was working, the process was repeated 
using wild-type mupM and all the variants of the antibiotic selection procedure worked out 
in trying the replacement with the mutants (MM agar with 15 µg/ml tetracycline and 50 
µg/ml kanamycin; 7 µg/ml tetracycline and 50 µg/ml kanamycin; and 50 µg/ml kanamycin 
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only). Kanamycin selection was maintained at 50 µg/ml for all three variations because of 
observations made from the preliminary matings of P. fluorescens ΔmupM pJH10mupM2 
and S17-1 pJHIle01. Although colonies were obtained from these matings, none grew well on 
re-streaking and so appear to have been false positives. 
To test whether the presence of a pJH10 plasmid affects the ability of P. fluorescens 
to accept a suicide plasmid (indicating a technical issue), P. fluorescens pJH10 was mated 
with S17-1 pJHIle01. Mating appeared to be unsuccessful with no true P. fluorescens pJH10 
pJHIle01 colonies. Due to time constraints, testing the functionality of the mupM mutants 
was not continued. Further work is required to understand whether it is technically possible 
to conjugate more than one plasmid into P. fluorescens. 
4.4 Discussion 
4.4.1 Functionality of mupM mutants 
The MIC results of the mupM mutants were interesting, although not all as 
hypothesised. All IleS1-like mutants showed a decrease in MIC values of thiomarinol and 
mupirocin, although only M2 and 3+4 for the former and M6 and 3+4 for the latter showed 
significant shifts above the two fold cut off point. Amongst the TmlM-like mutants, M1 and 
M7 were the only two to show improvement in their MIC values of mupirocin and 
thiomarinol respectively, although this was not considered significant based on their less 
than two fold change. This may still suggest that Ala65 and Arg604 are important residues 
that confer the resistance phenotype of TmlM; however, it is interesting that when these 
two changes are combined in M1+7, its resistance is noticeably and significantly reduced 
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against both antibiotics. Likewise, TmlM-like double mutant M5 also showed a similar 
decrease in phenotype. There appears to be a trend amongst the majority of the mupM 
mutants; there is a decrease in resistance against thiomarinol and mupirocin when residues 
are altered in the active site. This observation is also applicable to a certain extent to M1 and 
M7, as they only show improvement against one of the tested antibiotics and not both. 
Therefore, it is essential to confirm that the functionality of the mupM mutants has 
not been compromised, before any further conclusions can be drawn from the MIC results. 
The parent mupM gene was initially thought to be functioning correctly, as the gene was 
cloned from the template used in the QuikChange mutagenesis (pGBT30mupM) back to the 
expression vector pJH10 for all further MIC tests. The wild-type pJH10mupM had a 
mupirocin MIC value comparable to that identified before the start of this study, when 
original -80°C stock was used (64-128 µg/ml). 
However, revisiting the literature suggests that the pJH10mupM plasmid stock is 
behaving differently from the wild-type mupM gene in the P. fluorescens strain. While MIC 
values of 64-128 µg/ml mupirocin were consistently yielded against DH5α carrying 
pJH10mupM in this thesis, Yanagisawa and Kawakami reported values of 800-1,000 µg/ml 
against their DH5α strain carrying pEXR2 vector (expressing mupM) at cell densities of 106 
cells (Yanagisawa and Kawakami, 2003). They also showed the producer P. fluorescens to be 
resistant to > 1,000 µg/ml of mupirocin. Similarly, El-Sayed et al. (2003) reported an MIC of 
30 to 250 µg/ml when mupM was expressed in the pAKE900 construct in E. coli DH5α 
(Materials and Methods not specified). The MIC methodology and cell densities used in this 
study and by Yanagisawa and Kawakami differ slightly (broth dilution MIC with 5 x 105 cfu/ml 
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and agar dilution with 106 cells per 2 µl spots respectively); however the MIC breakpoint 
yielded in this study appear to be too low, suggesting two of the following: (1) that the 
mupM gene used is somehow compromised or (2) there is great difference in the level of 
mupM expression in the various pEXR2, pAKE900 and pJH10 plasmids due to difference in 
promoter sequence, ribosome binding site and/or plasmid replicon and copy number. 
Details of the pEXR2 expression vector, pEXPCR could not be found in the literature. 
However, the pAKE900 construct is based on the pGEM-TEasy vector, which is a high copy 
number vector containing the origin of replication pMB1 and it is under the control of T7 and 
SP6 RNA polymerase promoters (Promega, United Kingdom). pJH10, on the other hand 
contains an IncQ replicon and is a medium copy number vector. Although induced with IPTG, 
pAKE900 may express more MupM than pJH10, conferring high thiomarinol resistance than 
what was observed in this study. (See Chapter 2 for more discussion on mupM 
overexpression possibly conferring thiomarinol resistance.) 
After completion of the experimental procedures in this study, discrepancies 
between the published and recently re-sequenced mupM sequences were identified by 
Anthony Haines, University of Birmingham and updated on the NCBI database on the 14th 
February 2014. A total of seven mutations were found on the mupM gene used in this study 
and in Chapters 2 and 3 (Table 4.8).  
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Table 4.8. Summary of mutations identified on MupM used in this study, Chapter 2 and 3*. 
MupM Residues







939 Pro Ser  
*Residues highlighted in red are those identified in Chapter 2 and initially thought of as sequencing errors. 
 
It is suspected that five of the seven mutations were introduced by PCR when the 
gene was initially cloned out of P. fluorescens by A. Kassam El-Sayed (2003). This copy was 
then sequenced and the results published on the NCBI database (Accession number: 
AAM12927.1) and used for the purpose of this study, Chapter 2 and 3. This would explain 
the reason for the five mutations not being identified when spontaneous and UV mutants 
from Chapter 2 and QuikChange mutants from this study were sequenced. The additional 
two mutations identified in Chapter 2 are thought to have been introduced when mupM was 
subsequently cloned into pJH10 and pUC18 by Jo Hothersall and Elton Stephens, and hence 
noticeable when pairwise aligned with the published sequence. 
These additional seven mutations that were unknown during the duration of these 
studies may explain the low MIC values and the decrease in thiomarinol and mupirocin 
tolerance amongst the QuikChange mutants. The mutations were located on the MupM 
structure previously modelled in Chapter 2 using PyMOL (Figure 4.7). The structure revealed 
five out of seven mutations to be located away from the active site. The last two residues 
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were at the N-terminus end of the protein (after Cys805) and not modelled as it appeared to 







Figure 4.7. Mutations on the MupM copy used in this study and in Chapter 2. The mutated 
residues are highlighted in blue. The active site is highlighted by the red circle. 
 
Although the mutations were not located in the active site of MupM, the multiple 
mutations may have had a fitness cost on the enzyme and caused decrease in functionality 
and mupirocin-resistance. Some of the amino acid changes are quite drastic, such as the 
leucines in position 667 and 671 mutated to flexible proline residues. These changes may 
alter how the enzyme folds and/or behaves compared to the wild-type. This may also affect 
the solubility of MupM. Adding further mutations during this study may have further 
dampened the functionality of this enzyme. To test these theories, the correct mupM gene 
needs to be re-cloned into pJH10 and its MIC value verified. If the resistance phenotype is 
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similar to that reported by Yanagisawa and Kawakami, it would be of interest to repeat the 
QuikChange mutagenesis using the correct mupM gene to see if the residues identified in 
Chapter 2 are truly important in conferring the thiomarinol resistance phenotype. 
Once the correct mupM gene is cloned into pJH10, there may also be advantages in 
repeating the mating experiment of P. fluorescens pJH10 and S17-1 pAKE604ΔileS1. Colonies 
were yielded in the initial experiment, although the identity of these colonies needed to be 
confirmed as true P. fluorescens pJH10 pJHIle01 and not contaminants or P. fluorescens 
carrying one plasmid only. 
4.4.2 Mimicking TmlM does not necessarily increase thiomarinol 
resistance 
If the MupM mutants are functional yet have decreased mupirocin and thiomarinol 
resistance, it suggests that simply mimicking the active site of TmlM is not enough to gain 
thiomarinol resistance and that while changing Lys595 in MupM to an arginine may increase 
thiomarinol tolerance, perhaps a specific combination of changes is required to create the 
resistance phenotype. Furthermore, mimicking the active site of TmlM does not necessarily 
increase mupirocin resistance (as demonstrated by M7).  
Perhaps a better strategy for understanding the key residues involved in the 
thiomarinol resistance phenotype would be to substitute amino acids in TmlM to those 
found in MupM and to look for loss of resistance, rather than gain of resistance. However, it 
is also worth noting that not seeing an increase or decrease in MIC value does not 
necessarily mean that less binding is taking place between the ligand and the active site of 
the mutants, as discussed by Nikaido and Pages (2012). (See Chapter 6, Discussion.) 
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As discussed in Chapter 3 and in this study, Nakama and colleagues identified two 
residues (His581 and Thr48) on the mupirocin sensitive T. thermophilus to be important in 
conferring the mupirocin sensitive phenotype. When these residues were mutated to mimic 
those of an eukaryotic IleS (asparagine and phenylalanine), they found the Ki value to 
increase by a order of magnitude (Nakama et al., 2001). They did not perform MIC tests on 
their double mutant.  
The mutant M5 was created in this study carrying the two important residues 
asparagine and phenylalanine to mimic TmlM and similarly the eukaryotic IleS mentioned by 
Nakama et al. (2001). However, a decrease in MIC values was seen for both mupirocin and 
thiomarinol and not what was expected based on the paper by Nakama et al. (2001). It 
would be interesting to measure the Ki for mupirocin and thiomarinol against this mutant to 
see if Nakama and his colleagues’ results are reproducible in MupM.  
Overall, it would be useful to have soluble wild-type and mutant MupM protein for 
further work to understand more of the kinetics of these enzymes instead of relying on their 
MIC phenotype. It may be worthwhile continuing to troubleshoot for yielding soluble protein 
by ways of denaturing and re-naturing or changing the expression system. 
4.4.3 Insolubility of P. fluorescens proteins in heterologous system 
Previous protein purification works undertaken by colleagues have all faced difficulty 
in yielding soluble protein from the mupirocin biosynthesis cluster. By comparison, 
expressing and purifying IleS1s from E. coli DH5α, SBW25 and B. subtilis were 
straightforward and required minimal method optimisation as described in Chapter 5. As 
mentioned in Chapter 1, mupirocin is produced by a chromosomally encoded Type I 
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polyketide synthesis cluster called the mup cluster (Whatling et al., 1995). The biosynthesis 
genes are clustered into six multifunctional polypeptide modules. Previous works, including 
this study have attempted to express single proteins in the pET28a system and never entire 
modules. It is now hypothesised that soluble proteins may be more effectively yielded by 
expressing modules of proteins together, as laboratory and computational work are starting 
to elucidate the important interactions between proteins and their linkers in the same 
modules (Thomas et al., Unpublished). 
Alternative approaches to yielding soluble MupM would be to follow the protocol of 
Yanagisawa and Kawakami (2003). They were successful in producing soluble IleS1 and 
MupM (called IleRS-R2 in their publication) by expressing and purifying these proteins 
directly from P. fluorescens using DEAE-Sephacel Chromatography and multiple elutions 
using various buffers. They were also able to overexpress and purify the proteins by 
expressing the genes on plasmid pEXR1 (formerly called pPFNB7) in E. coli strain Ts331. The 
cultures were grown in large volumes at 3 L of rich SOB medium with 50 µg/ml ampicillin and 
0.5 mM IPTG at 30°C for 10 hours. The cells were harvested by sonication and the purified 
proteins yielded from a three-step chromatography method using DEAE-Toyopearl or DEAE-
Sephacel, n-butyl-Toyopearl and hydroxyapatite columns. Their second protocol suggests 
that increasing overall production volume may allow soluble proteins to be yielded from the 
pET28a system used in this study. 
4.4.4 Concluding remarks 
This study has made attempts to understand whether increased binding to the IleS 
target is an important mechanism behind thiomarinol’s potency. QuikChange mutagenesis 
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was performed in an attempt to confirm the importance of the residues identified in the 
computer modelling work of Chapter 3, and whether increased binding affinity of 
thiomarinol to its target IleS confers its potent activity. The underlying issues with the seven 
mutations in the mupM gene used in this study needs to be corrected and the QuikChange 
mutations repeated. The identification of unwanted mutations at the end of this study 
highlights the importance of confirming all materials prior to undertaking experiments – this 
is regardless of experimental repetition and additional costs such as in sequencing. There is 
great value in confirming the residues involved in the interaction with thiomarinol, as it will 
provide a comprehensive map of the target enzyme’s active site and allow a more informed 












5 PURIFICATION AND ENZYME ACTIVITY OF ILES 
5.1 Introduction 
The aim of the work described in Chapters 3 and 4 was to determine the specific 
residues in the IleS active site that may allow thiomarinol to bind more strongly than 
mupirocin to their target enzyme. Although the computational work in Chapter 3 identified 
eight residues of potential importance, the mutagenesis of these amino acids in Chapter 4 
did not confirm their role in increasing or decreasing thiomarinol/mupirocin resistance. 
In this section, a more direct approach of enzyme kinetics was taken to determine 
whether increased binding of thiomarinol to IleS is a major contributor to its potency. The 
mechanism of mupirocin inhibition of IleS from Staphylococcus aureus and Escherichia coli 
has previously been characterised using steady-state kinetics (Hughes and Mellows, 1980; 
Pope et al., 1998a) but work in characterising the activity of thiomarinol by scientists at 
Daiichi-Sankyo did not go as far as looking at its activity against purified enzymes (Shiozawa 
and Takahashi, 1994; Shiozawa et al., 1993, 1995, 1997). The aim of the study was to 
determine the inhibitor concentration (Ki) for thiomarinol via the aminoacylation assay using 
IleS1 from E. coli DH5α. If thiomarinol is a stronger inhibitor than mupirocin, the former 
would yield a lower Ki value than mupirocin. 
5.2 Materials and Methods 
5.2.1 Bacterial strains, growth conditions and plasmids 
All bacterial strains and plasmids used in this study are listed in Table 5.1. 
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For protein purification, various IleSs were individually expressed in E. coli BL21 
carrying plasmid pET28a (Novagen, United Kingdom) as outlined in Chapter 4. All strains 
were grown in L-broth at 200 rpm, with the appropriate antibiotic for selection. IPTG was 
added as appropriate, ranging from 0.1 to 0.001 mM concentrations. 
Table 5.1. Bacterial strains and plasmid used in this study. 
Bacterial Strain Genotype Phenotype Source/Reference
B. subtilis  1064
trpC2amyE::(spec Pxyl-gfp-lacI)
chr::pSG1196 (rrnD-lacO cat)
Inherently mupirocin sensitive. Moir et al.,  1979
E. coli  BL21 (DE3) F
-
 ompT hsdSB gal dcm  (DE3)
Strain for inducing high protein
expression. Contains the DE3 lysogen
that carries the gene for T7 RNA
polymerase under the control of the
lacUV5 promoter.
Invitrogen
E. coli  DH5α
endA1 recA hsdR17 lacZΔM15
supE44 gyrA96 thi-I relA1  F








Plasmid Properties Size (kb) Source/Reference
pET28a





5.2.2 Cloning IleS1 from various microorganisms 
IleS1 genes from E. coli DH5α, Pseudomonas fluorescens SBW25 and Bacillus subtilis 
1064 were PCR-amplified from boiled cell samples using Q5® High Fidelity DNA Polymerase 
(New England BioLabs Inc, United Kingdom). 1-2 single colonies were resuspended in 200 µl 
dH20 and vortexed before boiling for 10 minutes. The mixture was then centrifuged for 5 
minutes at 11,300 xg and 2 µl of supernatant used for each PCR reaction. Primers were 
designed with suitable restriction sites at the 5’ ends to allow subsequent cloning of the 
amplified gene into pET28a (Table 5.2). The PCR reaction (final volume of 50 µl) consisted of 
10 µl of 5x Q5® Reaction Buffer, 4 µl of 2.5 mM dNTP mixture, 2.5 µl of 10 µM forward and 
reverse primer each, 2 µl of boiled template DNA, 0.5 µl of Q5® High-Fidelity DNA 
polymerase, 10 µl of 5x Q5® High GC Enhancer and 18.5 µl of dH2O. The PCR programme was 
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set as recommended by the manufacturer but with 2 initial cycles at a lower annealing 
temperature optimal for the primer to correctly anneal to the ileS1 gene. To determine the 
optimal annealing temperatures, the Tm calculator provided by New England Labs was used. 
For the 2 initial cycles, the Tm was calculated using the primer sequence excluding the 
additional restriction site sequence. The remaining 28 cycles were run at the annealing 
temperature optimal for the whole primer (including the restriction site) (Table 5.3). 5 µl of 
the PCR reaction was run on 1 % agarose gel to confirm the presence of the correct product 
before cleaning the remaining reaction using a gel band purification kit (G.E. Healthcare, 
United Kingdom), digesting with the appropriate restriction enzymes and ligating into 
pET28a vector. The ligated vector and insert was transformed into E. coli BL21 for further 
protein expression and purification. The sequence of the cloned DH5α ileS1 gene was 
checked using primers described in Table 5.2. 
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Table 5.2. Oligonucleotide primers designed for amplifying and checking the sequence of 
ileS1 genes*. 
Organism PCR Primer
E. coli  DH5α 5’-aaaGCTAGCatgagtgactataaatcaaccct-3’
5’-aaaCTCGAGtcaggcaaacttacgtttttc-3’
B. subtilis  168 5’-aagGCTAGCatggattttaaagacacgct-3’
5’-aaaCTCGAGttatttttgatagtatttttcaacg-3’
P. fluorescens  SBW25 5’-aaaGCTAGCatgaccgactataaagcca-3’
5’-aaaCTCGAGttaggcatagtgacgaacc-3’
Organism Sequence Checking Primer
E. coli  DH5α 5’-taatacgactcactataggg-3’ (Universal T7 Promoter)





*All ileS1 genes were amplified with NheI or XhoI restriction sites at the 5’ end. Restriction sites are highlighted in capital 
letters.  
 
Table 5.3. PCR programme for using Q5® High-Fidelity DNA Polymerase as recommended 
by supplier1. 
Cycles Temperature Time
1 98°C 30 seconds
2 98°C 10 seconds
x°C 30 seconds
72°C 30 seconds/kb*
28 98°C 10 seconds
xx°C 1 minute
72°C 30 seconds/kb*
1 72°C 2 minutes  
1
The lower annealing temperature was used for x and the higher temperature for xx. Therefore 56°C and 65°C respectively 
were used for B. subtilis and 61°C and 70°C for DH5α and SBW25. *In this study, 90 seconds for the approximately 3 kb 




5.2.3 Protein expression and purification of IleSs 
For total and soluble protein expression, SDS-PAGE and protein purification by nickel 
affinity chromatography, methods outlined in Chapter 4 were followed.  
For dialysis, fractions containing the soluble protein of interest were collected from 
nickel affinity chromatography and pooled together. Spectra/Por 1 dialysis membrane 
(Spectrum® Laboratories, Inc., Europe) was cleaned as specified by manufacturer, prior to 
dialysis to remove sulphide and metal residues. Sulphide was firstly removed by washing the 
membrane for one minute at 80°C in two part dH2O and one part Solution A (1 g sodium 
sulphite in 100 ml H20). The membrane was then washed with dH2O at 60°C for two minutes 
before adding 2 ml of Solution B (0.4 ml 99.9% sulphuric acid in 100 ml dH2O) per 50 ml of 
total solution. The solution was mixed thoroughly for one minute before rinsing with dH2O 
for several minutes. Metal residues were then removed by washing the membrane with 
0.05M EDTA (pH 8.0) for 10 minutes before rinsing with dH2O. The pooled fractions of 
soluble protein were pipetted into the prepared dialysis membrane, clipped at both ends 
and left stirring overnight at 4°C in 100x the volume of soluble protein of Tris-HCl (50mM, 
pH7.9). Contents of the dialysis tube were transferred into a falcon tube and stored at 4°C 
until further use. 
5.2.4 Quantification of active IleS concentration 
The concentration of active enzyme in the dialysed IleS1 fraction was determined by 
the protocol outlined by Francklyn et al. (2008). An assay mix consisting of 10 µM [14C] 
isoleucine (final specific activity of 5 µCi/ml), 2 mM Mg-ATP, 144 mM Tris-HCl, pH 7.78, 10 
mM MgCl2, 1 U/ml inorganic pyrophosphatase and 5 mM β-mercaptoethanol was prepared 
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and equilibrated at the temperature selected for the assay (25°C or 37°C). The assay mix was 
then separated into individual 15 µl final volume aliquots and 1 µM of dialysed IleS1 (2 µl) 
added to start the reaction at the chosen temperature. After incubation periods of 5, 10 or 
20 minutes, the 15 µl aliquots with enzyme (in triplicates) were spotted onto dry 
nitrocellulose filters (Sigma-Aldrich, United Kingdom) in 144 mM Tris-HCl pH 7.78 buffer, left 
for varying periods to allow binding and then washed with 5 ml cold 144 mM Tris-HCl pH 
7.78 buffer. The filters were dried at 42°C, vortexed in 10 ml Ultima GoldTM MV scintillation 
cocktail (Perkin Elmer, United Kingdom) and counted in the scintillation counter. An aliquot 
of assay mix without the addition of IleS1 (in triplicate) was also spotted onto nitrocellulose 
filters and dried without washing to determine the specific activity of the assay mix. This 
specific activity was then used to calculate the concentration of active IleS2 i.e. the amount 
of IleS1 that contained bound [14C] isoleucyl adenylate. Equations used were as follows: 
Specific Activity (CPM/pmol) = Average of no wash (CPM) / Ile in aliquot (pmol) 
[Active IleS] (pmol) = Average of washed aliquots (CPM) / Specific Activity (CPM/pmol) 
5.2.5 Aminoacylation assay 
Aminoacylation assays were set up at a range of enzyme concentrations. The assay 
mix consisted of 50 mM Tris-HCl (pH 7.9), 10 mM MgCl2, 50 mM KCl, 2 mM dithiothreitol 
(DTT), 0.2 mg/ml BSA, 1 mM ATP, L-[U-14C] isoleucine (specific activity of 11.5 MBq/mmol) 
and 4 mg/ml final concentration of E. coli tRNA (equivalent to 4 µM tRNAIle) (Sigma-Aldrich, 
United Kingdom) and was equilibrated at 25°C before separating them into 15 µl final 
volume aliquots. Active IleS1 was diluted to chosen concentrations with 144 mM Tris-HCl, pH 
7.78 and left on ice prior to use. IleS1 was added to the assay mix to start the reaction and at 
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specific time points, the 15 µl aliquots (in triplicates) were mixed with 15 µl of 10% 
trichloroacetic acid (TCA) pre-chilled on ice to terminate the reaction and incubated on ice 
for 10 minutes. The contents were then filtered onto dry glass fibre filters and washed with 5 
ml 5% TCA, followed by 5 ml cold ethanol. The filters were dried at 42°C before vortexing in 
10 ml Ultima GoldTM MV scintillation cocktail for counting. 
5.3 Results 
5.3.1 Isolation of soluble IleS1 from DH5α, SBW25 and B. subtilis 
The ileS1 genes from E. coli DH5α, P. fluorescens SBW25 and B. subtilis were PCR-
amplified using the designed primers (Table 5.2) and each cloned into pET28a vectors as 
explained in the Materials and Methods. Once transformed into BL21 cells, growth 
conditions and IPTG concentrations were optimised to give a level of expression that would 
result in sufficient soluble IleS1. 5 ml LB cultures with 50 µg/ml of kanamycin were grown up 
to an OD600nm 0.4 at their respective temperatures of 25, 30 and 37°C before being induced 
with IPTG concentrations of 0.1, 0.01 and 0.001 mM for 4 hours at 37°C and overnight for 
the two lower temperatures (Figure 5.1; Figure 5.2; Figure 5.3). 
For soluble protein expression of IleS1 from DH5α and B. subtilis, 37°C growth 
temperature and 0.1 mM IPTG induction for 4 hours was deemed most suitable. For 
expression of SBW25 IleS1, growth at 30°C and 0.001 mM IPTG induction overnight was 
chosen. These conditions were then applied for up-scaling the production cultures to 100 ml. 
The larger volume cultures were treated with Bugbuster as outlined in the Materials and 
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Figure 5.1. SDS-PAGE gels of BL21 pET28a ileS1 from (A) DH5α, (B) SBW25 and (C) B. 
subtilis induced at various IPTG concentrations for 4 hours at 37°C. The red arrow indicates 





















































































































































































































































































































































































































Figure 5.2. SDS-PAGE gels of BL21 pET28a ileS1 from (A) DH5α, (B) SBW25 and (C) B. 
































































































































































































































































































































































































































Figure 5.3. SDS-PAGE gels of BL21 pET28a ileS1 from (A) DH5α, (B) SBW25 and (C) B. 
subtilis induced overnight at various IPTG concentrations at 25°C. (A) Sample supernatant 





























































































































































































































Figure 5.4. SDS-PAGE gels of Nickel Affinity Chromatography fractions from 100 ml 
production cultures of (A) BL21 pET28a DH5α ileS1, (B) SBW25 ileS1 and (C) B. subtilis ileS1. 
1 ml fractions were collected and 20 µl samples run on SDS-PAGE. The red arrows indicate 





The fractions containing the IleS band were pooled and dialysed to remove imidazole 
and other solutes that may interfere with downstream applications. The dialysed samples 
were quantified using the nanodrop for total protein concentration. The active enzyme 
concentration of IleS1 from DH5α was deduced in the following section for further use in the 
aminoacylation assay. The PCR-amplified sequence of DH5α was also sequence checked 
using the designed primers as outlined in the Methods (Table 5.2). 
5.3.2 Deducing the concentration of active DH5α IleS1 
To determine the amount of active DH5α IleS1 enzyme present in the dialysed 
sample, a protocol outlined by Francklyn et al. (2008) was followed as described in the 
Methods. As discussed in Chapter 1 (Figure 1.5), IleS is responsible for catalysing a two step 
process which involves first the activation of the amino acid and second the transfer of the 
activated amino acid to its cognate tRNA as outlined below: 
Step 1: IleS + Ile + ATP  IleS(Ile-AMP) + PPi 
Step 2: IleS(Ile-AMP) + tRNA  Ile-tRNA + AMP + IleS 
The protocol used in this study was designed to monitor the amount of IleS(Ile-AMP) formed 
in the first step of the aminoacylation reaction by using [14C] isoleucine. It also relied on the 
fact that IleS complexed with the activated [14C] isoleucine has a net positive charge (as most 
enzymes do) and will be trapped when passed through a nitrocellulose filter, which has a net 
negative charge. These filters were then counted on the scintillation counter to determine 
the CPM of the bound IleS([14C]Ile-AMP). Unbound [14C] Ile has a net negative charge and 
will therefore pass through the nitrocellulose filter.  
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The assay for quantifying the active concentration of DH5α IleS1 was optimised at 
various steps and all results summarised in Table 5.4. When a master mix assay was tested at 
the preliminary stages, in which the reaction was performed in one bulk and 15 µl triplicate 
samples taken at each time point, inconsistent CPM counts were observed between the 
triplicates (data not shown). The assay mix was therefore separated into individual 15 µl 
aliquots before adding the enzyme to start the reaction in Trial 1. This ensured that each 
sample should have equal amounts of [14C] isoleucine and prevented the introduction of 
variability when removing 15 µl samples from a master mix assay at different time points. 
In the second trial, the assay was equilibrated and performed at 25°C and 37°C to 
determine the optimum temperature. The samples were also passed through the 
nitrocellulose filter straight away after 0 or 10 minutes incubation, to see if the inconsistency 
in CPM values was due to the varying times in which the samples were left on the filters 
before further processing. The resulting CPM counts were very low compared to that of the 
initial trial and still inconsistent between the duplicates (Table 5.4). Some of the counts were 
mostly background, as 1 ml scintillation cocktail had a CPM of 24. 
The low counts were proposed to be caused by spotting samples onto nitrocellulose 
filters straight away without given them enough time to bind to the filters, causing the 
enzyme to be washed away. To address this possibility, the samples in the final assay were 
left to bind on dry nitrocellulose filters for five, 10 and 20 minutes after 20 minutes 
incubation. Additionally, the incubation times of the assay were trialled at 5, 10 and 20 
minutes to optimise the incubation period before allowing the samples to bind to the filters 
for one minute before washing and drying. 
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Table 5.4. Results of radioactive isoleucine binding to active DH5α IleS1: quantification Trial 1, 2 and 3*. 
Samples CPM Average Samples CPM Average Samples CPM Average
Specific Activity 1 179561 181919.67 Specific Activity 1 116922 119610.50 5 min 1 1140 1105.50
Specific Activity 2 183065 Specific Activity 2 122299 5 min 2 1071
Specific Activity 3 183133 0 min 1 156 97.50 10 min 1 2139 1420.50
2 min 1 3696 7754.00 0 min 2 39 10 min 2 702
2 min 2 12785 10 min 1 81 168.50 20 min 1 543 495.00
2 min 3 6781 10 min 2 256 20 min 2 447
5 min 1 1513 3236.67 20 min, 5 min filter 1 2344 1651.83
5 min 2 5100 Specific Activity 1 120115 114559.00 20 min, 5 min filter 2 1341
5 min 3 3097 Specific Activity 2 109003 20 min, 10 min filter 1 2243
10 min 1 5048 4086.00 0 min 1 32 40.50 20 min, 10 min filter 2 1276
10 min 2 1327 0 min 2 49 20 min, 20 min filter 1 1282
10 min 3 5883 10 min 1 90 117.00 20 min, 20 min filter 2 1425
10 min 2 144





*The Specific Activity samples are reaction mixes without IleS, spotted directly on the nitrocellulose filters and dried without washing to determine the specific activity of the assay mix. 






The resulting CPM counts were an improvement from the previous assays, with the 
duplicate counts higher and more consistent than before. All CPMs from samples that were 
incubated for 20 minutes and left to bind to the filters at 5, 10 and 20 minutes were 
averaged to calculate the concentration of active DH5α IleS1. The equations outlined in the 
Methods were used to calculate the concentration of active DH5α IleS1 and this was 3.11 
pmol in 15 µl (Table 5.5), hence 0.207 µM [IleS1]. 




C] Ile stock concentration 20 µg/ml
[
14
C] Ile used in 15 µl assay 1.5 µl
Molar Concentration of [
14
C] Ile 0.015 µmol/ml 20 µg/ml x 0.0015 ml = 0.03 µg
xM x 131.2 g/mol = 0.03 µg/15 µl
xM x 131.2 g/mol = 2 µg/ml
x = 0.015 µmol/ml
= Average of no wash CPMs/pmol isoleucine in aliquot [
14
C] Ile per 15 µl assay 225 pmol 0.015 µmol/ml x 0.015 ml = 0.000225 µmol
= 225 pmol
Specific activity 531.6 CPM/pmol 119610.50/225 = 531.60
Concentration of active IleS 3.11 pmol 1651.83/531.60 = 3.11






5.3.3 Aminoacylation assay 
The aminoacylation reaction catalysed by DH5α IleS1 was investigated by monitoring 
the formation of final [14C]Ile-tRNA product in a discontinuous steady state assay. Various 
protocols from previous studies were considered before deciding on the method used in this 
study. A summary of the assay mixtures is shown in the next table (Table 5.6). The method 
of Pope et al. (1998) was used with slight modifications in ATP and BSA concentrations. The 
incubation temperature of 25°C was used in this study based on observations that it was 




Table 5.6. Summary of aminoacylation assay mixes from this study (1) and previous literature (2-5). 
1 2 3 4 5
Total Reaction Mixture (µl)
15 100 500 200 -
Temperature (°C)
25 37 37 22 37
Materials
50 mM Tris-HCl 100 mM Tris-HCl 20 mM Tris-HCl 50 mM Tris-HCl 50 mM Tris-HCl
pH 7.9 pH 7.5 pH 7.2 pH 7.9 pH 7.5
2 mM dithiothreitol (DTT) 2 mM DTT 10 mM DTT 2 mM DTT 4 mM DTT
4 µM tRNAIle 12 A260 units of tRNA - 4 mg/ml tRNA (approx. 4 µM) Range
10 mM MgCl2 10 mM MgCl2 10 mM MgCl2 10 mM MgCl2 10 mM MgCl2
50 mM KCl 10 mM KCl 10 mM KCl 50 mM KCl 20 mM KCl
1 mM ATP 1 mM ATP 1 mM ATP 4 mM ATP Range
15.25 µM [14C] isoleucine 0.01-0.1 mM [14C] isoleucine 0-1 µM [14C] isoleucine 15.25 µM [14C] isoleucine Range
0-20 nM mupirocin/thiomarinol 0-50 nM mupirocin 0-50 nM mupirocin 0-50 nM mupirocin Range
5 nM IleS 0.1 µg IleS (approx. 9 µM) 0.33-1.06 nM/µl of cell volume* 0.2-5 nM IleS 1-5 nM IleS
0.2 mg/ml BSA - - 1 mg/ml BSA 0.2 mg/ml BSA  
1
Assay used in this study; 
2
(Dureković et al., 1973; Hughes and Mellows, 1980); 
3
(Capobianco et al., 1989); 
4
(Pope et al., 1998b); 
5
(Francklyn et al., 2008).  






This assay essentially recreates the aminoacylation reaction in a microfuge tube and 
stops the reaction at a suitable time by incubating on ice. Trichloroacetic acid (TCA) is added 
to precipitate proteins from the assay and then the mixture is passed through a glass fibre 
filter to trap [14C]Ile-tRNA for scintillation counting. Ethanol is used to remove traces of TCA 
from the sample. Following the selection of assay mix components and amounts outlined in 
Table 5.6, the concentration of IleS enzyme, incubation period and overall procedure for 
yielding consistent CPM counts were optimised before challenging the assay with mupirocin 
and thiomarinol. 
In the preliminary trial of the aminoacylation assay, the concentration of DH5α IleS1 
enzyme was varied in 10-fold steps between 20 nM to 0.02 nM, in order to deduce the 
optimal enzyme concentration. The resulting CPM counts were widely varying between 
duplicates and it was impossible to deduce which enzyme concentration was optimal for 
further assays. It was hypothesised that the widely varying results were due to the assay 
samples being spotted onto the glass fibre filters before putting them through a pulling 
vacuum for washing. The filters were individually sandwiched between a two-unit filter 
device and clamped to secure everything in place. This meant that when the vacuum began 
pulling, only the centre of the filter exposed to the buffers would be washed but not the 
outer rim of the filters. It was thought plausible that by allowing the samples to diffuse 
through the entire filter before washing, any sample at the edges was not efficiently washed, 
including the non-bound [14C] isoleucine. 
In order to correct this, samples were spotted on filters already set up to the vacuum 
filtration apparatus. The counts obtained in this next assay (incubation period of 5 minutes) 
had reproducible counts between the duplicates (Figure 5.5). The control assays with 20 nM 
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IleS but no tRNA yielded counts of 1793 and 1238 CPM. These counts suggest non-specific 
incorporation to be taking place; if these values are true background noise and deducted 
from the CPM values at 20 nM IleS in Figure 5.5, the remaining CPM is negligible and implies 
no specific activity in the aminoacylation assay. 
 
Figure 5.5. Aminoacylation of Ile-tRNA with decreasing concentrations of IleS enzyme. The 
assays were incubated for 5 minutes before measuring the CPM. The individual data are 
shown as sample 1 in blue and sample 2 in red. The average of the duplicates is shown by 
the dotted green line. 
 
The aminoacylation assay was repeated with 2 nM and 5 nM IleS concentrations and 
at time points of 0, 2, 5 and 10 minutes with and without tRNA (Figure 5.6). The resulting 
CPM counts with 2 nM IleS and 5 minutes incubation time were lower than from the 
previous assay (average of 245 and 792.5 CPM respectively), suggesting that the dialysed IleS 
stock is slowly degrading in the one month storage at 4°C between the two assays. The 
control assays with no tRNA were all consistently basal CPM of around 30 counts, indicating 





Figure 5.6. Aminoacylation assays performed with (A) 2 nM and (B) 5 nM IleS at different 
time points. The individual data are shown as sample 1 in blue and sample 2 in red. The 
averages of the duplicates are shown by the dotted green line. 
 
Although the trendline of the assay performed with 2 nM IleS was as expected – with 
CPM counts increasing as the assay was left to incubate up to 10 minutes, the variability of 
counts between the two samples was greater than that of the 5 nM IleS assay. Therefore, 
the experimental conditions of 5 nM IleS and an incubation period of 10 minutes were 
chosen, based on their reproducibility between samples, to perform the final aminoacylation 
assay challenged with various concentrations of mupirocin and thiomarinol (1.25, 2.5, 5, 10 
and 20 nM) in duplicates. These concentrations were chosen based on the K i value for 
mupirocin previously determined by Hughes and Mellows in 1980 using E. coli B IleS. They 
determined the values for both the activation of isoleucine (the pyrophosphate exchange 
reaction) and the overall aminoacylation reaction to be Ki 2.5 nM and Km 11.1 µM (Hughes 
and Mellows, 1980). 
The results were inconclusive, as the CPMs did not decrease as the competitive 




contrary, there was a general trend of the CPM values increasing and peaking unexpectedly 
at 10 nM mupirocin and 2.5 and 20 nM thiomarinol (Figure 5.7). 
 
 
Figure 5.7. Aminoacylation assay challenged with various concentrations of (A) mupirocin 
and (B) thiomarinol. The individual data are shown as sample 1 in blue and sample 2 in red. 
The averages of the duplicates are shown by the dotted green line. 
 
Table 5.7. CPM counts of specific activity and control with no antibiotic challenge. 







The control assays that were (1) not washed and (2) had no antibiotic challenge yielded CPM 
values that were as expected (an average of 122,456 and 217 respectively) (Table 5.7). The 
average count of the latter control with no antibiotics was comparable to the counts yielded 
in the previous assay (364 CPM). Considering that the assay produces counts on average 217 
and 364 CPM without the addition of antibiotics, it is concerning that at mupirocin 
concentrations of 5 and 10 nM, the average counts were 417 and 633 CPM respectively. The 




data not interpretable. The counts obtained from the assay with thiomarinol are lower than 
that of mupirocin but again, it is hard to differentiate between background noise and true 
counts at this stage. However, at the lowest concentration of thiomarinol (1.25 nM), IleS 
activity appears to be at baseline. If this can be reproduced and a more reliable set of data 
obtained for mupirocin, comparatively lower counts for thiomarinol would suggest that the 
antibiotic is indeed the more potent and stronger binding compound than mupirocin. It 
would be of great interest to continue this work to obtain the Ki value of thiomarinol. 
5.4 Discussion 
5.4.1 Solubility of the IleS proteins in an heterologous system 
Unlike the difficulties faced when attempting to obtain soluble MupM in Chapter 4, 
soluble IleS1 from E. coli DH5α, SBW25 and B. subtilis was achieved by a straightforward 
protocol with minimal optimisation of the growth conditions. As discussed in Chapter 4, this 
may be because IleS is not part of a modular protein like MupM and therefore easier to 
express and solubilise in the pET28a system. For future protein solubilisation, it may be 
advantageous to check first whether the translated protein is singular or modular, in order 
to select for the optimal heterologous expression system prior to method optimisation. 
5.4.2 Future Work on aminoacylation assay 
The aminoacylation assay challenged with mupirocin and thiomarinol needs further 
optimisation before reliable Ki values can be measured for the latter antibiotic. Further 
troubleshooting is required to understand why the CPM values did not decrease as the 
concentration of inhibitor was increased by 2-fold steps in this study and why at some 
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antibiotic concentration, the counts exceeded that yielded in the control assay with no 
antibiotics. A possible reason for this discrepancy is the gradual degradation of the purified 
IleS stock. This was observed between the first and second aminoacylation assay performed 
without inhibitors and the resulting counts were lower for the latter assay. A possible 
solution to this discrepancy would be to perform the aminoacylation assay in a master mix, 
instead of individual aliquots, and to remove samples at the required time points. However, 
the latter was tested during the optimisation stages of deducing the active IleS 
concentration and it was deemed to cause the large fluctuations between the triplicate 
samples. 
Another possibility is that the 15 µl total volume of each assay is too small and only 
provides low counts that cause high fluctuation/variability. This was also observed in 
Chapter 6, where low incorporation of [14C] into pseudomonic acid A and thiomarinol A gave 
widely variable and inconclusive counts when used in preliminary uptake studies. Perhaps it 
is worth repeating the assays but at larger sampling volumes of 100-200 µl like in other 
methods considered in Table 5.6. 
Once optimised, the aminoacylation assays will ideally be repeated using increasing 
concentrations of [14C] isoleucine and thiomarinol to determine the Ki value using the 
secondary Dixon plot (Hughes and Mellows, 1980). Determining the Ki for thiomarinol would 
allow better comparison against the binding strength of mupirocin and elucidate whether 
the former antibiotic is more effective due to its increased binding capabilities.  
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5.4.3 Concluding remarks 
This study has made attempts to optimise the aminoacylation assay for determining 
the Ki value for thiomarinol. Although no Ki value was obtained in this study for thiomarinol, 
altering the total volume and concentrations of IleS, [14C] isoleucine and antibiotic may 
develop a useful standardised assay for future use. Determining the Ki for thiomarinol will 
assign kinetic parameters to this antibiotic and the optimised assay will allow easier 












6 INVESTIGATING THE ROLE OF UPTAKE AND EFFLUX IN 
THIOMARINOL POTENCY 
6.1 Introduction 
In the previous sections, the hypothesis that increased binding of thiomarinol 
(relative to mupirocin) to its target IleS enzyme contributes to the antibiotic’s increased 
efficacy has been investigated. This section focuses on the other hypothesis that efficient 
transport of thiomarinol into sensitive bacterial cells and/or inefficient efflux by the cells 
allows the antibiotic to increase its potency on a wider range of Gram-positive and negative 
microorganisms than occurs with mupirocin. 
Antibiotics such as mupirocin that target intracellular enzymes must be able to enter 
the bacterial cell through its membrane(s). This is more of a challenge for antibiotics that 
target Gram-negative microorganisms, as they need to overcome the outer membrane as 
well as the inner membrane. Generally, hydrophobic antibiotics (such as macrolides) 
penetrate the outer membrane by diffusing through the lipid bi-layer (a mechanism poorly 
understood) while smaller hydrophilic drugs (such as β-lactams) pass through porins 
(Delcour, 2009; James et al., 2009). Some antibiotics typically penetrate the inner membrane 
by forming oligomeric pores that are substrate-selective in electric charge and size; for 
example, daptomycin forms pores in the presence of calcium and only on membranes 
containing phosphatidylglycerol (Zhang et al., 2014). It is crucial for the efficacy of the drug 




As briefly mentioned in Chapter 1, upregulation or acquisition of efflux transporters 
is one of the mechanisms of resistance against antimicrobials. In particular, multidrug efflux 
transporters are an important group associated with intrinsic and acquired resistance in 
bacteria. This group consists of five families based on their amino acid sequence homology 
and mode of energy-coupling (Paulsen, 2003) (Figure 6.1). 
 
Figure 6.1. The five families of multidrug efflux transporters (reproduced from Paulsen, 
2003). 
 
The ATP-binding cassette (ABC) and major facilitator superfamily (MFS) are the 
largest families within the group and consist of ATP and chemiosmotically-driven 
uptake/efflux systems respectively. The resistance-nodulation division (RND) and small 
multidrug resistance (SMR) superfamilies consist of proton-driven systems. Finally, the 
multidrug and toxic compounds efflux (MATE) transporters are sodium ion-driven. In Gram-
negative organisms, RND-type transporters play a significant role in conferring resistance 
because: (1) their tripartite complex creates a direct efflux pathway from the cytoplasm to 
the extracellular medium; and (2) they efflux a wide range of substrates from various 
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antibiotics to detergents (Blair and Piddock, 2009; Yu et al., 2003). It is the combinatory and 
balancing effect of efflux transporters and the outer membrane slowing the entry of 
antibiotics that confers this high-level intrinsic and acquired resistance phenotype against 
many drugs (Cox and Wright, 2013; Webber and Piddock, 2003).  
While the transport mechanism of thiomarinol is yet to be elucidated, mupirocin has 
been observed to indiscriminately enter both sensitive and resistant bacteria by passive 
diffusion (Capobianco et al., 1989), although not most Gram-negative organisms. The 
difference that was noted by Capobianco and colleagues was not in the uptake but in 
accumulation – they noted mupirocin to accumulate in sensitive bacteria (Staphylococcus 
aureus and Bacillus subtilis) due to binding to the IleS target. Likewise, they noted that 
resistant strains restrict this access to the binding site. No efflux mechanism to remove 
mupirocin from the cells after passive influx was mentioned in their study. Much later, 
Huang et al. (2004) noted mupirocin to be a substrate for the chromosomally-encoded efflux 
transporter MdeA (part of MFS) in S. aureus. When MdeA was overexpressed, an increase in 
mupirocin tolerance was observed; with the MIC increasing by 16-fold from 0.03 to 0.5 
µg/ml. However, Huang et al. concluded that the contribution of MdeA to mupirocin 
resistance was most likely insignificant, as the strain was still susceptible to the antibiotic 
even after the MIC increase. 
As discussed in previous sections, high level mupirocin resistance has been attributed 
to a eukaryote-like IleS2 such as MupM in the mupirocin-producer Pseudomonas fluorescens 
NCIMB 10586 (El-Sayed et al., 2003; Yanagisawa and Kawakami, 2003). Along with the 
mupirocin biosynthesis cluster, the expression of mupM is also controlled by the mupI/R 
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quorum sensing and occurs at the onset of the log phase (El-Sayed et al., 2001; Hothersall et 
al., 2007). This gene is thought to play a dominant role in conferring high level mupirocin 
resistance in the producer because P. fluorescens NCIMB 10586 ΔmupM exhibited a lower 
MIC value of mupirocin than ΔileS (0.2 mg/ml and > 2 mg/ml respectively) (Hothersall et al., 
Unpublished). However, high level resistance against mupirocin was also detected during 
exponential phase, when mupM should not be expressed (Hothersall et al., Unpublished). 
This led to the investigation of additional resistance mechanisms and the identification of a 
multifunctional efflux transporter that may provide both the resistance phenotype and a 
transport mechanism for exporting mupirocin from the producer (Whatling et al., 1995). 
Interestingly, when the homologue of this efflux transporter in S. aureus was over-expressed, 
no increase in resistance was observed against mupirocin in this microorganism (Thomas et 
al., Unpublished). 
This study focuses on the possible role of uptake and efflux in bacterial cells in the 
potency of thiomarinol. It attempts to investigate whether thiomarinol accumulates at a 
faster rate and/or higher concentration in susceptible cells than mupirocin and whether this 
is an explanation for the former antibiotic’s low MIC against a wider range of 
microorganisms than the latter (Chapter 1, Table 1.5). As a tool for detecting the 
accumulation and efflux of thiomarinol and mupirocin in bacterial cells, attempts were made 
to prepare [14C] thiomarinol A and pseudomonic acid A with high specific activity isotopic 
labelling. The aim was to use these radioactive ligands to investigate uptake and efflux in E. 
coli as a representative organism for Gram-negative mupirocin resistance and B. subtilis for 
Gram-positive mupirocin sensitivity. This study also investigates the role of efflux 
transporters (in Salmonella enterica serovar Typhimurium or S. typhimurium) in 
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mupirocin/thiomarinol resistance and whether less efficient efflux allows thiomarinol to be a 
more effective antibiotic than mupirocin. 
6.2 Materials and Methods 
6.2.1 Bacterial strains and growth conditions 
All bacterial strains used in this study are listed in Table 6.1. 
Table 6.1. Bacterial strains used in this study. 
Bacterial Strain Genotype Phenotype Source/Reference
B. subtilis  1064 trpC2 Inherently mupirocin sensitive. Kunst et al.,  1997
E. coli  DH5α
endA1 recA hsdR17
lacZΔM15 supE44
gyrA96 thi-I relA1  F
-







Hothersall et al. , 2011
P. rava  sp.
SANK73390
- Thiomarinol Producer. Daiichi-Sankyo
S. enterica  serovar
Typhimurium
ATCC14028s
- Wild-type (WT). Fields et al. , 1986
ΔtolC ΔtolC ::CmR ATCC14028s with tolC  deletion. Nishino et al.,  2006
ΔacrB ΔacrB ::KmR ATCC14028s with acrB  deletion. Nishino et al.,  2006
ΔacrD ΔacrD ::CmR ATCC14028s with acrD  deletion. Nishino et al.,  2006
ΔacrEF ΔacrEF ::CmR ATCC14028s with acrEF  deletion. Nishino et al.,  2006
ΔmdtABC ΔmdtABC ::CmR ATCC14028s with mdtABC  deletion. Nishino et al.,  2006
ΔmdsABC ΔmdsABC ::CmR ATCC14028s with mdsABC  deletion. Nishino et al.,  2006
ΔemrAB ΔemrAB ::CmR ATCC14028s with emrAB  deletion. Nishino et al.,  2006
ΔmdfA ΔmdfA ::CmR ATCC14028s with mdfA  deletion. Nishino et al.,  2006
ΔmdtK ΔmdtK ::CmR ATCC14028s with mdtK  deletion. Nishino et al.,  2006
ΔmacAB ΔmacAB ::CmR ATCC14028s with macAB  deletion. Nishino et al.,  2006  
 
[14C] thiomarinol was produced by inoculating 2 ml of Pseudoalteromonas rava sp. 
SANK 73390 overnight Marine Broth culture into 200 ml of Marine Broth. For production of 
[14C] mupirocin, a 50 ml seed culture of P. fluorescens carrying pJH2 (Hothersall et al., 2011) 
was prepared from a single colony in L-broth and incubated overnight at 25°C shaken at 200 
rpm. 10 ml of the seed culture was diluted into 170 ml of Secondary Stage Medium (SSM) 
with 20 ml of 40% glucose and 0.5 mM IPTG. SSM was prepared as outlined (Table 6.2) and 
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the pH adjusted to 7.5. The medium was split into 170 ml aliquots in individual bottles and 
autoclaved. Prior to use, 20 ml of 40% (w/v) glucose (to give 4 % final concentration) and 0.5 
mM IPTG were added. 
Table 6.2. Preparation of Secondary Stage Media (SSM). 
Secondary Stage Media (SSM) Preparation
25 g soya flour







Volume adjusted to 850 ml with dH2O
 
 
6.2.2 [14C] radioactive feeding of antibiotic production cultures 
A total of 4 µCi of [14C] acetate or [14C] methionine (Perkin Elmer, United Kingdom) 
was fed to the production culture at various time points and incubated at 23°C for P. rava 
and 22°C for P. fluorescens at 220 rpm for 48-50 hours. The specific activity of the [14C] 
acetate stock used was 328 mCi/mmol (12.136 GBq/mmol) and for [14C] methionine, 56.3 
mCi/mmol (2.083 GBq/mmol).  
6.2.3 Solvent extraction and HPLC quantification of [14C] thiomarinol A and 
pseudomonic acid A 
The process of extracting [14C] thiomarinol and pseudomonic acid A was based on the 
method for thiomarinol extraction and quantification outlined in Chapter 2 with minor 
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alterations. For [14C] thiomarinol, 200 ml acetone and ethyl acetate were used for the 
solvent extraction steps and the final antibiotic dissolved in 2 ml methanol. For [14C] 
mupirocin, the cells and SSM residues were first separated by centrifugation at 5,000 xg for 
20 minutes. The supernatant was then acidified to pH4.5 using 2 M HCl and extracted twice 
with equal volume of ethyl acetate (200 ml). For double extraction, the upper phase of the 
first ethyl acetate extraction was collected. The lower phase was then treated with another 
200 ml ethyl acetate and the upper phase collected. The two upper phases were then pooled, 
evaporated and dissolved in 2 ml methanol. 
The labelled antibiotics were quantified by HPLC. [14C] thiomarinol was quantified as 
outlined in Chapter 2. [14C] mupirocin was quantified on the same HPLC system but at a UV 
detection of 233 nm and a mobile phase water/acetonitrile gradient of 30% and 70% 
respectively. The programme was run for 60 minutes at a flow rate of 1 ml/min and 
pseudomonic acid A detected at around 20 minutes. 
6.2.4 Fraction collection 
Fraction collection was performed using the Gilson system to isolate [14C] thiomarinol 
A and pseudomonic acid A. The same Unipoint LC system software, column and conditions 
were used as with the HPLC programmes for detecting thiomarinol and mupirocin but with 
additional fraction collecting steps at various time points. Due to restrictions in volume size 
of the analytical column and tubes, multiple 100 µl samples were injected into the Gilson 
system for fraction collection of [14C] thiomarinol A and pseudomonic acid A.  
The fractionated [14C] thiomarinol A and pseudomonic acid A samples were pooled 
and the acetonitrile and water evaporated using the speed vac. The remaining [14C] 
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thiomarinol A and pseudomonic acid A residues were re-dissolved in absolute methanol and 
quantified using the HPLC as previously described. 
6.2.5 Scintillation counting 
The amount of total [14C] incorporation was measured using a scintillation counter 
(Packard 1600 TR and Perkin Elmer Tri-Carb 2810 TR). 10 or 20 µl of [14C] thiomarinol and 
mupirocin were mixed in a final volume of 1 ml Instagel (Perkin Elmer, United Kingdom) and 
counted for 1 or 10 minutes. 
6.2.6 Monitoring the window of thiomarinol/mupirocin production 
Production cultures (200 ml) of thiomarinol and mupirocin were set up as described 
above and grown for up to 24 hours. At 1 hour intervals, 100 µl samples were taken and 
diluted with 900 µl L-broth for measuring cell growth at an absorbance of 600 nm. Samples 
(1 ml) were also taken at the same intervals for thiomarinol/mupirocin quantification. P. 
fluorescens pJH2 samples were centrifuged at 14,000 xg for 5 minutes before passing the 
supernatant through a filter for HPLC quantification. P. rava samples were treated with 1 ml 
acetone and ethyl acetate as previously described to extract thiomarinol before HPLC 
quantification.  
6.2.7 Uptake Study 
Various volumes of E. coli and B. subtilis overnight cultures were set up from single 
colony inoculation and incubated overnight at 37°C, 200 rpm to yield appropriate cell 
densities. The cultures were then centrifuged at 5,000 xg for 10 minutes and the cell pellets 
re-suspended in various volumes of L-broth before dividing into aliquots for addition of [14C] 
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antibiotics or as control background counts. 100 µl samples were also taken at this stage for 
10-fold serial dilutions and plating out 100 µl of each dilution onto L-agar plates to 
determine the viable cell counts of each culture.  
[14C] thiomarinol A or pseudomonic acid A was added to the re-suspended samples 
and incubated at 22 or 30°C, 200 rpm for various incubation periods. 100 µl samples were 
taken at various time points and mixed with 900 µl Instagel for scintillation counting. This 
was to determine the overall total radioactivity in the sample. Other 100 µl samples were 
centrifuged at 12,200 xg for 1 minute and the supernatant mixed with 900 µl Instagel to 
determine the radioactivity outside the bacterial cells in the L-broth. The cell pellets were re-
suspended in 100 µl standard distilled water (SDW) before mixed with 900 µl Instagel to 
determine the amount of intracellular radioactivity. The same procedure was performed on 
the background samples with no addition of [14C] antibiotics. 
6.2.8 Transport Study 
100 µl samples were taken in triplicates for B. subtilis (a total of four samples 
including the background control sample) and single for E. coli after 30 or 60 minutes 
incubation at 30°C from the uptake study and immediately centrifuged at 12,200 xg for 1 
minute to separate the cells from the L-broth. The cell pellets were re-suspended 
individually in 2 ml L-broth and incubated at 30°C. 100 µl samples were taken at 2, 5, 10 and 
20 minute intervals and centrifuged at 12,200 xg for 1 minute. The cell pellets, supernatants 
and total samples were processed and mixed with Instagel as outlined in the uptake study 
and counted on the scintillation counter for 10 minutes to obtain intracellular, extracellular 
and total counts. 
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6.2.9 MIC Test 
Ten efflux transporter deletion mutants of Salmonella typhimurium ATCC 14028s 
were tested for their sensitivity to mupirocin and thiomarinol as outlined in Chapter 2.  
6.3 Results 
6.3.1 Optimisation of [14C] thiomarinol and mupirocin radioactive 
incorporation, extraction and quantification 
Various materials and methods were tested in an attempt to extract highly 14C-
incorporated thiomarinol A and pseudomonic acid A for their downstream applications. 
Firstly, [14C] acetate was fed to the 200 ml producer cultures in three separate feeds as 
advised by Dr. Zhongshu Song, University of Bristol. The first feed was given to the cultures 
at late afternoon on the day of the production medium inoculation (13 µl of [14C] acetate 
after four hours incubation), followed by a feed early the next morning (14 µl after 20 hours) 
and late afternoon (13 µl after 27 hours). After a total of 50 hours incubation, the cultures 
were harvested as described in the Materials and Methods. From the re-dissolved 2 ml 
stocks of [14C] thiomarinol and mupirocin in absolute methanol, 100 µl of each sample was 
quantified by HPLC. The resulting chromatograms showed the expected yields of [14C] 
thiomarinol A at a retention time of 8.28 minutes (Figure 6.2). However, the yield of 
pseudomonic acid A was higher than expected and so the [14C] mupirocin stock was diluted 
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Figure 6.2. HPLC chromatogram of [14C] thiomarinol A (in red). The x-axis represents the 
time lapsed in minutes on the HPLC programme. The retention area of [14C] thiomarinol A is 
1.29 x 108. 
 
Figure 6.3. HPLC chromatogram of [14C] mupirocin re-run with 10-folds diluted stock for 
improved detection of pseudomonic acid A (in blue). Peak detected at 20.10 minutes. The 
retention area of Peak 13 is 1.67 x 108. 
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This greater yield of mupirocin compared to thiomarinol was as expected, as the 
mupirocin producer P. fluorescens used in this study carried the mupR gene in the pJH10 
vector. The mupR gene encodes a transcriptional regulator and together with mupI, it is 
responsible for quorum regulating mupirocin biosynthesis in the exponential and stationary 
phases (El-Sayed et al., 2001). Hothersall et al. (2011) showed that expression of mupR in 
trans increases mupirocin production by up to 17-fold. All future mupirocin and 
pseudomonic acid A stocks were diluted 10-folds prior to HPLC quantification. 
Total concentrations obtained were 4.4 mg/ml and 6.9 mg/ml [14C] thiomarinol A and 
pseudomonic acid A respectively. The overall incorporation of 14C in the thiomarinol and 
mupirocin stocks was measured by counting 10 and 20 µl of the samples in 990 and 980 µl of 
Instagel respectively in the scintillation counter (Packard 1600 TR). The two volumes of 
antibiotics were used as a control to check the radioactive counts doubled accordingly and 
showed no great variability based on sample size. Non-14C labelled thiomarinol and 
mupirocin were used as negative controls and 1 ml of Instagel as a blank control for 
detecting the background CPM. All 14C samples were counted for 1, 3 and 10 minutes to 
determine the optimal length of scintillation counting for accurate CPMs. 
The CPM results were encouraging; values across the different counting times were 
consistent and approximately double when 20 µl of each antibiotic was counted (Table 6.3). 
One minute counting time was used for all further scintillation analysis in this study. 
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Table 6.3. CPM of [14C] mupirocin and thiomarinol at 1, 3 and 10 minutes. 
1 min 3 min 10 min Average
Scintillant (Blank) 21.00 22.00 19.90 20.97
Thiomarinol 10 µl (Control) 9.00 - - -
Mupirocin 10 µl (Control) 19.00 - - -
[14C] Thiomarinol 10 µl 1153.00 1205.33 1174.60 1177.64
[14C] Thiomarinol 20 µl 1924.00 1875.33 1896.10 1898.48
[14C] Mupirocin 10 µl 629.00 614.33 609.50 617.61




6.3.2 Optimisation of fraction collection and further processing of [14C] 
thiomarinol A 
The method for [14C] thiomarinol A and pseudomonic acid A fraction collection and 
processing to yield final products was firstly optimised using non-14C labelled antibiotics. This 
was done as a safety measure as well as a way to conserve the available [14C] acetate and 
methionine stocks. Non-labelled thiomarinol and mupirocin were obtained following the 
same procedure as with the labelled antibiotics but at a larger production culture volume of 
500 ml and without the 14C feeding. The final extraction of thiomarinol and mupirocin were 
dissolved in 5 ml absolute methanol. 
The UniPoint LC programmes used for quantifying thiomarinol was altered to include 
the fraction collection steps. Fraction collection of thiomarinol A was attempted first, with a 
collection window set from 7 to 11 minutes. Samples were collected at one minute intervals 
per tube. The window for collection was kept relatively wide to ensure no thiomarinol A was 
lost in the initial optimisation of the parameters. 100 µl of thiomarinol stock was injected 
into the HPLC column and five samples consisting of the thiomarinol A peak obtained at a 
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retention time of 7.03 minutes (Figure 6.4). The chromatogram confirmed that the first two 
fractions collected consist of the thiomarinol A peak; therefore these two samples were 
pooled together with two more samples from another run (data not shown) to a total 
volume of 4 ml.  
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Figure 6.4. HPLC chromatogram of non-radiolabelled thiomarinol A (Peak 17) fractionated 
at 7, 8, 9, 10 and 11 minutes (shown by the green and red lines). 
 
The samples collected by this method consist of thiomarinol A dissolved in 35% 
acetonitrile, 65% water and negligible amounts of methanol (as the carrier of the injection 
sample) and formic acid. Before processing the 4 ml sample obtained, the appropriate 
method for removing the solvents was established by a series of small scale experiments as 
indicated in Table 6.4 to determine whether it is better to (1) evaporate the acetonitrile 
before ethyl acetate extraction of thiomarinol A; or (2) add ethyl acetate directly into the 
pooled fractions for thiomarinol A extraction. 
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Table 6.4. Materials used to determine the optimal processing method of fractionated 
thiomarinol A samples. 
Trial Water (µl) Acetonitrile (µl)
Thiomarinol
(10 mg/ml) (µl)
Ethyl Acetate (µl) Methanol (µl)
 1* 100 100 5 800 -
2 650 350 10 2000 -
3a 650 350 - 2000 10
3b 650 350 10 2000 -  
*In Trial 1, an unrepresentative water to acetonitrile ratio of 1:1 (100 µl:100 µl) was used. During HPLC and fraction 
collection, a ratio of 65:35 (water to acetonitrile) is used and therefore, all further trials were 650 µl:350 µl respectively. 
 
Trial 1 showed that if extraction is done on too small a scale, it is very hard to 
distinguish the two phases. Trial 2 showed that a total volume of 3 ml facilitated the phase 
separation but showed that analysis of the phases by HPLC required much more thiomarinol 
to be present. Trial 3a started from a mix consisting of just water, acetonitrile, ethyl acetate 
and methanol in the absence of thiomarinol to read the background OD385nm of 1 ml of the 
ethyl acetate and water emulsion layer. Following this, Trial 3b added 10 µl thiomarinol and 
determined the OD385nm of the upper layer. The difference in OD385nm values of Trial 3a and 
3b allowed the thiomarinol concentration in the upper ethyl acetate and water emulsion to 
be determined. The results are summarised below in Table 6.5. 
Table 6.5. Summary of Trials 1-4 results from Table 6.4. 
Trial Aim Results/Issues
1
Separate soluble (ethyl acetate) and aqueous
layers to detect thiomarinol by measuring
absorbance of soluble phase at OD385nm.
Volumes too small for handling and thiomarinol detection.
2 Increased volumes, same aim as above.
Clearer separation of phases observed, however upper
phase consisted of ethyl acetate with emulsions which
caused background problems during thiomarinol
absorbance reading.
3a
Sample excluding thiomarinol to obtain
background absorbance reading of emulsion.
OD385nm of 0.678.
3b
Repeat of Trial 2 but with background
absorbance deduced from overall reading of
upper phase.






These small experiments proved the importance of evaporating acetonitrile from the 
fraction collections prior to the addition of ethyl acetate for thiomarinol A extraction. 
Furthermore, the residual amount of methanol was not expected to interfere with the 
overall process of isolating thiomarinol A from the fractions, as it has the lowest boiling point 
amongst all solvents (64.7°C) and would evaporate before the acetonitrile. 
6.3.3 Is thiomarinol A stable in prolonged heat treatment during isolation 
from fraction collections? 
The above observations, that prior acetonitrile evaporation is important for 
successful ethyl acetate extraction, raised a question about the thermal stability of 
thiomarinol A. During standard thiomarinol extraction as outlined in Chapter 2, a 45°C water 
bath was used to evaporate ethyl acetate from the thiomarinol-ethyl acetate mixture in a 
vacuum sealed glass flask. The vacuum allows the solvent (with a boiling point of 77.1°C) to 
evaporate at the lower water bath temperature. The boiling point of acetonitrile is slightly 
higher than that of ethyl acetate and evaporates at 82°C. This suggested a possible 
requirement for treatment of the collected fractions with higher temperature but the level 
of heat stability of thiomarinol was not known or documented in the literature. Therefore, 
small scale experiments were set up to determine the heat stability of thiomarinol A and if 
stable, to determine whether all solvents could be removed from the fractions by 
evaporation instead of ethyl acetate extraction. 
The 4 ml pooled sample of thiomarinol A fraction collections was transferred into a 
glass flask and placed under vacuum for evaporation in a 50°C water bath. Approximately 30 
minutes was required to evaporate 1.4 ml acetonitrile from the sample. At this stage, 100 µl 
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of the sample was removed and analysed by HPLC to quantify the pre-existing amount of 
intact marinolic acid before increased heat treatment (using the mupirocin detection 
programme) (Figure 6.5). Following this, the water bath temperature was increased to 60°C 
and eventually 70°C to evaporate the remaining water. The remaining residue was dissolved 
in methanol and 100 µl of the sample run on the HPLC for any detection of marinolic acid 
hydrolysis (Figure 6.6). 
 







































































>  C:\G ILSON\YUI KO 2\03SEP12A.001\ 03sep12a.GDT  : U. V. Det  : Thio A FC1 Hydrolysis Check: I nj.  Number:  2
Solvent  A 1 W at er
Solvent  B 1 Acetonitr ile  
Figure 6.5. HPLC chromatogram of fractionated thiomarinol A after heat treatment under 
vacuum in 50°C water bath for 30 minutes. The programme for detecting mupirocin was 
used to quantify the amount of marinolic acid (Peak 27, highlighted in blue), as they share 
structure similarity and hence the same absorbance at 233 nm. The retention area of Peak 

























































> C:\ GILSON\YUIKO 2\ 03SEP12B.001\03SEP12B.GDT :  U.V.Det  : T hio A FC2 (F inal 600 ul): Inj.  Number: 1
Solvent  A 1 Water
Solvent  B 1 Acetonitr ile  
Figure 6.6. HPLC chromatogram of final fractionated thiomarinol A product in methanol, 
after 60-70°C water bath evaporation, ethyl acetate extraction and speedvac evaporation. 
Marinolic acid A is detected by the mupirocin HPLC programme (Peak 18 highlighted in blue). 
The retention area of Peak 18 is 4.00 x 106. 
 
The results showed no significant decrease, indicating that thiomarinol A can 
withstand high temperature treatments. These results were encouraging and indicated that 
thiomarinol A could be isolated from the fraction collection solvents without the ethyl 
acetate extraction step. To test this, 100 µl of thiomarinol was fractionated (Figure 6.7) and 




























































































































> C:\GILSON\YUIKO2\03SEP122.002\03s ep122.GDT  : U.V.Det : T hiomarinol 13 FC: In j. Number: 1
  C:\GILSON\YUIKO2\03SEP122.002\03sep122.GDT : PreELS : Thiomarinol  13 FC: Inj . Number: 1
Solvent A 1 Water
Solvent B 1 Acetonitrile  
Figure 6.7. HPLC chromatogram of 100 µl thiomarinol A sample fractionated (Peak 17). The 
retention area of Peak 17 is 1.46 x 108.  
 
A total of 4 hours was required to completely evaporate all solutions. The sample was re-
dissolved in 200 µl methanol and half of the sample run on the HPLC for detection of 












































































































































































> C:\GILSON\YUIKO2\04SEP122.001\04SEP122.GDT  : U.V.Det : FC T hio 13A 100 u l: In j. Number: 1
  C:\GILSON\YUIKO2\04SEP122.001\04SEP122.GDT : PreELS : FC T hio 13A 100 ul : Inj . Number: 1
Solvent A 1 Water
Solvent B 1 Acetonitrile  
Figure 6.8. HPLC chromatogram of fractionated and processed thiomarinol A (Peak 33). The 
retention area of Peak 33 is 6.89 x 107. 
 
The peak area before and after fraction collecting thiomarinol A showed no significant loss in 
yield during fraction collection. In conclusion, multiple 100 µl injections for fractionation and 
speedvac evaporation of the pooled samples were deemed an appropriate method for the 
isolation of [14C] thiomarinol A.  
6.3.4 Fraction collection of [14C] thiomarinol A 
Using the optimised protocol above, 10 individual 100 µl [14C] thiomarinol injections 
(from the 2 ml total stock) were fractionated. A representative chromatogram is shown in 


























































































































>  C:\ GI LSO N\YUI KO 2\04SEP12A. 001\04SEP12A. GDT  : U.V. Det  :  C14 T hiom ar inol F C 2:  I nj. Num ber : 1
  C: \G ILSON\ YUIKO 2\ 04SEP12A.001\ 04SEP12A.G DT  :  PreELS : C14 T hiom ar inol F C 2: In j.  Number:  1
Solvent A 1 W ater
Solvent B 1 Acetonit rile  
Figure 6.9. One of the ten HPLC chromatograms of 100 µl [14C] thiomarinol A fraction 
collection (Peak 19). Fraction 1, 2 and 3 were pooled for evaporation and pooling for the 
final 1 ml [14C] thiomarinol A stock. The retention area of Peak 19 is 1.24 x 108. 
 
The fractions containing thiomarinol A were all evaporated on the speedvac for 23.5 hours 
and re-dissolved in a total of 1 ml methanol. A final 1 ml [14C] thiomarinol A stock of 357 














































































































































> C :\GIL S ON \Y U IK O2\0 7S E P 1 2.0 01\ 07s ep 12. GD T  : U .V .D e t : C 14 T hio m a rino l  A : In j . N um ber: 2
  C : \GILS ON \ Y U IK O2\0 7S E P 12 .00 1\0 7s ep1 2.GD T  :  P reE L S  : C 1 4 T h iom ar ino l  A : I n j . N u m b er:  2
S ol ve nt A  1 W ater
S ol ve nt B  1 A c eto ni tr i le  
Figure 6.10. HPLC chromatogram quantifying the final [14C] thiomarinol A stock highlighted 
in red (Peak 34). The retention area of Peak 34 is 8.19 x 107. 
 
6.3.5 Optimisation of fraction collection and further processing of [14C] 
pseudomonic acid A 
Similar to the optimisation process for thiomarinol A isolation, non-radioactively 
labelled mupirocin was also used to determine the best method for isolating pseudomonic 
acid A. However, the 100 µl sample coil attached to the HPLC column was first exchanged 
with a 1 ml coil to accommodate larger sample sizes. The mupirocin programme is 60 
minutes in duration compared to that of thiomarinol (24 minutes). It was hoped that by 
changing the coil to handle larger volumes, 2 x 500 µl of the [14C] mupirocin stock could be 
fractionated within 2 hours instead of 10 x 100 µl as performed with [14C] thiomarinol (which 
would take 10 hours). 
The UniPoint programme for detecting mupirocin was altered to collect pseudomonic 
acid A fractions from 17 to 23 minutes. A 500 µl injection of 10 mg/ml mupirocin stock was 
181 
 
first tested using the new coil. The resulting chromatogram indicated that the window was 
too short, as the highly concentrated and larger injection volume of mupirocin took longer to 
pass through the column and into the collection tubes (Figure 6.11). The fraction collection 
window was increased to 10 to 30 minutes for isolation of [14C] pseudomonic acid A. 
 



























































































> C :\GILS ON \YU IKO2\10SE P122.001\10S EP 122.GD T  : U .V .Det : Mupi roc in 10 m g/m l  FC 500 u l  T es t Run: In j . N um ber: 1
S olvent A  1 W ater
S olvent B  1 Ac etoni tri le  
Figure 6.11. HPLC chromatogram of 500 µl mupirocin injection for fraction collection of 
pseudomonic acid A from 17 to 23 minutes.  
 
6.3.6 Fraction collection of [14C] pseudomonic acid A 
2 x 500 µl of previously obtained [14C] mupirocin was fractionated (Figure 6.12) as 



















































































































































































































































>  C: \GILSON\YUIKO2\12SEP12.001\12SEP12. GDT  :  U. V. Det : C14 Mupirocin FC 500 ul: Inj. Number:  2
Solvent A 1 Wat er
Solvent B 1 Acetonitrile
 






























































































































































































































































>  C:\GI LSO N\YUIKO2\12SEP12.001\12SEP12.G DT  : U. V. Det : C14 Mupirocin F C 500 ul: Inj. Num ber: 3
Solvent A 1 W ater
Solvent B 1 Acet onit rile
 
Figure 6.12. Chromatograms of (A and B) 2 x 500 µl injections of [14C] mupirocin for 
fraction collecting [14C] pseudomonic acid A. The peaks containing [14C] pseudomonic acid A 
are not numbered due to the excess concentration and are located between (A) Peaks 10 





The fractions were dried on the speedvac for approximately 16 hours and re-dissolved in a 
total of 1 ml methanol. 100 µl of the final [14C] pseudomonic acid A stock was diluted 10-fold 
and quantified on the HPLC (Figure 6.13). A concentration of approximately 5 mg/ml of [14C] 
pseudomonic acid A was obtained. 
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> C:\GILSON\YU IKO2\16S EP 12.001\16S EP 12.GDT  : U.V.D et : C14 Ps eudom onic  ac id A FC (1:10 d i lu tion): In j . Num ber: 2
Solvent A 1 W ater
Solvent B 1 Ac etoni tri le  
Figure 6.13 HPLC chromatogram of 100 µl injection of [14C] pseudomonic acid A (Peak 23 in 
blue). The retention area of Peak 23 is 2.34 x 108. 
 
6.3.7 Quantification of [14C] incorporation on fractionated thiomarinol A 
and pseudomonic acid A 
The scintillation counter used for generating the data in Table 6.3 (Packard 1600 TR) 
was replaced with a new machine (Perkin Elmer Tri-Carb 2810 TR) at this stage of the study. 
Hence, 10 µl of the original [14C] thiomarinol and mupirocin stocks were re-counted on the 
new machine along with the newly isolated [14C] thiomarinol A and pseudomonic acid A 
stocks in total volume aliquots of 1 ml Instagel. The samples were counted at 1 minute and 
again at 10 minutes (Table 6.6). 
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Table 6.6. 1 and 10 minute counts in CPM and DPM of original [14C] thiomarinol and 
mupirocin stocks and after fractionation (AF) [14C] thiomarinol A and pseudomonic acid A 
(PA-A) stocks (10 µl volumes)* 
1 min 10 min Average 1 min 10 min Average
Scintillant (Control) 26 28 27 27 30 29
Thiomarinol (Control) 34 46 40 36 49 43
Mupirocin (Control) 34 33 34 36 35 36
[
14
C] Thiomarinol 374 410 392 396 438 417
[
14
C] Thiomarinol A AF 74 79 77 78 84 81
[
14
C] Mupirocin 919 1006 963 970 1068 1019
[
14
C] PA-A AF 434 390 412 458 414 436
CPM DPM
 
*The CPM and DPM counts of [
14
C] thiomarinol stock are negligible due to stock evaporation during storage. 
 
The original counts for [14C] thiomarinol and mupirocin were 1177.64 and 617.61 
CPM respectively (Table 6.3). The discrepancy between the original and new counts was 
unexpected; therefore a third counter was used to count the CPM value of the [14C] 
thiomarinol stock. The value yielded was 388, indicating the new value of 392 to be reliable.  
The high initial count was disregarded. 
An approximately 2-fold decrease in radioactivity was seen between the original [14C] 
mupirocin and the fractionated pseudomonic acid A. The final level of 14C incorporation in 
thiomarinol A was low, with an average CPM of 77 in 10 µl sample (from a 358 µg/ml stock). 
This is only double that of the background counts, with non-labelled thiomarinol yielding an 
average CPM of 40. Further attempts were made to obtain thiomarinol A and pseudomonic 
acid A stocks with higher specific activity. For the new machine, 10 minutes counting time 
was selected for accurate scintillation counting. In parallel, the stocks obtained already were 
used in preliminary uptake studies to determine whether their low incorporation was 
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enough to allow any differences in uptake between thiomarinol and mupirocin to be 
detected. 
6.3.8 Determining the optimal feeding window for 14C incorporation 
Preliminary time course experiments performed by colleague Ahmed Omer-Bali 
observed thiomarinol production to take place at the onset of stationary phase, between 18 
to 24 hours and peaking at around 21 hours of culture incubation (Omer-Bali, 2013). 
Observations of antibiotic production occurring at stationary phase have also been made in 
the literature, such as with actinomycete antibiotic genes being expressed at the onset of 
stationary phase in liquid cultures (Bibb, 2005). It was thus hypothesised that for efficient 
incorporation of [14C] acetate into thiomarinol and mupirocin during biosynthesis, feeding 
should be done just before stationary phase instead of spaced across three feeds during lag, 
exponential and stationary phase as previously performed. To test this, the growth curves 
and levels of antibiotic production were monitored at 1 hour intervals using absorbance and 
HPLC, to determine the optimal window for feeding radioactive precursors. 
First, thiomarinol and mupirocin production was monitored based on Omer-Bali’s 
observation of the 18 to 24 hour stationary phase window for P. rava. 1 ml samples were 
collected from 17 hours up to 25 hours of incubation and processed as described in the 
Materials and Methods for HPLC quantification. Chromatograms revealed both thiomarinol 
and mupirocin to already be in production at the tested window (a selection of data shown 
in Figure 6.14 and Figure 6.15). The thiomarinol samples all had approximately 11 µg/ml of 
thiomarinol A. Likewise, the mupirocin samples all had approximately 25 µg/ml of 
pseudomonic acid A – although the concentration of the last sample taken at 25 hours 
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incubation was 45 µg/ml. This suggested the stationary phase windows to be earlier for both 
P. rava and P. fluorescens (pJH2) than previously determined by Omer-Bali. 
 
















































































































































































































































































































































































































































>  C:\ G ILSO N\ YUIK O2\27SEP12.001\27SEP12.G DT  : U.V .Det  :  T hiom ar inol 1  (17 hrs):  I nj.  Num ber:  2
  C: \G I LSO N\YUI KO 2\ 27SEP12. 001\ 27SEP12. G DT  :  PreELS :  T h iomarinol 1 (17 hrs ):  I nj. Num ber:  2
Solvent  A 1 W at er
Solvent  B 1 A cet onit rile  
Figure 6.14. HPLC chromatogram of thiomarinol A peak detected at 17 hours incubation. 
The peak is highlighted in red and its retention area is 2.62 x 106. 
 
 














































































































>  C: \GILSON\YUIKO2\26SEP12.001\26sep12.GDT :  U.V. Det : Mupirocin 9 (25 hrs): Inj.  Num ber: 10
Solvent A 1 Wat er
Solvent B 1 Acetonitrile








































































































>  C: \GILSON\YUIKO2\26SEP12.001\26sep12.GDT :  U.V. Det : Mupirocin 8 (24 hrs): Inj.  Num ber: 9
Solvent A 1 Wat er
Solvent B 1 Acetonitrile
 
Figure 6.15. HPLC chromatograms of pseudomonic acid A peaks detected at 24 hours 
incubation. The peak is highlighted in blue and its retention area is 1.75 x 107. 
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Growth curve experiments were set up to monitor the changes in cell density of P. 



























P. rava sp. SANK 73390
P. fluorescens pJH2
 
Figure 6.16. Growth curves of thiomarinol producer P. rava (in red) and mupirocin 
producer P. fluorescens pJH2 (in blue).  
 
The samples were diluted 10-fold before absorbance determination, mainly to offset the 
high absorbance background of the P. fluorescens samples in SMM media. Nevertheless, the 
onset of stationary phase in P. fluorescens growth was not as clear as on the growth curve of 
P. rava. Stationary phase occurred anywhere between 7 and 24 hours for P. fluorescens. For 
P. rava, this phase was clearly between 8 and 9 hours in the first trial and between 7 and 8 
hours in the repeated growth curve (data not shown). Overall, it was concluded that the 
onset of stationary phase for P. rava was somewhere between 7 to 9 hours. Subsequent 
time course experiments performed by Ahmed Omer-Bali found thiomarinol production to 
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also begin at around 9 hours, which increased exponentially until 18 hours before reaching a 
plateau of production, with a peak at around 36 hours (Omer-Bali, 2013). 
6.3.9 Further optimisation of 14C incorporation in thiomarinol A and 
pseudomonic acid A 
Based on the above findings, feeding experiments were repeated but with one bulk 
feed of [14C] acetate at 8 hours incubation for both thiomarinol and mupirocin production 
(Trial 2). When incorporation of radioactivity into antibiotics was determined in 10 µl of the 
ethyl acetate extract, the counts and overall yield had improved for thiomarinol A but 
surprisingly not for pseudomonic acid A (Table 6.7). 
Table 6.7. Summary of [14C] thiomarinol and mupirocin concentrations and counts before 









C] Thiomarinol 542 392 417 22
[
14
C] Thiomarinol A AF 358 77 81 7
[
14
C] Mupirocin 6358 963 1019 4
[
14
C] PA-A AF 4952 412 436 2
[
14
C] Thiomarinol 1048 1871 2027 56
[
14
C] Thiomarinol A AF 650 222 235 10
[
14
C] Mupirocin 11017 704 744 2
[
14
C] PA-A AF - - - -
[
14
C] Thiomarinol 698 2001 2181 90
[
14
C] Thiomarinol A AF - - - -
[
14
C] Mupirocin 11453 2207 2331 5
[
14





*Abbreviation: AF after fractionation; PA-A pseudomonic acid A. 
1







[14C] thiomarinol was collected after fractionation and quantified for use in the fourth 
uptake study described later in this section. [14C] mupirocin was discarded due to its low 
incorporation and a third feeding experiment set up with the mupirocin-producing culture 
being fed after 21 hours of incubation instead of 8 hours. The feeding time was delayed to 
be closer to the production peak of 36 hours identified by Omer-Bali, in an attempt to 
encourage better incorporation.  
The counts were a vast improvement from Trial 2 (Table 6.7) but the uptake studies 
had determined at this stage that much higher incorporation was necessary for the 
radioactive antibiotics to be useful in downstream uptake experiments. Hence, fractionation 
and collection of the antibiotics from Trial 3 was not pursued and the carbon source was 
changed from [14C] acetate to methionine.  
Methionine was the carbon source recommended by Dr. Zhongshu Song, University 
of Bristol due to its specific incorporation into the antibiotics in comparison to acetate that is 
readily used by metabolic pathways such as fatty acid synthesis. However, because labelled 
methionine is significantly more expensive than acetate, the latter was initially used in 
attempt to produce [14C]-labelled antibiotics. Following the failed attempts to produce high 
specific activity radiolabelled antibiotics, [14C] methionine was purchased and 4 µCi fed to 
each of the mupirocin and thiomarinol production cultures following the same procedure as 
in Trial 3. The collected [14C] thiomarinol A fractions gave an apparent level of incorporation 
(Table 6.8) that was approximately 4 times more counts than the stock obtained from 
acetate feeding in Trial 2. 
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C] Thiomarinol - 9548 10384 -
[
14
C] Thiomarinol A AF 485 873 930 55  
 
Unfortunately, the ethyl acetate extracted [14C] mupirocin could not be quantified and 
fractionated due to unforeseen problems with the HPLC machine. The extracted stock was 
stored at -20°C for future work. 
6.3.10 Preliminary uptake study 
In parallel to the optimisation of procedures to yield higher [14C] thiomarinol A and 
pseudomonic acid A stocks, attempts were made to identify any differences in uptake of the 
two antibiotics by sensitive and/or resistant bacteria using the [14C] antibiotic stocks already 
produced. The ability of antibiotics to enter the cells is of great importance, as the drugs are 
ineffective if unable to pass through the primary protective barrier of their target 
microorganisms. As such, it was hypothesised that thiomarinol may be more effective 
against a wider range of Gram-positive and negative organisms due to its superior ability 
(compared to mupirocin) to accumulate faster and better, and perhaps also avoid efflux to 
maintain a potent concentration in the cells. 
The following uptake study was based on the method used by Capobianco et al. 
(1988) but altered to allow for the lower specific activity of the 14C incorporated into 
thiomarinol A and pseudomonic acid A stocks used. It was aimed to address the possible role 
of uptake in thiomarinol efficacy. E. coli and B. subtilis were chosen as the test organisms to 
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represent mupirocin resistance and sensitivity respectively. It was expected that mupirocin 
would accumulate to a greater extent in B. subtilis cells than E. coli, as the latter has been 
proposed to be resistant due to its impermeable outer cell membrane (Capobianco et al., 
1989). Various preliminary experiments were undertaken to determine the optimal bacterial 
density, sampling intervals and scintillation counting times for this study. 
First, the optimal bacterial cell density for recovering the original amount of 
radioactivity put into the assay was determined. Due to the low specific activity of 14C in the 
antibiotics, it was possible that too many cells in the assay might quench or obscure the 
counts and thus require increased volumes of antibiotics in the assay which were not 
available due to limitations described in the previous section. 
[14C] pseudomonic acid A was used for this exploratory experiment, as a more 
concentrated stock with higher specific activity was available compared to thiomarinol A. 2 
ml L-broth volumes were chosen for the assay and amounts of bacteria to give the 
equivalent 2 ml intracellular cell volumes added to give an equal ratio of L-broth to 
intracellular volume. The appropriate intracellular volume was calculated based on the E. 
coli aqueous volume at 6.7 x 10-15 L per cell (Neidhardt et al., 1996) and B. subtilis at 1.0 x 10-
14 L per cell (Bergey et al., 1974). A total of 3 x 1011 E. coli cells and 2 x 1011 B. subtilis cells 
were estimated to equate to 2 ml intracellular volumes. 
Based on the estimation that 1 ml of bacterial overnight from one single colony 
inoculation yields approximately 109 bacteria, E. coli overnight cultures of 60, 150, 300 ml 
were set up to produce total intracellular volumes 0.5, 1, 2 ml (or 10, 25, 50% of the total 2 
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ml extra and intracellular volumes). Likewise, B. subtilis overnight cultures of 40, 100, 200 ml 
were prepared. 
The overnight cultures were centrifuged as described in Methods and the pellet re-
suspended in 2 ml L-broth before being separated into two 1 ml samples. 100 µl of each 
sample was taken for viable cell determination to confirm the number of cells added to the 
L-broth. 28 µl of [14C] pseudomonic acid A was added to one of the 1 ml sample (equivalent 
to 140 µg/ml and 1220 DPM) and incubated at 30°C at 200 rpm for up to 30 minutes. This 
amount of [14C] pseudomonic acid A was chosen to yield approximately double the DPM of 
blanks in the 100 µl samples to be taken (with Instagel blank samples counting 
approximately 30 DPM) and thus detectable over the background. The other 1 ml sample 
was not treated with [14C] pseudomonic acid A but incubated under the same conditions as 
with the radioactive sample to identify any background noise. 100 µl samples were taken in 
triplicates at 5 and 30 minute intervals for B. subtilis and 30 and 60 minute intervals for E. 
coli from both 1 ml samples and processed as outlined in Methods to determine the 
extracellular and intracellular radioactive counts. The E. coli cultures were incubated longer 
before sampling than B. subtilis, as the latter was tested first in this initial experiment and 
indicated the need for longer incubation to check whether the samples had reached extra 
and intracellular equilibrium of [14C] pseudomonic acid A concentrations. 
Viable cell counts were obtained the day after the initial uptake study. The 
intracellular volumes of B. subtilis were approximately 13, 24 and 43% of the total 2 ml extra 
and intracellular volume, which is close to the proposed 10, 25 and 50% volumes. However, 
the intracellular volumes of E. coli were 25, 50 and 69% of the total 2 ml volume and far too 
dense. Nevertheless, results showed that the original amount of [14C] pseudomonic acid 
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counts (122 DPM per 100 µl sample) could still be detected in the total counts of the cell 




























Figure 6.17. DPM counts of [14C] pseudomonic acid A accumulation in cell pellet, 
supernatant and total B. subtilis samples at (A) 5 min and (B) 30 min incubation intervals. 
13, 24 and 43% refer to the intracellular volumes of B. subtilis. The red dotted line indicates 
the 122 DPM per 100 µl of [14C] pseudomonic acid A originally added to the experiment. The 
cell pellet and supernatant stacked bars (in red and blue) represent the intracellular and 
extracellular radioactive counts respectively that were detected from sample preparation 
described in the Methods. The total bars (in green) represent the total radioactive counts 
detected from 100 µl of non-processed samples. The “Background” samples represent the 
background DPM detected from the control non-radioactive samples. The cell pellet and 
supernatant samples were prepared in triplicates (and SD error bars determined) but the 
































Figure 6.18. DPM counts of [14C] pseudomonic acid A accumulation in cell pellet, 
supernatant and total E. coli samples at (A) 30 min and (B) 60 min incubation intervals. 25, 
50 and 69% refer to the intracellular volumes of E. coli. The red dotted line indicates the 122 
DPM per 100 µl of [14C] pseudomonic acid A originally added to the experiment. The cell 
pellet and supernatant stacked bars (in red and blue) represent the intracellular and 
extracellular radioactive counts respectively that were detected from sample preparation 
described in the Methods. The total bars (in green) represent the total radioactive counts 
detected from 100 µl of non-processed samples. The “Background” samples represent the 
background DPM detected from the control non-radioactive samples. The cell pellet and 
supernatant samples were prepared in triplicates (and SD error bars determined) but the 





In general, the total counts of cell pellet and supernatant when measured individually 
or combined were much higher than the original 122 DPM of [14C] pseudomonic acid A 
added per 100 µl sample. This may be due to several reasons. First, there may be a limit to 
the cell density used in this experiment. While setting up samples for scintillation counting, 
cell densities of over 50 % appeared to settle in the sample when left static for scintillation 
counting. When vortexed, the samples remained cloudy, indicating that the cell densities 
had exceeded the Instagel’s holding capacity. Counting efficiency decreases drastically when 
the sample is not in completely clear suspension with the Instagel because cloudiness causes 
interference with the counter detecting the photons emitted by the scintillant after collision 
with emissions from radioactive substrates. Hence, cell densities above 50% of the total 
volume were deemed inappropriate for future experiments. 
Second, background counts may need to be taken into account to detect radioactive 
accumulation in the cell pellets. The total samples (in green, Figure 6.17 and Figure 6.18) had 
counts closer to the original 122 DPM and when the background total counts were deducted 
from the former counts (to take into account the issue mentioned above of sample viscosity), 
the total radioactivity was similar to what was originally added. Likewise with the 
individually measured samples (in red and blue, Figure 6.17 and Figure 6.18), once 
background was deducted, the remaining counts were also closer to 122 DPM (although 
more varied than the total (green) counts). 
When background is taken into account, there is no evidence of uptake, i.e. no 
detection of radioactive accumulation in the cell pellet, at 13 and 25% bacterial density of B. 
subtilis and E. coli respectively (except B. subtilis at 5 minutes interval, Figure 6.17A). 
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However at around 50% cell density for both organisms, there is some radioactive detection 
after background deduction; therefore, a 50% bacterial suspension was chosen for further 
investigations. This preliminary experiment also identified the need to increase sampling 
intervals to determine whether the reactions reached equilibrium within the 60 minute time 
frame. It was hard at this stage to speculate on any differences in accumulation of [14C] 
pseudomonic acid in B. subtilis and E. coli cells due to count variability across the triplicate 
samples and the high background noise.  
The uptake experiment was repeated with 50% cell density for both organisms but 
with larger sampling intervals of 0, 1, 2, 4, 8, 10, 20, 30, 60, 90 and 120 minutes (in 
triplicates) to determine the time point in which the reactions reach equilibrium. The 
samples were counted for 1 minute on the scintillation counter. The total sample volumes 
were set up to be 4 ml total as initially intended, and therefore the overnight cultures were 
set up to yield 2 ml total intracellular volume. 
The results obtained from this second uptake study were inconclusive, with high 
variability between the triplicate counts (as shown by the standard deviation error bars) 
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Supernatant)
 
Figure 6.19. DPM counts of [14C] pseudomonic acid A accumulation in cell pellet, 
supernatant and total E. coli samples at various time points. (A) The DPM counts are raw 
data and do not take into account the high background noise. (B) Background counts 
deducted from the above data points. The total samples (in green) represent the total 
radioactive counts detected from 100 µl of non-processed samples (which should 
theoretically equate to the sum of the cell pellet and supernatant counts but this is not 
always the case in this study.) The cell pellet and supernatant samples were taken and 
counted in triplicate (and SD error bars determined) but the total samples were prepared 
singly. The 0 min time point represents the sample taken as soon as the [14C] pseudomonic 
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Supernatant)
 
Figure 6.20. DPM counts of [14C] pseudomonic acid A accumulation in cell pellet, 
supernatant and total B. subtilis samples at various time points. (A) The DPM counts are 
raw data and do not take into account the high background noise. (B) Background counts 
deducted from the above data points. The total samples (in green) represent the total 
radioactive counts detected from 100 µl of non-processed samples (which should 
theoretically equate to the sum of the cell pellet and supernatant counts but this is not 
always the case in this study.) The cell pellet and supernatant samples were taken and 
counted in triplicate (and SD error bars determined) but the total samples were prepared 
singly. The 0 min time point represents the sample taken as soon as the [14C] pseudomonic 





The most concerning observation from the above data was the inconsistency in total 
counts (in green). While this should be more or less 122 DPM across all [14C] samples, overall 
the counts were high. When the background DPM was deducted, the counts were still 
widely variable – with some samples having greater or less counts than what was initially 
added. This suggested the unreliability and unreproducibility of the results and also did not 
indicate at what time point the samples reach equilibrium. 
In the third experiment, the scintillation counting time was increased from 1 to 10 
minutes and the cell densities were lowered to 20% in an attempt to get more consistent 
counts across the triplicate samples. The total assay volume was increased to 5 ml to provide 
enough samples for the transport study, described below. 100 µl samples were taken at 0, 2, 
5, 10, 20, 30 and 90 minutes intervals in triplicates and further processed as outlined above. 
In addition to deducing the optimal incubation period, this experiment also ensured 
that the pH of the samples was optimal and consistent, by spotting each sample onto pH 
paper at all time points. This was done to settle any concerns of changing pH in high density 
cultures, which may affect the rate in which [14C] pseudomonic acid A is influxed and/or 
effluxed out of cells. Additionally, pseudomonic acid A is known to lose activity outside the 
pH range of 4-9 (Clayton et al., 1979) and hence, a low pH would introduce unwanted 
experimental error. The pH of all samples was at the optimal 8.0. This eliminated pH from 
being a possible contributor to the inconsistent results. 
Viable cell counts showed the intracellular volumes of E. coli to be 21% and B. subtilis 
to be 19% and within the 20% aim. A vast improvement was seen in the counts at this cell 








































Figure 6.21. DPM counts of [14C] pseudomonic acid A accumulation in cell pellet, 
supernatant and total samples of (A) E. coli and (B) B. subtilis at various time points. 
Background counts (on average 25 DPM) were deducted from (A) but not from (B) due to 
experimental error. The cell pellet and supernatant samples were taken and counted in 





Although the issue of counting inconsistencies appear to have been solved by 
decreasing cell density to 20% and by increasing scintillation counting time to 10 minutes, no 
change in intracellular counts (in the cell pellet samples) suggested that at lower cell density, 
uptake cannot be detected using low specific activity antibiotics. Unfortunately at higher cell 
density of 50%, uptake can be detected but the results are too variable. 
6.3.11 Uptake study using increased radioactivity of [14C] thiomarinol 
A 
[14C] thiomarinol A yielded from bulk feeding acetate was used for the later uptake 
studies. This antibiotic stock had an increased count of 235 DPM per 10 µl sample compared 
to the 81 DPM yielded in the initial stages (and 436 DPM [14C] pseudomonic acid A used in 
the above uptake studies). E. coli was prepared to an intracellular volume of 25% of the total 
4 ml L-broth assay culture. The assay temperature was lowered to 22°C in an attempt to 
slow the rate of uptake to capturing this phenomenon, as previous experiments set at 30°C 
all appeared to have reached equilibrium at 0 minutes. Scintillation counting time was 
maintained at 10 minutes. 
The results were promising, with a visible increase in intracellular radioactive count, 




















Figure 6.22. Average DPM (in triplicates) of [14C] thiomarinol A accumulation in E. coli cell 
pellet, supernatant and total samples. Background counts were deducted from all sample 
counts. 
 
The experiment was repeated at the lower temperature with E. coli and B. subtilis 
and using the remaining [14C] pseudomonic acid A from previous uptake studies and [14C] 
thiomarinol A. Unfortunately, the counts were inconsistent, with high DPM reads for 
background samples with no added radioactivity (data not shown). The samples were re-
vortexed and recounted on the scintillation counter but were still inconsistent. At this stage, 
the last of the quantified [14C] antibiotics had been used and therefore the experiments 
could no longer be continued. 
6.3.12 Preliminary transport study 
Contrary to uptake, inefficient efflux of thiomarinol from susceptible cells was 
considered as a possible contributing factor to the antibiotic’s efficacy. To address this 
hypothesis, a transport study was devised in parallel to the uptake experiments to 
investigate the rate of [14C] pseudomonic acid efflux from E. coli cells compared to B. subtilis. 
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Additional 100 µl samples were taken at the 60 minutes incubation interval from the 
third uptake experiment and processed as outlined in the methods. By re-suspending the 
cells with intracellular [14C] pseudomonic acid A in fresh 2 ml L-broth and taking scintillation 
counts at various time points, it was hoped that the rate in which the antibiotic either 
passively diffused or effluxed out of the organisms could be observed. Further application of 
this study with thiomarinol A would determine whether slower rate of passive diffusion and 
/or efflux of the antibiotic out of the cells were contributing factors to its potency. 
The uptake experiment was performed using B. subtilis cells before proceeding with E. 
coli. 100 µl samples were taken in triplicates and the cell pellets re-suspended in L-broth. 
100 µl samples were taken in quadruplicates from each of the three uptake assays at 0, 2, 5, 
10 and 20 minutes intervals and three from each assay processed to obtain counts in the cell 
pellet and in the supernatant. The last sample of each assay was counted for total 
radioactive counts. Due to the large sampling size of 9 samples per assay, timing issues were 
introduced, with cell pellets not being separated from the supernatants immediately after 
centrifugation. This created the concern of [14C] pseudomonic acid A diffusing out of the cells 
while left static in the supernatant. 
For assaying the transport of [14C] pseudomonic acid A in E. coli cells, the starting L-
broth volume was prepared at 3 ml and the sampling size was decreased to three assays 
with one sampling to avoid time delays in processing the samples. The sampling times were 
also delayed to start from 2 minutes instead of 0. The results obtained in both transport 
studies suggest basal to no radioactivity in the samples; background counts were 








































Figure 6.23. DPM counts of [14C] pseudomonic acid A efflux from cell pellet to supernatant 
and total samples of (A) E. coli and (B) B. subtilis at various time points. Background counts 
have not been deducted. The cell pellet and supernatant samples were taken and counted in 
triplicates (and SD error bars determined) for E. coli and replicated nine times for B. subtilis. 





This experiment required further optimisation and due to limitations in time and [14C] 
antibiotics, efforts were placed solely on the uptake study. This preliminary transport study 
was put on hold for future work.  
6.3.13 Thiomarinol appears not to be transported out of cells as 
efficiently as mupirocin 
Although the above transport study was inconclusive in identifying any differences 
between the efflux of mupirocin and thiomarinol from bacterial cells, a different approach 
was taken in an attempt to address the hypothesis that thiomarinol’s efficacy is due to its 
ability to avoid/delay efflux from sensitive cells. Ten efflux transporter deletion mutants of S. 
typhimurium were subjected to mupirocin and thiomarinol MIC testing as outlined in 
Chapter 2. These mutants carried single knockouts in various efflux transporter components 
ranging from TolC to MacAB. They were a kind donation from Dr. Jessica Blair and Prof. 
Laura JV Piddock from the University of Birmingham. 
The MIC values obtained for each mutant was compared to that of the wild type S. 






Figure 6.24. S. typhimurium ATCC14028s wild type and efflux transporter mutants tested 
against mupirocin (left in blue) and thiomarinol (right in red). The geometric MIC average 
of each strain is presented in the above tables, while the fold decrease in MIC (relative to 
wild type) is shown by the bar graph. The MIC tests were performed in triplicates. The MIC 
tests of wild-type, ΔtolC, ΔacrB, ΔacrD and ΔmdtK were repeated four times for mupirocin 
and six times for thiomarinol to confirm the reproducibility of the results. All other mutants 
showed no difference in MIC value compared to wild type and hence the MIC test repeated 
once for mupirocin and 3 times for thiomarinol. 
 
The MIC tests identified two mutants, ΔtolC and ΔacrB to cause a much greater factor 
decrease in resistance against mupirocin compared to all other mutants tested. Furthermore, 
the effect on the mutants was greater with mupirocin than with thiomarinol, although there 
is still a significant 3-4 fold decrease in MIC of the latter. TolC and AcrB are part of a multi-
drug resistance efflux transporter called the TolC-AcrAB complex. This complex is part of the 
Resistance Nodulation Division (RND) superfamily of efflux transporters and is commonly 
associated with intrinsic and acquired antibiotic resistance in Gram-negative microorganisms 
(Blair and Piddock, 2009). The MIC results suggest that one of the reasons why thiomarinol 
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may be a more effective antibiotic than mupirocin to Gram-negative pathogens is that it is 
able to avoid efficient efflux by the TolC-AcrAB complex. 
6.4 Discussion 
6.4.1 Limitations on producing enough [14C] thiomarinol A and 
pseudomonic acid A 
The above experiments attempted to optimise the parameters to yield highly 
radioactive [14C] thiomarinol A and pseudomonic acid A. The preliminary counts obtained 
from the methionine feeding experiment showed promise and further optimisation may 
yield enough radiolabelled antibiotics to use in the uptake and transport studies. However, 
there were several issues that arose during this study that need to be rectified for future 
work.  
First and foremost, the sample coil was changed half way through the study from the 
100 µl volume to 1 ml volume to allow larger 500 µl injections of mupirocin to be taken up 
for fractionation. Although this minimised the number of times required to repeat the 
fraction collecting programme, the limiting factor still laid in the analytical HPLC column. 
When fraction collection was repeated with the larger injection, the peak area of 
pseudomonic acid A began to decrease and at times disappeared all together (data not 
shown). It was hypothesised that the analytical HPLC column was reaching saturation due to 
the higher volume of mupirocin being injected repetitively and the column washing 
incorporated at the end of each mupirocin HPLC programme was not enough to remove 
residual samples from the column before the next run. 
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An additional washing programme was run between each sample and absolute 
methanol periodically run on the HPLC mupirocin programme to check for residual samples 
coming off the column. This prevented the column from being saturated but was not the 
most time efficient solution. A preparative HPLC column (Discovery C18, Sigma-Aldrich, UK) 
was purchased for future fraction collection of larger antibiotic volumes. 
Although a higher radioactive count was detected from the [14C] thiomarinol A fed 
with [14C] methionine, uptake studies need to be repeated using this antibiotic stock to 
determine whether there is enough 14C incorporation. If incorporation is insufficient, a 
possible solution to yield more radiolabelled antibiotics would be to produce methionine 
auxotrophs of P. fluorescens and P. rava. Possible candidates for gene knockouts were metH 
or metE, responsible for the downstream and final steps of methionine biosynthesis from 
homocysteine (Augustus and Spicer, 2011). The methionine auxotrophs would be 
supplemented with non-radioactive methionine during its growth stage and only fed [14C] 
methionine at onset of the stationary phase and antibiotic production as identified by Omer-
Bali (2013). This should ensure all antibiotics produced to be 14C labelled. 
6.4.2 The possible role of efflux in the potency of thiomarinol 
The MIC results obtained from testing S. typhimurium efflux transporter mutants 
suggest that the TolC-AcrAB multidrug-resistant efflux transporter is crucial for removing 
mupirocin from the cells. The complex also appears to remove thiomarinol but the decrease 
in MIC of ΔtolC and ΔacrB mutants is not as drastic. Mutants that were tested represented a 
range of efflux transporter families. These families included the resistance-nodulation 
division RND (acrB, acrD, acrEF, mdtABC and mdsABC), major facilitator MFS (emrAB and 
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mdfA), multidrug and toxic compound extrusion MATE (mdtK) and ATP-binding cassette ABC 
(macAB) transporter families. (tolC, mdtA, mdsA and mdsC genes encode outer membrane 
and membrane fusion proteins) (Nishino et al., 2006). The MIC results suggest that perhaps 
the TolC-AcrAB complex does not remove thiomarinol from S. typhimurium as efficiently as it 
does with mupirocin and this allows the former to have increased activity against this 
bacterium and other Gram-negative microorganisms compared to mupirocin. Interestingly in 
Gram-positive S. aureus, overexpression of the major facilitator mdeA was reported to 
increase its mupirocin MIC by 16-folds (0.03 to 0.5 µg/ml), although the increase and 
contribution of the transporter were deemed insignificant as it was still susceptible to the 
drug (Huang et al., 2004). The multifunctional efflux transporter identified by Whatling et al. 
(1995) showed 88% homology to the MATE family; however ΔmdtK in the MIC tests 
appeared not to be involved in the efflux of mupirocin nor thiomarinol. 
Similarly to the work carried out by Huang et al. (2004), it would be of interest to 
challenge S. typhimurium overexpressing tolC-acrAB with mupirocin and thiomarinol, and to 
see whether there is an increase in resistance against either antibiotic. If thiomarinol is not 
as efficiently transported out of the cell by this tripartite complex as mupirocin, it should be 
evident from the lack of MIC increase. 
Nikaido argues in his published review that MIC results are not at all indicative of the 
ligand’s affinity to the transporters and that kinetic parameters must be determined to 
measure the efficiency of drug efflux (Nikaido and Pagès, 2012). As an example, he observed 
the MIC values of isoxazolylpenicillins to decrease by 256-fold or more when AcrB was 
deleted in wild-type E. coli K12. In traditional MIC methods, this would indicate AcrB to have 
strong affinity to these antibiotics. On the contrary, compounds such as ampicillin were 
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considered to be poor substrates due to the smaller decrease in MIC by 2-fold. However, 
efflux kinetics showed that both antibiotics had identical K0.5 values and only a 2-fold 
difference in Vmax, indicating they are both good substrates of AcrAB (Lim and Nikaido, 2010). 
It would thus be sensible to determine the kinetic parameters of TolC-AcrAB and 
mupirocin/thiomarinol to ensure the difference in efflux efficiency is true. 
It would be of interest to replicate the work done by Jo Hothersall and determine 
whether tmlM is expressed from the onset of the log phase and whether high thiomarinol 
resistance is detectable at the exponential phase of the thiomarinol producer or only during 
antibiotic production. If resistance is conferred throughout the producer’s growth cycle, it 
would also suggest additional resistance mechanisms involved in the thiomarinol resistance 
phenotype. This may shed further light on the role the pyrrothine moiety plays in 
thiomarinol potency and any other contributors to the antibiotic’s increase efficacy 
compared to mupirocin.  
Finally, it would also be useful to search for homologues of the MATE-type 
transporter found in P. fluorescens in P. rava. A possible transport transporter gene tmlY 
(Thomas, unpublished data) was found on the pTML1 plasmid (Fukuda et al., 2011). When a 
BLAST search was performed on this gene, the search results indicated it to share 
approximately 50% identity with membrane proteins from various bacteria. Interestingly, 
one of these microorganisms was Yersinia ruckeri, a fish pathogen and holomycin-producer, 
recently observed to carry an RNA methyltransferase called Hom12 (Qin et al., 2013b). 
Hom12 methylates RNA and is thought to protect the host from autotoxity, by somehow 
interfering with the interaction of holomycin and its target RNA polymerase. The expression 
of hom12 in E. coli has also been shown to confer tolerance to holomycin (Qin et al., 2013b). 
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Although only a hypothetical membrane protein from Y. ruckeri, it would be interesting to 
determine the kinetic parameters of this transporter and of tmlY, in order to elucidate 
whether specific efflux transporters are important in thiomarinol and/or pyrrothine export, 
resistance and prevention of autotoxicity. 
6.4.3 Concluding Remarks 
In summary, this study heavily focused on optimising the methodology for producing 
highly 14C labelled thiomarinol A and pseudomonic acid A. Although high enough specific 
activity was not achieved in this study for subsequent use and collection of data in the 
uptake and transport studies, the MIC results from the S. typhimurium efflux transporter 
mutants suggest efflux of thiomarinol to differ from mupirocin in at least Gram-negative 
organisms. This leads to further questions of whether the pyrrothine moiety has any role in 
hindering the efflux efficiency of thiomarinol from susceptible cells and whether a 
holomycin-specific membrane transporter (such as tmlY) is required for thiomarinol 
resistance. This study has merely scraped the surface of understanding the transport 
mechanisms of thiomarinol and much more work is required to truly understand the 












7 GENERAL DISCUSSION 
With the ever increasing prevalence of multidrug resistant bacteria and the urgent 
need for newer or improved antibiotics, there is great relevance in understanding the mode 
of action of the hybrid antibiotic thiomarinol. This thesis has attempted to understand what 
mediates the potency of thiomarinol compared to its structural companion, mupirocin by 
computational and experimental means. It was hoped that from the data obtained, informed 
changes could be made to mupirocin and/or thiomarinol to produce analogues with 
increased specificity and binding to target enzymes of clinically significant microorganisms 
such as mupirocin-resistant MRSA. 
Chapters 2 to 5 explored the possibility that increased binding of thiomarinol to its 
target IleS enzyme is a contributing factor to the antibiotic’s potency. Chapter 2 showed that 
it is possible for Escherichia coli, carrying pJH10mupM and subjected to high concentrations 
of thiomarinol, to acquire thiomarinol resistance mutations; however, this resistance 
phenotype appeared to be caused by overexpression of the target. Chapter 3 highlighted an 
important hydrophobic patch near the KMSKS loop and multiple amino acids in the IleS 
active site that may increase or decrease the binding affinity of thiomarinol. However, 
Chapter 4 showed that changing these active site residues on MupM to mimic the active site 
of TmlM does not increase the thiomarinol resistance phenotype. This was in agreement 
with the findings of Chapter 2, that perhaps it is difficult for single or even multiple amino 
acid changes in MupM to confer the thiomarinol resistance phenotype. Finally in Chapter 5, 
preliminary results of the aminoacylation assay indicated that thiomarinol may have a 
greater binding affinity to IleS than mupirocin. 
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Chapter 6 on the other hand explored the role of transport in thiomarinol potency 
and found that thiomarinol may be able to avoid efficient efflux from a wide range of efflux 
transporter families in Gram-negative organisms, allowing it to accumulate and effectively 
reach its intracellular target at a lower external concentration. The results obtained in all 
chapters suggest the potency of thiomarinol to be a combination of increased binding and 
inefficient efflux out of susceptible cells. The current proposed model (Figure 7.1) of 
thiomarinol potency is as follows: 1) thiomarinol is able to accumulate rapidly in susceptible 
cells due to its ability to avoid efflux, maintain its potent intracellular concentration and 
reach its IleS target and 2) thiomarinol binds strongly to its target which may consequently 
quicken the rate of protein synthesis inhibition and eventual cell death. 
Furthermore, findings from Chapter 2 suggest that overexpression of the target IleS 
may be a mechanism for thiomarinol tolerance/resistance – a phenomenon that has not yet 
been reported for thiomarinol. As to date, no resistance mechanism against thiomarinol has 
been observed except TmlM in the producer. There is great importance in understanding the 
possible resistance mechanisms of antibiotics, as this knowledge can be utilised to develop 

















Figure 7.1. Proposed model of thiomarinol mode of potency. The mechanism of thiomarinol 
uptake is yet to be elucidated. Thiomarinol accumulates in the cell and binds strongly to its 
target IleS enzyme. Intracellular thiomarinol is unable to be removed from the cell by the 
major efflux transporter families (except SMR – no representative transporters were tested 
in this thesis). For Gram-negative organisms with an outer membrane, TolC is a common 
outer membrane protein that forms a complex with the transporters situated in the inner 
membrane (Piddock, 2006). Abbreviations: OM, outer membrane; IM, inner membrane; MFS, 
major facilitator superfamily; SMR, small multidrug resistance; RND, resistance-nodulation 
division; MATE, multidrug and toxic compounds efflux; ABC, ATP-binding cassette. 
 
7.1 The proposed mechanisms of increased thiomarinol binding to 
susceptible IleS 
There were some key findings from the computational work in Chapter 3 that 
proposed how the pyrrothine moiety on thiomarinol may be increasing its binding to the IleS 
enzyme in comparison to mupirocin. These were the hydrophobic patch identified by Pocket 
v.2 near the KMSKS motif, the specific length of the 8-hydroxyoctanoic acid and the 
additional amide groups on the pyrrothine moiety with their hydrogen bonding capacity. The 
pharmacophore model of MupM complexed with mupirocin (Chapter 3, Figure 3.2A) 
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suggests that the 9 carbon chain length of the antibiotic’s carboxylate tail is optimal for 
binding by forming a salt bridge with the amine of the second lysine of the KMSKS loop. 
However for thiomarinol, the pharmacophore model suggests a shorter eight carbon chain 
to be more appropriate – a longer fatty acid chain could push the additional pyrrothine 
moiety out of the hydrophobic patch and into solution, causing an overall decrease in the 
binding strength of thiomarinol to IleS. Although the model for thiomarinol A structure has 
not yet been optimised as discussed in Chapter 3, the pharmacophore suggests that the two 
amide groups on the pyrrothine moiety could interact by hydrogen bonding with the 
residues on the KMSKS loop in the hydrophobic patch. The multiple hydrogen bonds formed 
by the pyrrothine would also be more stable in the hydrophobic patch compared to the 
single salt bridge formed with mupirocin. An even shorter fatty acid chain, on the other hand, 
would also be disadvantageous, as the pyrrothine would fall short from the hydrophobic 
patch for KMSKS interaction, suggesting that the eight carbon chain has been selected to 
optimise binding to this target. 
These computational observations are partially supported by results from our 
collaborators, who isolated new compounds from P. rava sp. Nov. SANK73390 that only 
consisted of the fatty acid chain (in varied lengths) and the holomycin moiety (Figure 7.2) 
(Murphy et al., 2011). They observed all analogues to be less effective against B. subtilis and 
MRSA than thiomarinol A but their ineffectiveness appeared to increase with the longer 
carbon chains (n>8). It would be useful to create analogues that are identical to thiomarinol 
A, except for the altered length in the fatty acid chain, to determine whether the length of 8-




Figure 7.2. Pyrrothine metabolites isolated by Murphy et al., 2011. The isolate with R = 
octanyl has been identified NMR as the metabolite xenorhabdin 3, commonly produced by 
Xenorhabdus spp. 
 
The overall decrease in effectiveness of these analogues compared to thiomarinol A 
can perhaps be explained by the absence of the marinolic acid component and suggests that 
this component is as important in thiomarinol potency as the additional pyrrothine moiety. 
During detailed analysis of the IleS active sites of 1QU2, MupM and TmlM in Chapter 3, most 
residues that appeared to be involved in thiomarinol sensitivity or resistance were found in 
the catalytic groove where the marinolic acid was hypothesised to bind. Although their 
importance is yet to be confirmed by testing the functionality of some of the mutants 
created in Chapter 4, it would be hard to believe that the marinolic acid has no importance 
in the binding affinity of thiomarinol to IleS. The observations from this thesis suggest that 
thiomarinol has increased binding affinity due to a combination of the marinolic acid and 
pyrrothine moiety interacting with the IleS active site. 
Detailed kinetic and computational analyses of mupirocin and analogues by Brown 
and colleagues revealed that the closer the analogue is to isoleucyl-adenylate (Ile-AMP), the 
stronger the binding to the active site (Brown et al., 2000). This is because mupirocin binds 
219 
 
where Ile-AMP normally sits in an aminoacylation reaction (Brown et al., 2000; Pope et al., 
1998a). However, the C14 terminus of mupirocin does not mimic isoleucine very well and 
analysis of the X-ray structure of IleS complexed with mupirocin showed that the terminus 
arm is too short to bind to the isoleucine binding site. Brown and colleagues found that if 
this terminus was changed to better mimic isoleucine and be within similar distance to the 
pyran ring as the amino acid is to the ribose ring in Ile-AMP, the Ki values are significantly 
reduced (by up to <0.001). It would be of great interest to continue the work carried out in 
Chapter 5 and to deduce the Ki value of thiomarinol. This could then lead to the generation 
of thiomarinol analogues with perfect isoleucine side chains and deduction of their K i values 
to see whether they render greater potency than the original antibiotic and also than the 
analogues created by Brown et al. 
In addition to the proposed future work on thiomarinol analogues, further 
computational work can also be undertaken to improve the quality of the structures used 
and the consequent data obtained in Chapter 3. As discussed previously, quantum 
mechanics calculations were undertaken to determine the rotation of the pyrrothine moiety 
using MolPro. Once this pyrrothine is attached to the marinolic acid and the overall 
thiomarinol A structure optimised, molecular dynamics simulations can be run to determine 
the flexibility of the 8-hydroxyoctanoic acid of the marinolic acid, which will allow 
visualisation of where the pyrrothine moiety can bind to in the IleS. The same simulations 
can be run on thiomarinol analogues with shorter or longer fatty acid chains. This will allow 




7.2 The proposed role of inefficient efflux in thiomarinol potency 
The MIC tests of Salmonella typhimurium efflux transporter mutants in Chapter 6 
suggest that the efficacy of thiomarinol is not only due to its increased binding to the target 
enzyme but also from its ability to avoid efflux from susceptible cells. If efflux can be avoided, 
drugs in theory can accumulate quicker in cells and consequently be effective at lower 
concentrations. The MIC of thiomarinol is significantly lower than mupirocin against a wide 
range of microorganisms (Chapter 1, Table 1.5). Furthermore, thiomarinol appears not to be 
a substrate for a range of efflux transporter families. It appears to be transported by the 
wide substrate specific TolC-AcrAB tripartite RND transporter; however the MIC results 
suggest its efflux efficiency to be lower than when transporting mupirocin. Efflux 
transporters can be substrate-specific or accept a wide range of substrates. The broad range 
of substrates exported by some transporters has led to the theory that antimicrobial 
resistance via efflux transporters is a coincidental phenomenon (Piddock, 2006). If 
thiomarinol is able to slow down efflux by these broad substrate transporters, and no 
organism other than the producer carries the hypothetical thiomarinol-specific transporter 
(TmlY), it bodes well as an effective antibiotic.  
In essence, thiomarinol may be an antibiotic that encompasses what the combinatory 
therapy of antibiotic and efflux pump inhibitors (EPI) is trying to achieve. The hope is that 
EPIs are a class of drugs that, if used in combination with existing antibiotics that have been 
made redundant by acquired resistance, will restore their efficacy (Schindler et al., 2013; 
Zechini and Versace, 2009). By understanding the mechanism by which thiomarinol avoids or 
slows efflux, a new method for reviving redundant drugs may be a possibility. Perhaps 
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simple alterations to existing antibiotics to hinder or prevent their efflux would allow many 
drugs to be effective once more. 
In terms of investigating the role the pyrrothine moiety plays in the proposed 
inefficient efflux of thiomarinol out of susceptible cells, it would be interesting to test 
analogues of marinolic acid hybridised with other bulky and non-bulky moieties other than 
holomycin, against the S. typhimurium efflux transporter mutants (either overproducing or 
deleted) and to also determine their kinetic affinity to different efflux transporters as 
outlined by Nikaido in Chapter 6 (Nikaido and Pagès, 2012). 
On the other hand, the uptake of thiomarinol into cells is yet to be understood. 
Whether accumulation plays a role also needs further experimentation with better labelled 
[14C] antibiotics or perhaps even the exploration of other tracking methods such as 
visualising transport with fluorescently tagged antibiotics and confocal laser scanning 
microscopy (CLSM), as demonstrated with S. aureus and BODIPY-vancomycin (Oubekka et al., 
2012). By using fluorescently tagged antibiotics, efflux in theory can also be tracked in the 
same experiment. Alternatively, the use of LC-MS requires no labelling of the antibiotics and 
can rapidly identify the presence of intracellular and extracellular thiomarinol. It would be 
interesting to visualise the difference in uptake, accumulation and efflux of mupirocin, 
thiomarinol A and marinolic acid, to see whether holomycin is crucial for improved transport 
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